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Introduction 
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1.1 HEMATOPOIESIS 
Peripheral blood cells are in majority short lived and exert a whole spectnull of actions, 
ranging from the transport of oxygen and carbon dioxide to the production of highly 
specific immunoglobulins targeted at antigens. The system is velY adaptive and 
substantially increased numbers of cells can be produced after, for example, major losses 
of blood, or in response to infections. 
Peripheral blood cells originate from a small population of bone marrow progenitor cells, 
together approximately 1.5 % of all bone marrow cells, which are morphologically nearly 
identical and share the expression of the CD34 antigen. (I) These cells all derive from an 
even smaller population of hemopoielic stem cells, which have the potential to self renew 
and are muliipotent. (2) Most of the slem cells in Ihe bone matTow do not actively 
participate in blood cell formation but remain in a quiescent state. The process from the 
hemopoielic stem cell to mature peripheral blood cells and several specific tissue cells, 
termed hematopoiesis, takes approximately 20 to 30 cell divisions, through which cells 
become increasingly 1110re specialized. TIlis whole process is tightly controlled by 
hormone like proteins, the hemopoietic growth factors or cytokines, in combination with 
envirOllllental influences conducted by stromal cclls and direct cell-cell contact. (2,3) 
Many cytokines have become known in the last 20 years, and new cytokines and 
cytokine receptors are still being identified. 
Immature cells in the bone marrow ,u-e positive for the CD34 antigen. TIlis 
transmembrane glycoprotein was identified in 1984. (I) It is expressed on early 
hemopoietic progenitor cells (I) and on vascular endothelium in almost any organ. (4) Its 
function in hematopoiesis is as yet unknown. (5) Since CD34 expressed on endothelial 
cells has a function in leukocyte adhesion during inflammation, where it serves as the 
ligand for the adhesion molecule L-selectin on lymphocytes (6), it has been proposed 
that CD34 expressed on hemopoietic progenitor cells plays a role in progenitor cell 
adhesion in the bone matTOW. However, mice deficient in CD34 expression have a 
normal hematopoietic system and do not display defective adhesion of hemopoietic 
progenitor cells and a stromal cell line in vitro. (7) The only abnormality found in these 
mice is an impainnent of eosinophil accumulation in the lung after inhalation of an 
allergen. (7) 
Although CD34 has apparently no functional significance for hemopoietic stern cells, its 
unique distribution pattern makes it a useful marker to select for inuuature cells, including 
stem cells. Transplantation experiments with CD34 negative cells showed that long teInl 
repopulating cells, which contain the presumed stem cells, are all CD34 positive, since 
depleting such cells from a bone matTOW graft results in severe impairment of 
engraftment in experimental animals. (8,9) Several monoclonal antibodies against 
different epitopes of the CD34 antigen have been widely used for experimental 
applications such as cell sorting. (5,10) 
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1.2 MEGAKARYOCYTOPOIESIS 
The production of blood platelets from the hemopoietic stem cell through 
megakaryocyte precursors is termed megakaryocytopoiesis. Platelets are anucleate cells 
circulating in the peripheral blood that play an active part in hemostasis. Normal platelet 
counts in humans are 200-400 x lO'/L and platelet life span is approximately 8 days. 
Assuming a total blood volume of 5 liter (so a total platelet mass of approximately 1500 x 
109), in a steady state situation each day the large number of lOll new platelets are 
formed. TillS probably is an underestimate because it does not account for the bone 
malTOW pool of platelets, which has not been quantified. Platelets arc released from 
megakaryocytes, rare cells in the bone manow, although they compensate for small 
numbers by large size. This large size is due to the last phase of megakaryocyte 
production in which no further mitoses take place but instead the complex process of 
endoreplication occurs, during which the nuclei duplicate repeatedly, but the cells do 
not divide. Megakaryocytes are the product of their more immature progenitor cells 
which ultimately afe all derived from the hemopoietic stem cell. (11-13) 
The process of megakaryocyte production and platelet formation has long been difficult 
to study ill vitro, because of the low frequency of megakaryocytes in the bone lllalTOW 
and the lack of a proper identifation of early stages of megakaryocyte progenitors. 
which are difficult to recognize morphologically. Furthermore, ill vitro analysis has been 
hampered by the lack of a puritied cytokinc that regulates megakaryocytopoiesis. A 
specific regulator for megakaryocytopoieses has been postulated as far back as 1958 
(14), and could indeed be demonstrated in serum and urine of thrombocytopenic patients 
and animals. (15,16) Injection of this semlll in Bonnal experimental animals induced a 
thrombocytosis that was inversely related to the degree of thrombocytopenia in the 
donor. However, it proved to be velY difficult to purify this substance, due to its minute 
concentrations. 
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Assays to study megakaryocytopoiesis have been developed using senun from 
thrombocytopenic or aplastic donors. (17-19) Cell were grown on various semisolid or 
viscous media and interlaboratory comparison and standardization of the assays was 
difficult. However, the results were encouraging in that gradually the process of 
megakaryocyte development was clarified. The nomenclature for this process is similar to 
that used for describing the proliferation and maturation of the erythroid lineage (Fig I). 
In fact, many similarities exist between the erythrocytic and megakaryocytic lineage. The 
two lineages share common transcription factors (20,21) and both express several surface 
antigens that are similar. (22,23) It has been postulated that a common precursor cell 
exists (24,25), and BFU-E colonies often contain megakatyocytes. (26) 
The first cell in the megakaryocytic lineage that is identified by colony assays has been 
labeled burst fonning unit-megakaryocyte (BPU-Meg). (27-29) Human colonies derived 
from this cell type require 21 days in culture to develop and are composed of multiple 
clusters of megakaryocytic cells which often number in the hundreds. TIus cellulat· 
entitiy is the precursor of the colony forming unit megakaryocyte (CPU-Meg), which is 
more mature, and gives tise to single cluster colOIues in 10 to 12 days. (28,29) Early and 
late stages of CPU-meg differ in the number of cells per colony. Not identifiable by 
colony assays, but present in bone matTOW as phenotypically or morphologically 
recognizable cells are the megakaryoblast and the megakaryocytes themselves. (30) 
These cells have lost the capacity to proliferate. Megakaryoblasts express the membrane 
markers Gplb and GpIIb/IIla on the cell surface (31-33) and start endoreplication (34-36), 
a process unique to the megakaryocyte lineage. Megakaryocytes are large polyploid 
cclls (37) which in the last stage of development develop demarkation membranes and 
complete cytoplasmic maturation. As a final step, functional circulating platelets are 
released from proplatelets formed in the demat'cation membrane area of megakaryocytes. 
(38-42) 
1.2.1 CYTOKINES INVOLVED IN MEGAKARYOCYTOPOmSIS 
The cytokines intluencing hematopoiesis can be subdivided in different classes, early 
acting cytokines, lineage restricted cytokines that act relatively late in the development 
of their mature end cell, and a pleiotropic class of cytokines, which influence more than 
one lineagc or act at other stages in the development of blood cells as well. (3) Apart 
from such an empirical classification, one may also classify the growth factors based on 
their genetic relationship and/or growth factor receptor type. The lattcr classification 
would seem to be the more appropriate, since the target ccll range of the growth factors 
and the resulting biological effects are strictly determined by the receptor distribution. 
Some growth factor receptors have a broad distribution pattern and, consequently the 
action of the ligand is pleiotropic, others have a more restricted receptor distribution and 
are as a consequcnce highly specialized. 
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In megakaryocytopoiesis, it is thought that a Meg-CSF stimulates the early proliferative 
events, and a maturation factor enhances colony formation by stimulating cytoplasmic 
maturation. (43,44) Growth factors that in the past two decades have been shown to 
affect megakaryocytopoiesis are IL-Ia (45,46), IL-3 (47-50), IL-6 (51-53), IL-ll (54,55), 
GM-CSF (48-50,56), EPO (57-60), SCF (61,62), LIF (63,64) and Oncostatin M. (65) 
Although, for example, IL-3, SCF and GM-CSF stimulate megakaryocyte progenitor 
proliferation, and IL-6, JL-ll, LIF and EPO influence megakarycyte maturation, none of 
those cytokines were demonstrated to be similar to the megakaryocytopoietic activity 
found in aplastic sera. The identification of thrombopoietin and the cloning of its gene 
filled the gap of a physiologic regulator of platelet production. 
1.3 THROMBOPOIETIN 
The existence of a cytokine specific for the megakaryocyte lineage had been postulated 
for decades. In 1958 Kelemen and coworkers first proposed the term tln'ombopoietin, on 
the analogy of erythropoietin, for the protein present in the plasma and urine of 
thrombocytopenic animals. (14) Although many cytokines were shown to influence 
megakaryocytopoiesis, none of them had all the attributes of the activity found in plasma 
from thrombocytopenic subjects, and complied with the characteristics of a physiologic 
regulator of platelet production. Efforts to purify the substance were initially 
unsuccessful. The discovery of Francoise Wendling and coworkers of a mminc 
retrovirus that led to myeloproliferative leukemia (MPLV; myeloproliferative leukemia 
virus) in mice (1986)(66) and the subsequent cloning of a cellular homolog c-lIIpl that 
proved to be an orphan cytokine receptor (1992)(67), were of decisive importance for 
the discovery of the nature of thrombopoietin. The cellular variant of this VilllS, the 
oncogene c-mpl. was found to be expressed throughout the megakaryocytic lineage in 
the bone marrow, while antisense deoxynucleotides to c-mpl blocked CFU-meg colony 
growth (68), suggesting an important role in the regulation of megakaryocytopoiesis. 
Several groups cloned the gene encoding the ligand for this receptor simultaneously (69-
73), and named it either thrombopoietin, megakaryocyte growth and development factor 
or megapoietin. In this thesis only thrombopoietin (TPO) will be used to refer to the 
recombinant mplligand. Mass production of the recombinant protein enabled an early 
start of preclinical experiments. 
1.3.1 STRUCTURE OF TPO 
Thrombopoietin is a glycoprotein, with a highly conserved amino acid sequence. (70) 
The gene for human thrombopoietin is located on chromosome 3q27-28 and consists of 
6 exons. (74-76) Human TPO consists of 332 amino acids, and is in structure closely 
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related to erythropoietin (23% amino acid identity and 50% similarity) (Fig 2). (70,74) Its 
functional domain is the amino telminal part of 153 amino acids (70), where four highly 
conserved cysteines form two disulfide bridges which are both required for functional 
activity. (77) The amino and carboxy temlinal regions m'e separated by a potential Arg-
Arg cleavage site at position 153 that is conserved among species. (69,70,74) The 
carboxy tel111inal domain contains six potential N-linked glycosylation sites (69,70) and 
probably has a function in stabilization of the molecule. 
xx x x xx 
I I I I IIIII RR TPO 
x x 
* I II IIII II EPO 
Figure 2. Schematic structures of TPO and EPO. The black boxes represent secretory leader 
sequences, the shaded boxes a helical segments, *: N-Iinkcd glycosylation sites, RR: two arginine 
residues at position 153-154. 
The predicted molecular weight for the non glycosylated molecule is 35-38 kD (69,74), 
whereas immunoprecipitation of native material from the liver revealed a kD of 68 to 85 
(74), indicating that indeed the molecule is heavily glycosylated. However, native TPO 
from plasma sources is smaller than 60 kD, varying from 18 to 36.7 in various species. 
(70-73,78) TPO isolated from rat hepatoma cell supernatants is also heterogenous in size, 
ranging from 17-43 kD. (79) 
Isofol111s of a protein can be created tlnough alternative splicing or proteolysis. 
Alternatively spliced isof0l111S of TPO are found in the kidney, termed TP02, (74), fetal 
liver (80), and mouse bone marrow. (77) The different fomls of TPO arise from the use of 
alternative splice acceptor sites. However, agonist activity was not observed with the 
variant form ofTPO in the Ba/F3-mpl proHferatioll assay (74,77), and inununoprecipitation 
experiments suggest that TP02 is poorly secreted. (74) 
Selective proteolysis ofTPOby purified tlu·ombin has been described as well (81), which 
also may account for some of the naturally occuring variants of TPO. 111is mechanism 
could playa role in the degradation of the molecule. 
TPO mRNA has been demonstrated in fetal and adult liver and the kidney, which are the 
m'\ior places of thrombopoietin production. (69,70,76) The TPO producing cells in the 
liver are the hepatocytes. (79,82) Furthermore, TPO mRNA has been demonstrated in 
skeletal muscle (69,79,83,84), spleen (76,79,84), bone marrow stromal cells (82,85,86), brain 
and intestine. (79,84) 
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1.3.2 REGULATION OF TPO LEVELS 
Levels of the humoral physiologic regulator of platclet production need to be adjusted 
according to the need for new thrombocytes, resulting in an inverse correlation between 
thrombocyte counts and cytokine levels. Long before the gene for 1P0 was cloned, it 
was demonstrated that the thrombopoietic activity present in selUlll, plasma and urine 
from thrombocytopenic animals and patients was inversely related to platelet counts. 
(16,87,88) 
Increased levels of a protein can be achieved either by an increase in production rate or 
by a decrease in clearance or degradation, resulting in an increased half life. 
Upregulation of TPO mRNA levels as a measure of increased production, has been 
investigated in the liver, kidney and spleen of animals made thrombocytopenic by anti-
platelet antisenllll or chemotherapy (84,89-91), and in thrombocytopenic C-/IIp! -/- mice 
(92) that display high levels of TPO. (93) An upregulation of TPO mRNA has however 
not bcen found (84,89,90,93), with the possible exeption of an increase of bone manow 
TPO transcription. (91) The significance of the latter observation is not clear, since the 
authors did not take into account the altered bone marrow cellularity after cytoreductive 
treatment. 
~ ° 00 °0 0 000 -°00 0 0 
III 
0 ~ ° °0°0 0 ~ °00 0 
liver and kidney TPO circulating TPO bone marrow new 
platelets megakaryocytes platelets 
Figure 3. Schematic diagram of the regulation of TPO levels. The liver and kidney produce constant 
amounts of TPO. In steady state hematopoiesis (upper part of the figure) circulating platelets bind 
most of the TPO and the resulting plasma levels are sufficient for the production of normal numbers 
of new platelets. In the case of thrombocytopenia (lower part of the figure) plasma TPO levels will 
rise and cause increased numbers of megakaryocyte (progenitors) and higher ploidy values, resulting 
in increased thrombocyte production. 
It is thought that the level of 1P0 is mainly regulated by the total mass of platelets and 
mcgakaryocytes, through a receptor mediated clearance mechanism (Fig 3). Platelets and 
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megakaryocytes both express the TPO receptor, and an excess of TPO in the plasma can 
be bound, internalised and degraded. (92,94) Isolated mouse platelets are able to reduce 
TPO levels in plasma in I! dose dependent way. (90,92,95) Platelets from C-/IIp! -/- mice 
could not bind and internalize 125I_TPO, resulting in a slower clearance of injected TPO in 
those mice. (92) 
Apart from platelets, megakaryocytes also playa role in regulating TPO levels. 1l1is can 
be deduced from differences in TPO levels between amegakaryoeytic thrombocytopenic 
patients, who have high TPO levels (96,97), and patients with IfP, whose TPO levels are 
close to normal. (97) Also NF-E2 knockout mice, which have no thrombocytes due to a 
defect in cytoplasmic platelet formation in megakaryocytes, do not have elevated TPO 
levels (98), and the clearance time of radiolabeled TPO from the circulation is not 
prolonged. (99) 
The current concept of a constitutive production of 1PO, its plasma levels being 
regulated by binding to C-/IIp! on megakaryocytes and platelets and subsequent 
degradation after internalization, would seem to be appropriate to explain variations in 
TPO levels in various disease states and may serve as a useful working hypothesis to 
explain the pharmacokinetics of exogenous TPO. 
1.3.3 RECEPTOR AND SIGNAL TRANSDUCTION 
c-lIIpl 
Analysis of the stmcture of C-/IIp! indicated that it belonged to the hemopoietic growth 
factor receptor superfamily (Fig 4). (67,100,101) The members of this superfamily share 
certain structural features in the extra-cellular domain, such as 4 cysteine residues in the 
N terminus, and a WSX:WS motif just above the transmembrane portion. The 
intracytoplasmic regions of these cytokine receptors lack any known signal transduction 
motif such as a tyrosine, or a serine/threonine kinase domain but contains two regions of 
partial sequence homology, termed box I and box 2.( 102) They are formed in a double 
barrel, each barrel is result of antipru'allel ~-sandwiches. (103) This receptor family is very 
large and consists of the receptors for a number of interleukins, the colony stimulating 
factors, erythropoietin, leukemia inhibitory factor and a few nOll-hemopoietic cytokines 
such as oncostatin M, prolactin, growth hormone and ciliary neurotrophic factor. Some 
of the receptors homodimerize after ligand binding, others require association of a signal 
transducing p-chain, which may be shared by several members within the family. 
Expression of the TPO receptor has been demonstrated on cells in the megakaryocytic 
lineage, from precursors to the final product, thrombocytes. (68,101,104) The TPO 
receptor on human platelets displays a high affinity for TPO with a kD of 190 pmol/l; 
there ru'e approximately 30 receptors/platelet. (105,106) In normal mouse platelets an 
approximate receptor affinity of 560 pmollL was found and Scatchard analysis suggests 
220 binding sites per platelet. (92) 
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Figure 4. Schematic structure of c-mpl. SS ::: signal sequence, HRD ::: haemopoietin receptor domain, 
WS ::: WSXWS motif, TM ::: transmembrane region, I =cysteine residue and the thick black lines in the 
cytoplasmic domain are box I and 2 respectively. 
TPO receptors are also found on multi potential murine cell lines (101) and on immanlre 
human and murine bone marrow cells. (68,107,108) Other cells which express the TPO 
receptor are endothelial cells. (68,100,109) 
The TPO receptor is detected on human BFU-E colonies by RT-PCR and flow 
cytometlY. (106) Those receptors are few in number but display a high atlinity. Cross 
competition with erythropoietin could not be demonstrated in assays using BalF3 cells 
expressing the TPO receptor. (106) These results suggest that the stimulatOlY ellects of 
TPO 011 red blood cell recovery after myelosuppressive therapy ill l·ivo and to enhance 
BFU-E generation ill vitro (as discussed later) are directly mediated by c-mp/ on 
elythroid progenitor cells. 
Signal transduction 
Binding of TPO to c-mplleads to its homodimerization (110), which initiates downstream 
activation of the receptor. (101,111) The cytoplasmic domains of receptors transduce 
signals along pathways of successive second messengers ultimately culminating in gene 
activation and transcription. 
Deletion analysis of the intracellular domain of c-/IIpl showed that the 63 amino acids 
proximal to the transmembrane domain, containing box 1 and box 2 motifs, are 
responsible for proliferation, whereas the C-tenninal domain was not necessmy for this 
activity. (112,113) TillS induction of proliferation by the membrane proximal part of the 
receptor is mediated through activation of the JAK-STAT pathway. (112) The tyrosine 
kinases involved in signal transduction of the TPO receptor are JAK2 and Tyk2. 
(112,114-118) The STAT proteins activated by TPO were shown to be STATI, STAT3 and 
STAT5. (112,116-118) 
In similar experiments the C-terminal 33 amino acids were shown to be necessary for 
differentiation and not for proliferation. (119) The C-tenninal part of the receptor is 
necessary She phosphorylation and the association of She with Grb2. (112,114,119,120) 
Thus activation of components of the Ras signalling cascade, initiated by interaction of 
She with c-mpl, may play a decisive role in differentiation signals emanating from the 
receptor. (112,119) 
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Platelet function 
Expression of the TPO receptor on a-nuclear cells such as thrombocytes might indicate 
that TPO servcs functions beyond the maturation of the megakaryocyte lineage. One of 
these functions is regulation of TPO levels, but another function could be modulation of 
hemostatic properties of platelets, through receptor mediated influences on platelet 
aggregation. 
An effect of TPO on thrombocyte aggregation in platelet rich plasma or whole blood has 
indeed been demonstrated by several groups. On itself TPO does not influence 
aggregation of platelets, but when added to other agonists such as ADP, EPI, fibrinogen 
and thrombin, it rendered platelets more sensitive to aggregation. Addition of soluble c-
/lip! inhibitcd this priming effect, indicating a direct etTect of TPO through receptor 
mediated mechanisms. Tltis receptor-mediated ell'ect of TPO on platelet aggregation is 
also suggested by the tyrosine phoshorylation of several platelet proteins, including the 
85 kD subunit of phosphatidylinositol 3-kinase (PI 3-K) upon treatment of platelets with 
TPO. (l2t-124) The precise mechanism ofTPOenhancedaggregationofplatelets,and the 
physiologic implications of these observations arc as yet not clear. It is important to note 
that tlu·ombotic events after the administration of TPO have not been reported in specific 
altimal models. (125,126) 
1.3.4 IN VITRO ACTIVITY OF TPO 
Contrary to the idea that megakaryocytopoiesis needed a Meg-CSF, which acts on 
progenitors inducing their proliferation, and a maturation factor, inducing platelet 
formation (28,44,127-129), TPO fulfilled the postulate of both the proliferation and 
maturation inductive activity. TPO influences cens at several maturation stages of 
megakmyocytopoiesis, and was shown to increase megakaryocyte size, polyploidization, 
expression of differentiation markers and formation of CFU-Mk on its own. (69-71,130-
134) Using lintiting dilution assays or single cell cultures, it was demonstrated that 
accessory cells were not necessary to obtain this effect (134-136), and semm free culture 
assays showed that it was independent of other factors present in SCHUll. (133,134,136-
138) 
Adding TPO to BM megakaryocytes did not induce secretion of other cytokines such as 
IL-I a and ~, GM-CSF, IL-6, G-CSF, TNFa and TGF-~ I or 2. (133) The expression of 
adhesion molecules on megakaryocytes did not change when TPO was added to the 
culturcs. Furthermore, antibodies neutralizing IL-3, GM-CSF, IL-I~ and ILII did not 
influence TPO activity. (133) 
Apart from prominently stimulating in vitro megakmyocytopoiesis, TPO also stimulates 
multilineage outgrowth of early murine (107,133,135,139-142) and human (136,143-145) 
hematopoietic progenitor cells, limited in the presence of TPO alone, but greatly in 
synergy with SCF and lL-3. Also, TPO suppresses apoptosis of immature cells. (146-149) 
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Other cells on which TPO was shown to be effective are cells from the erytroid lineage. 
Adding TPO to EPO containing cultures results in increased numbers of BFU-E. 
(106,136,145,150-152) This was not fully unexpected, since the erythroid and 
megakatyocyte progenitor cells probably have a common bipotential precursor (24-26), 
and they share a number of transcription factors (20,21) and cell surface proteins.(22,23) 
1.3.5 IN VIVO ACTIVITY OF TPO 
In the initial studies TPO proved to be a potent stimulator of in vivo thrombocytopoiesis 
in mice during rebound thrombocytosis. (70) IP injection into 110nnal mice resulted in a 
fourfold increase in circulating platelet levels after 7 days. (131) Tlus was very well 
illustrated by an enlarged buffy coat in hematocrit tubes, existing primarily of platelets. 
(69) Concurrently, au increased number of megakaryocytes with higher ploidy values 
was found in bone marrow and spleen. (131) Evidence exists that under certain 
conditions TPO, when applied in vivo will affect not only megakaryocytopoiesis and 
platelet levels but also erythropoiesis and inunature cells. 
Another approach to evaluate the function of TPO in vivo was to generate mice 
deficient for the receptor C-lIIp! (93,153-155), or for TPO. (153,156) c-Mp! -/- mice show an 
85% decrease in the number of megakaryocytes and circulating platelet levels and also 
show increased concentrations of circulating TPO. (93) Peripheral blood cell counts of 
other hematologic lineages were not affected. (93,153) Interestingly, in both C-lIIp! -/- and 
TPO -/- mice the levels of granulocyte, erythroid and nmltilineage progelutor cells in the 
bone marrow were reduced, which might indicate that TPO plays a physiolocigal role in 
the maintainance of immature multilineage cells. (153,154) 
1.4 RATIONALE OF THE STUDY 
Thrombocytopenia is a major adverse effect of current chemotherapy regimens. Also 
after allogeneic and autologous bone malTOW or stem cell transplantation, prolonged 
periods of thrombocytopenia may present prominent problems. Tlus results in 
considerable morbidity, the need of intensive platelet transfusion support as hemorrhagic 
profylaxis, and in case of refractoriness to transfusions, mortality. Thrombopoietin, if 
effective, could reduce the duration and severity of thrombocytopenias. 
The in vitro activities and the first in vivo effects of TPO in nuce were encouraging. 
However, to define possible therapeutic applications, a critical evaluation in preclinical 
studies is required to define dose and dose schedule for optimal efficacy, predict 
interactions with other growth factors and detect possible adverse effects. 
In this study, rhesus monkeys were used as a preclinical model to evaluate the biological 
effects and define possible therapeutic applications of recombinant TPO in coilditions 
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that may be clinically relevant. TPO was administered to animals subjected to 5 Gy total 
body irradiation to evaluate its efficacy in mitigating the thrombocytopenia induced by 
cytoreductive therapy. Five Gy TBl results in approximately two log stem cell kill and a 
period of three weeks of profound pancytopenia. Placebo treated monkeys need on 
average 2 to 3 thrombocyte transfusions to prevent spontaneous bleeding. A 
combination of TPO and the myeloid growth factor G·CSF was also tested, since it is not 
unllkely that TPO will be combined with this cytokine that is already in clinical use. 
According to our experiences the initial dose schedules appeared supraoptimal, so that a 
substantial dose reduction of 1PO could be achieved. In an extension of the Shldy a 
single dose of ITO was administered, in combination with another registered myeloid 
growth factor GM-CSF. To evaluate the efficacy after bone marrow transplantation, 1PO 
was administered to rhesus monkeys subjected to 8 Gy TBl and autologous purified 
stem cell transplantation, alone and in combination with G·CSF. To elucidate the 
background of the multilineage effect of TPO, and to adjust dose and dose schedule to 
achieve a maximum effect, additional experiments were carried out in myelosuppressed 
mice. 
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Abstract 
Simultaneous treatment with human thrombopoietin (TrQ) 
and granulocyte colony~stlmu!ating factor (G.CSF) was evalu· 
ated In a placebo-controlled rhesus monkey study ming 5 Gy 
total body Irradiation (IBI) to induce 3 weeks of pancytope-
nia_ Dally administration ofTPQ (IO pglkglday iqjected sub· 
cutaneously [scI days 1-21 aftN TBI) promoted platelet and 
reticulocyte re<:O\'ery, resulung in less profound nadirs and a 
rapid recovery to normal levels. Platelet transfusions were not 
required in these animals, In contrast to controls, and 
hemoglobin levels stabilized rapidly. TPQ treatment did not 
Influence neutrophil counts. G·CSF (5 pg/kg/day sc days 
1-20 stimulated neutrophil regeneration and had no effect 
on plate!et levels. Simultaneous treatment \\1th TPQ and G-
CSF was as eff('{:tlve as treatment with TPQ alone In prewnt-
Ing thrombocytopenia, although with the former regimen 
platelet levels did not rise to the supranonnallevc1s seen with 
the latter. Neutrophil recowl)' was greatly augmented com· 
pared with G·CSF treatment alone, resulting in a less pro· 
found nadir and a recowl)' that started much earlier. as did 
monocyte, CDllb+, CDI6'. and CD56' cell reconstitution. In 
addition. TPQ strongly promotcd the recovel)' of bone mar-
row cellularity and granulocyte/macrophage and erythroid 
progenitor cells: The number of bone marrow CD34' cells was 
greater by two orders of magnitude in TPQ·treated animals 
than In controls in the second week of treatment. whereas G-
CSF by Itself had no Influence. In the third week after TBI an 
elevation of lDHI values was obsen'cd in TPO·tre,lled mon-
keys concurrent with normoblastosis: both of thcs(' findings 
were attributed to rapid el),thropoiesis TPQ had 110 effet.:t all 
hemostasis parameters. Adverse TPO andlor G·CSF effects 
were not observed. This study demonstrates that simultane· 
ous TPQ and G·CSf treatment after C)10reductivc trC.1\nll.'nt 
prc\'cllts thrombocytopenia, accelerates platelet and red (ell 
reconqitution, alleviates neutropenia, and prol1llltl'~ tile 
n:OCOH'rV of immature ballp mano\\' cdls The ('ffen 011 CD3-\' 
G'\! prog<'llitor cells may explain Ill<' <Iugn1('llted G·CSf' 
responses in TPO·treated monkeys; it also suggests that TPQ 
may become a key growth factor in ule design of treatment 
regimens to accelerate both immature bone marrow and 
mature blood cell re<:onstitution after cytoreductive therapy. 
Key words: Thrombopoletin-Myelosuppressioll 
-Granulocyte colony·stlmulating factor 
-Total body irradiation-Rhrsus monkeys 
Introduction 
Thrombopoietin (IPQ), the ligand for the receptor encoded 
by the protooncogene c-mpl, was flrts Idenul1ed and its gene 
cloned in 1994 [1-3J. Because Its blood levels arc Inversely 
related to platelet counts 11-31. and because mice lacking 
either the receptor for TrQ or the lig,md are severely throm· 
bocytopenic [4,5J, TPQ Is considered the major regulator of 
platelet production. Administration of recombinant TPQ to 
experimental animals showed It to be a potent thrombopolN 
Ic agent. In norillal mice, platelet counts rose more than four 
fold after a 5.day adrninlstration of TPQ without affecting 
other blood Iineagesl3,6J. in !lomlal rhesus mOllkeys, platelet 
counts Increased to supranormal levels in a dose-dependent 
manner after TPQ administration for 9 days 17J. Neither red 
nor white blood cell counts were affected, indicating that 
TPO's activity is selective. TPQ has also been shown to be 
effective In Illyelosuppressed mice /6.8-10), After a single dose 
of carboplatin, thrombocytopenia was counteracted by TPO 
in a dose-dependent manner 161. In an extended protocol 
\Ising calboplatln and irradiation as myelosuppressive thrlilPY 
together wilh a combination of TPQ and G-CSF in mice, 111(' 
combined treatment fully prevented mortality associated with 
bleeding. although it had no effect on platelet n~dir [9J, In a 
similar lIlodel 181, stimulation of the red cell lineage was also 
observed. Stimulation of progenitor cen recovery has also 
been reJlnrt~d in min' after myelosllppressi\'p treatmcnt. In 
;Jllilll~b ITt'il\e\! with TPO. IO-fold higlll'r numb('rs of mcg,] 
karyocyte. erythroid. ,11111 grilnulocyte/manoph,lgt> p((lgenitor 
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cells were observed In femur and spleen midway through the 
platelet rewvery period In control animals /10]. TID was not 
effective after nlyc!oab!atlve trc3tment and bone marrow 
transplantation 111]ln a syngeneic mouse model, whl'reas 
marrow from IPQ-pretreated donors In the same study 
showed an ilugmented regeneration of platelet numbers. 
The pharmaceutical development afTPO to counteract the 
adver.;e effects of bone marrow suppression and thrombocyto-
penia In patients subjected to cytoreductlve therapy requircs 
preclinical feasibility and efficacy studies In outbred nonhu~ 
man primates. Because It [s anticipated that TPQ will be used 
in conjunction with other growth factors that accelerate 
white cell (econstltutlon, rhesus monkeys were treated with 
TPQ and G·CSF In the present study 112-16). The monkeys 
were subjected to 5 Gy (x-ray) total body irradiation [fBi} to 
induce myeJosuppres.sion, resulting in strm cell reduction of 
approximately two orders of magnllUde and 3 weeks of pro. 
found pancytopenia. under full supportive care. In addItion 
to blood cell parameters. Immature bone marrow cell regener-
ation was monitored by analysis of C034+ cells [17} and 
ciollogenlc progenitor cell assays 
Materials and methods 
AIIlmJ/$ 
For the present study, purpose· bred male rhesus monkeys 
(Maraca mu!a/ta), each weighing 2.5 to 4.0 kilograms and aged 
2 to 3 years old, were used. The monkeys were housed In 
groups of four to six in stainless steel cages in rooms equipped 
with a reverse filtered air barrier. provided with nonnal day. 
light rhythm. and conditIoned to 20'C with a relative humldj. 
ty of 70%. Animals were given free access to commercially 
available primate chow, fresh fruits. and acidlOed drinking 
water. /\11 animals were free of Intestinal parasites and seroneg-
ative for herpes B. simian T-Iymphotrophlc viruses (STLV), and 
simian Immunodeficiency virus (SIV). Housing. experiments. 
and all other conditions were approwd by an ethics commit-
tee in conformity with legal regulatiom in The Netherlands. 
Totalbody Irradiatkm 
Monkeys received a single dose of 5 Gy TBI deJiwred by two 
opposing x·ray generators. op€ratlng at a tube yoll<lge of 300 
kV and a current of 10 mAo The half·layer thickness was 3 mm 
Cu. The focus skin distance was 0.8 m imd the average dose 
rate 0.20 to 0.22 Gy/mlnute. During TBI. the animals were 
placed In a cylindrical polycarbonate cage that rotated slowly 
(3 times per minute) around Its \'ertlcill axis. 
$upparlire ure 
Two weeks before TBI. the monkeys lIen' placed in a lilminar 
flow cabinet and their gastrointestinal trilets were selectively 
decontaminated by oral administration of ciproOoxadn 
(Bayer, Mijdrecht. The Netherlands). nystatin (SanofJ BV. 
Maassluis. The Netherlilnds). and polymyxin B (Pfizer. New 
York, NY). This regimen wa~ supplemented with systf'mir 
antibiotic medication when leukocyte counts dropped brloll 
lO'lf!.; in most rases the antllliotk regimen, guided by f(,(i11 
bactl'riogr,HllS. consiSled of a comhination of ticafe/lIin 
(BI'('dlilm Ph<lfrna. Armtl'lvet'n. TIl(' i\'ttlwrlanrls) and CtflrfOX 
im (Glaxo, Zeist. TIle Netherlands). and II was continued until 
leukocyte CO\lnt~ rose to levels hlgber than 109fL Dehydration 
and electrolyte disturbances were treated by appropriate sc 
II1Jections of nulds and electrolytes. The monkeys received 
Irradiated (15 Gy 'f lrrildiation) platelet tr.msfusions whenever 
thrombocyte counts reached valurs below 40x 109ft.. and 
packed red cells whenever hematocrit levels declined to below 
20%: on those occasions when both thrombocytes ilnd hemat-
ouits dropped to these levels, the monkeys received whole 
blood transfusions. The level at which thrombocytes were 
transfused was set at <40x 109ft.. beciluse monkeys already 
develop a prop€oslty to petechiae and other hemorrhages at 
this level, which Is (also) associated With mortality at the 
mid!ethal dose of radiiltion used In this studyl 181. The hemor· 
rhaglc diathesis of monkeys subjected to 3 to 8 Gy of x·radla· 
tlon has been desnibed and reviewed earlier 1191. 
TestdnJg$ 
One-milliliter vials containing 0.5 mgfml. recombinant 
human TPO were supplied by Genentech {South San Frands· 
co. CAl. The dose usrd was 10 pglJ.;gfday i'ljected sc once per 
day from days I to 21 after irradiation. The dally doses were 
diluted to a volume of I mL with phosphate. buffered ~line 
{PBS)fO.O 1 % Tween 80. Placebo· treated monke)'5 were given 
the same volume of d!luent. Recombinant human G·CSF 
(Neupogerl. Amgen. Thousand Oaks. CAl was administered in 
a dose of 5 pg/kgfdilY Injected sc once per day frolll days 1 to 
21 after Irradiation. The daily doses were diluted to a volume 
of I mL in the solution recommended by the manufacturer. 
Study groups 
The 5·Gy irradiated monkeys were treated in groups of three 
or four. and in each group the monkeys were randomly 
assigned the four different growth factor regimens. FOllr 
monkeys were treated with TPO illone. four With G-CSF 
alone. and four with a combination of the two. four mOll-
keys were treated with the diluent alone to serve as historic 
controls (n '" 8). 
Bone marrow aspirate 
Bone Illilrrow was aspirated while the anima!s were under nell 
roleptlc anesthesia using ketalar (Aphatrllo. Arnhem. The 
Netherlands) and vetranqull (Sanofi, Maassluis, The Nether· 
lands). Small bone marrow aspirates were obtained for analytl. 
cal purposes from the shafts of the humeri using pediatric 
spinill needles and collected In bottles containing 2 mL Hanks' 
buffered Heprs solution (HIIBS) with 200 IU sodium hep-
arlnfmt.. (leo Pharmaceutical Products. Weesp. The Nether-
lands). low-density (ells were isolated using FlcoJ[ (density 
1.077) (Nycomed Pharma AS. Oslo. Norway) separation-
Colonya$$lJ)'$ 
Cdls were plated In 35·mm dishes (Becton Dickinsun) in 
m!. n-MEM (Gibeo, Gaithef5burg, 1\10) containing 0.8% 
methyicellulose. 5% fetal calf srnlm (FeS). <lnd addltiws as 
dC5crlbcd car Her [20-22J. For bur5t-formlng unit~-('r)'throhJ 
(BFU-E). cultures w{'re supplemented with hrlllin (2 x 10 1 
mol/l). humall rerlJmblnant ef)'lhrup[)i~tiJ1 (Fpl): -I U/mL: 
Bl'llring. Germany) .lIld Kit ligand (KL: lOll J1g/mL: "llHIIJ' 
provilif'd hy Dr. S. Gillis. 11IlJlllJlll'x. S(',mip. \VJ\j. for grdlllJ 
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locyte/macrophage colony. forming units (GM·CFUj, cultures 
were supplemented with recombinant human Gl\I·CSF (5 
ng/mt: Behring). recombinant rhesus monkey IL-3 (30 
ng/mL). produced in B. Iicheniformls and purified as 
describ£d previously [23.241 and KL. Low demlty cells were 
plated at 5x 10' cells per dish In duplicate. Colony numbers 
represent the mean ± standard deviation of bone marrow 
samples of individual monkeys. 
Hemat%gic.1l examinatiOrl$ 
Complete blood cell counts were measured dally using a Sys· 
ffiex F·SOO hematology analyzer (Toa Medical Electronic, 
Kobe. Japan). The differential of the total nucleated cells (fNC) 
was determined by standard counting after ~fay·GrUnwald· 
GienlSa staining. For reticulocyte measurements. 5 pL ethylene 
diamlne tetraaceHc acid (EDTA) blood was diluted in I mL 
PBS/EDTNazlde and I mL of a thialOle orange dilution was 
added using thlazole In a final concentration of 0.5 I1g/m1. 
Measurements were done on a FACScan (Becton Dickinson) 
and analyzed using Reticount software (Becton Dickinson). 
Me.uuremems of sulface antigens 
Once per week. a FACScan analysis was performed on periph· 
l'ral blood (PB) and bone marrow samples on the following 
surface antigens: COB. CD·t, CD20. COllb. C056. and C016. 
Directly labeled monoclonal antibodies were used for COS. 
C04, C020. C056. and COl6 (Leu 2a·FITC. Leu 3a·PE. Leu 
16·PE, Leu 19-PE, and Leu Ila·FITC [Becton DicklnsonJ. 
resp&t\vely). For COl lb. we used the monoclonal antibody 
MQI·FiTC (Coulter Immunology. Hialeah, florida) and for 
C034, a monoclonal antibody (mAh) against human C034 
(mAb 566. kindly prOVided by T. Egeland. UniwfSit)' of Oslo, 
Oslo. Norway) that had been fluoresceinated \\ith fluoresccln 
Isothlocyanate (FITC: Sigma) according to standard proce· 
dures. 0.5 mL of whole blood or bone marrow were lysed In 
10 mL lysing solution (S.26 g ammonium chloride/I.O g 
potassium bicarbonate and 0.037 g EDTNL) for iO minutes at 
4"C. After lysing. the cells were washed t\\ice with HHBS con· 
talnlng 2% FCS and 0.05% (wt/vol) sodium azide (HFN). The 
cells were resuspended In 100 pL HFN containing 2% normal 
monkey serum to prevent aspeclfic binding of the monoclo-
nal antibodies. Monoclonal antibodies were added in a vol· 
ume of 5 pL and Incubilted for 30 minutes on Ice. After two 
washes, the cells were measured on the flow cytometer. 
Ungated list mode data were collected for 10,000 events and 
analyzed using Lysis II software (Becton Dickinson). 
Clinical clwn1stty 
Serum concentrations of sodium. potassium. chloride, glu. 
cose, albumin, total protein. aspartate·amlno transfcrase, ala· 
nine·amlno transferase. alkaline phosphatase. lactate 
dehydrogenase (LOH). gallliila.g!utamyl transfl€ptJdasc. total 
bilirubin. C reactive protein. creatinine. ure,l. and bicarbonate 
were analyzed twice pl'r \\eek using an Elan Analyzer (Eppen· 
dorfMerck. Hamburg. Grrmany). 
Hemostasis Piffilmeters 
Plasma for measurements of fibrinogen. prothrombin time-
(PT). ilnd activated partial thromboplastin time (APTf) was 
collected twice per wel·k ami ~tored at -80T. l\l\-awrements 
were performed on an Automated Coagulation Laboratory. 
100 (ACL·lOO, Instrumentation Laboratory, Milan, Italy). For 
fibrlnogl'n measurements a commercial kit was used (fibrino-
gen·test: OiaMed AG, Cressler sur Morat, Switzerland): 
Thromborel S (Behrlngwerke AG, Marburg. Germany) was 
used for the PI and Platelin LS (Organon Teknlka, Durham. 
NC) for the APTf. 
Platelet aggregation tests were performed before treatment 
and at day 21 on a whole blood luml aggregometer 
(Chronolog, Hawrtown. PAl using the standard agonlsts AOP 
(Sigma. SI. Louis, MO) at a concentration of 5x 10"5 M. throm· 
bin (Central Laboratory of the blood bank, Amsterdam. The 
Netherlands) at a concentration of 5 U/mL or collagen 
(Sigma) at a concentration of 5 pg/mL. 
TPOlt'ltis 
Plasma for measurements ofTPO levels was SilmpJed from the 
monkeys just before cytoklne administration tWice per week 
and stored at -SO'C. A full description of the TPO enzyme· 
linked immunosorbent assay (ELISA) has been describ£d else· 
where [25,26]. Briefly, ELISA plates Wl're Incubated overnight 
at 4'C with 2 pglmL rabbit F(ab')2 to human TgG Fc (Jackson 
ImmunoResearch, West Grove. PAl and for 2 hours at room 
temperature with conditioned medium containing 100 nglmL 
of mpl.IgG 12]. Twofold serial dilutions of Silmples (starting at 
I; 10) and standards (r&olllbinant full·length human andlor 
rhesus TIO) were added to wells and Incubated for 1 hour. 
Bound TPO was detected using blotlnylated rabbit antibody 
to fun·length human TPO (Genentech) followed by peroxl. 
dase·labl'led streptavldln. The range of the assay for rhesus 
plasma samples was 0.32 to 10 ng/mL TPO. The assay prefer· 
entlalJy detects active full.length TPO In both rhesus monkl'Ys 
and humans. and correlates wel\ with a bioassay using the 
megak3I),oblastlc HU·3 cell line. 
Statiftks 
If relevant, standard deviations were calculated and are given 
In the text, the figures. and the table on the assumption of 
normal distribution. The statistical significance of differences 
was calculated using Fisher's exact test for categorical data. 
and for continuous data by one·way analysis of variance fol· 
lowed by Studenfs He-st. 
Resutts 
Peripheral blo<xI cell counts 
Irradiated placebo-treated monkeys showed a regeneration pat· 
tern similar [Q that of historic controls for all lineages. On 
average. the nadir for platelets was far below 40x 1O'1/L and Its 
tliIll' course was Influenced by platelet transfusions (Fig. i). 
The control monkeys needed on average 2.7 ±. I.S transfu· 
sions. Transfusion independence (a level above 40x 109/L) was 
reached on day IS.5 ± 3.7. IPQ·treated monkeys did not 
require platelet transfusions because they had an average 
thrombIXyte nadir of 175x 109/L (range 7S-J99x 109/L). In the 
IpQ·treated animals there was an Increase in platelet levels to 
supranormal values (775x i0911, to 2130X I 091L). The recowry 
to nO[lJl~1 platelet values was ac(elerated In these animals. Pre· 
treatm~ll! values were reached on day 131n IPO·treated /llon· 
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keys and on day 32 in placebo. treated controls. The effect of 
TPQ on platelet nadir, transfusion requirement. and recovery 
time (defined 35 the first day on which thrombocyte levels 
remained >300XI091L) was statistically slgnlfkant (p < 0.02, p 
< 0.02, and p < 0.001, rcspc<:tiveiy). 
TPQ also showed a beneficial effect in monkeys treated 
slmultaneous)y with TPQ and G·CSF. with a nadir of 
118x109/L (range BJ-145x 109/L) (p < 0.02). The maximum 
platelet levels reached In these monkeys were less pronounced 
than In monkeys treated with TPQ alone (615-786x109/L) 
(Fig. I), although the difference did not reach statistical slgnlf. 
icance. G·CSF treated monkeys showed a pattern similar to 
the placebo-treated monkeys. 
Mean platelet ,'olumes dropped over the first week to 9 to 
10 fL for all groups. Thls was Influenced by platelet transfusions 
and started to return to nonnal volume.s (11.5-13.0 fL) after the 
third week In all but the WO + G-CSF treated ilnimals. where 
volumes stilblllzed at levels between 10 and 11.5 fL. 
TPO also had an efTect on the red blood cel! lineage. Ret!c~ 
ulocyte regeneration was InItiated 10 days earlier In both 
TPQ- and TPQ + G·CSF~treated monkeys compared with 
placebo. and G·CSF·treated monkeys (p < 0.001 and p < 
0.002, respectively). Reticulocytosis was followed by nor-
moblilstosls in the TPO~ and TPQ + G-CSF-treated monkeys. 
which also occurred 10 days earlier and was more pronounced 
than In the placebo-treated animals (Fig. 2). The beneficial 
effect of TPO on the red blood cell lineage was reflected in a 
less profound nadir for hemoglobin and hematocrit levels and 
a stablllziltion of those values after day 30. For G·CSF· and 
placebo-treated monkeys the hematocrit nadir always came 
close to the transfusion level of 20% and four of these eight 
animals were given a whole blood or packed cell transfusion. 
Regeneration of neutrophll!c granulocytes in TPQ· and 
placebo·treated animals followed exactly the silme pattern, 
with vaiues greater thiln 0.5X 105/mL at day 22 (rilnge 20-25 
days) (FIg. I). Monkeys treated with G-CSF alone reached this 
value on average at day 19 (range 18-21 days), and combina-
tion-treated monkeys reached It ilt day 14 (range 12-15 days): 
this difference was statistically significant (p < 0.(05), ilS was 
the difference between the G·CSF·tceated and the placebo-tre<lt-
ed monkeys (p < 0.05) Remarkably. in the monkeys treated 
with TPQ and G·CSF the neutrophil nadir was less pronounced 
and of much shaner duration than in the G·CSF-treated mono 
keys. There were no dlfTerences in lymphocyte regeneration 
(data not shown). For Ulonocyte.s. however, the regeneration 
patterns were similar to those of tile neutrophils (Fig. 3). 
White blood cell su~ts mNsured by flow cytomelty 
A profound nadir was observed for all the surface markers 
tested in the peripheral blood In all ilnimals. CDS' T cells 
regcnerated filster thiln CD4' T cells. but no difference was 
observcd betwccn the various growth facto! tr€'iltment groups 
(data not shown). Full recovcry of CD20· B cells took longer 
than the observation period of 6 weeks; no significant dlfTer-
ences were noted between the four treatment groups (data not 
shown). The monkeys treated with TrQ and G·CSF showed 
enhilnced recover), of CDI Ib' cells. reflecting the recovery of 
mutrophlls and !\lonoc)'tes. All TPO-treilted monkeys had a 
slightly enhan(('d rccover)' of CD56' and CDI6' cclls com-
pare<1 with pla{"('ho- and G-CSF·treilted monkeys (Fig. 4). 
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Fig, 1. Peripheral blood counlS arler 5·Gy TBI (day 0). 
Shown are changes in levels of Ihromboeyles (upper 
panel), retfwloeytes {middle panel} and neutrophils 
(tower panel) In response to TPO (open squares,n=4), 
TPO and G·CSF (half·filled squares, n=4), G·CSF (blaek 
squares, n=4) and placebo treated monkeys (open clr-
cles,n=4). Data fllpreSllnl the arithmetic mean ± SO of the 
various treatment groups. Horizontal lines define the 
degree of eytopenla: 40x t09/l for thrombocytes, 
O.OSx10"/l for reUculocytes and O.Sx10 i /l for neu· 
trophils. Verticat Hnes indicate SO, given in a positive 
direction only 10 avoId confusIon. 
Booe marrow u/luliJrity and progenitor cell comem 
The monkeys treated with TrQ dJ5pJayed i1 markdJy acceler-
atcd recovery of bonl' IllJrrow cellularity, as shown by the 
bone illarrow cell (ount\ of 13 ± 23 106 cells/ml. 3~pirilt(' 
obwrved in thc animals on day 15 comparl'd \\ith 0.3;t 0.2 
for the pl"cebo monkcys nil Ill{' SOlmr day (Table n. This fCJ-
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Fig. 2. Regeneration of the red blood cell lineages. 
Shown are normoblaH (upper panel), hematocrit (middle 
panel), and red blood cell numbers (lower panel). See fig· 
ure 1 for an explanation of ~ymbols. Data repre:;cnt means 
± SO of the various treatment groups. Vertical lines indio 
eate SO, given in either a positive or a negative direction. 
ture was also apparent In the TPO· and G·CSF-treated man· 
keys and could not be attributed to the G·CSF treatment. 
However. G·CSF treatment also improved bone marrow 
regeneration. a5 was apparent from the data obtilined I week 
later. There was a declIne In bone marrow cellularity in TPO 
and TPO· + G-CSF-tre.1ted monkeys at the end of the fourth 
wcek. probably reflrcUng thr ce~tion of growth factor treat-
ment at 3 weeks. 
IrQ stimulation of bOIlE' Inarrow recovery also occurred in 
bune marrow progenitor cells. I.e .. GM·CFU and BFU-E. 
illthollgh 10 a grraU'r degn'l' in the TPO-treated monkeys than 
in Iho'i(,- trl"1tcd with G-CSF (Table I). Pt'rhaps of grt'ilter r('-Ie· 
V,'ln!'{'. inHll,'llllre CD3·1' ({'II, in the TPQ-treilted monkeys 
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fig. 3. Ab~otute numbers of monocytes after S·Gy TBI. 
See FTgure 1 for 3n explanation of symbol~. 
showed a IOO-fold Increase at 2 and 3 weeks after TBl com 
pared v.ith the same cells In monkeys treated \\ilh G-CSF or 
placebo (p < O.OS) (Fig. 5). In general. cellularity and pro 
genitor cell content followed the same pattern. 
Clinical chemlslry parameters In serom 
In most of the parameters. abnormalities were not obsefyed 
Albumin concentrations were stable at approximately 40 giL 
Electrolyte disturbances were minor during the first week 
after TBI because of gastrointestinal radiation damage. In 
addition, liver enzyme alkaline phosphatase. ALAT, and 
ASAT showed only minor changes. The only enzyme show· 
Ing abnormalities was lactate dehydrogenase Isotype I 
(LDHi). I.DHI was markedly elevated on day 3 in all treat-
ment groups and in ali TpQ·treated monkeys also in the third 
week after TSI. In contrast to the placebo.treated controls In 
which It remained Within the normal range. A correlation 
was noted b€tween elevations in LDHI levels and the abso-
lute number of normoblasts appearing in the drculaUon 
(Figs. 2 and 6). suggesting that rapid (and perhaps somewhat 
Ineffective) erythropoIesIs was the source of these elevated 
levels. The day 3 I.DHI levels. which wt're elevated to the 
same extent in all monkeys. arc most likely attributable to 
rapId cell disintegration shortly ilfter irradiation. 
Hemosul$is parameters 
No differences were found between APTT, PT, and flbrlno-
gen levels among the various treatment groups. and fluctua-
tion over time after irradiation did not occur (data not 
shown). Platelet aggregation measurements in the treatment 
groups did not differ from those in placebo.treated controls 
(data not shown). 
TPOleye/s 
TrO levels were below dete<:tion le\'el (320 pg/mLJ In all pre-
treatment samples. TPO levels varied from 6 to 24 ng/mL In 
samples taken from IpQ·treated monkeys on days 3 to 21 
post.lBl, after which TrQ administration was Slopped. These 
levels decrea'ied 10 less than 2 ng/mL on day 24 ilnd became 
undetectable Oil day 28 (Fig. 7). In ilnimais treated with G-CSI' 
and in control monhys. low levels nf TPO were detedcd in 
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samples taken on days 10. 14. and 17. concurrent with 
thrombocytopenia (Fig. 1): the TPO levels In these animals 
varied from 0.3 to 0.6 ng/mL Obviously. the rise in lPO lev-
els in the placebo-treated controls had been suppressed by 
deliberate thrombocyte transfusions in these animals whenev-
er their platelet counts fell below -lOx 109fL 
Discussion 
This study shows that TPO was highly effective in preventing 
thrombocytopenia following radiation-Induced myelosup-
pression, an affect characterized by alleviation of platelet 
nadirs, acceiewted platelet recovery, and substantial reduction 
in the lime needed to reach normal platelet levels. TPO also 
stimulated red (I'll reconstitution and exerted no influence on 
mUlroph!llc granulocytes. monocytes. or lymphocytes, In 
addition, TPQ markedly promoted illlJimture CD34' bone 
ilIarrow cell re<:onstltution. as was reflected In the Increased 
numb€~ of Immature progenitor cells observed in the granu· 
locyte/macrophage and erythroid lineages. Concurrent 
administration of G-CSF did not enhance IPQ·stimulated 
recovery of platelets. although platelet levels in monkeys the 
third week of combined G·CSFrrPQ treatment tended to be 
lower than in the monkeys treated with only TrQ during the 
5ame period. A similar dampening effect of G·CSF on the TPQ 
response has recently been described in mice 127] and may be 
related to the protracted thrombopenia observed in stem cell 
transplanted monkeys 128). which were treated with G-CSF. 
Remarkably. TPQ treatment considerably augmented G-CSF-
stimulated neutrophil and monocyte reconstitution. Adverse 
systemic effects were not observed with administration of 
either growth factor. 
The thrombopoiesis-stimulating effect of TPQ was already 
sufficiently effective in the first week of treatment. as was 
shown by an Increase in platelet numbe~ starting at day 8, In 
addition, the effect of IPQ on bone marrow cellularity and 
immature bone malTow cells was already clear by the end of 
the second week of treatment. This supgests that a dose sched-
ule of 21 consecutive days of treatment is e.xcessive. as was 
clear from the very high platelet numbers reached in the sec-
ond and third weeks after TBI. It is conceivable that a short 
course of TPO treatment initiated immediately after c)toreduc-
U\'e therapy would be sufficient to prevent thrombocytopenia. 
We have previously shO\\n in a mouse model of thrombocy. 
topenia that a single dose of ITO given 24 hours after cytore-
ductive therapy is as effecth'e as daily dosing for 8 consewtive 
days 1291. The effect of single injections in this model was also 
highly dose-dependent. 
TPO was clearly more effective in stimulating platelet rccO\'-
ery than other growth racto~ kno\\ n to stimulate platelet pro-
duction. including IL-6 [30-33J. IL-II [34.35J. IL-3 [32,33J. and 
11.-1 J361. All of these cytokines slimulilte pliltelet production 
but not sufficiently to prevent thrombocytopenia at tolerable 
doses. especially in view of the many side effects obsen·ed. 
A central issue regarding ITO treatment is prevention of 
bleeding as a consequence of myelosuppression. Our policy of 
transfusing donor thromooqtes when platelet levels decline 
to 40x I09/L is based on the finding that this le\'C1 coincides 
with the first appearance of petcchiJ{' ;md OIlwr bleedlnR: ils 
ralionale is to prevent undue df'aths resulting from hemor-
rhages. For obvious re<lsons. this lew'l is higher than the I{'wl 
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Fig. 4. Absolute number of peripheral blood cells positive 
for ~ufface markers CDllb (upper panel). CD56 (middle 
panel), and CD16 (lower panel). See figure 1 for an expla· 
nation of symbols. 
used in human patients. to whom instructions can be given 
and sensitization to alloantigens should be a\·olded. Bas('d of 
the decrease in thrombocyte counts in placebo-treated mono 
keys one week after IBi. and b<lsed on the fact that these levels 
began to increase In the third week after IBI. it can be infefTed 
that without transfusion~ the thromhocyte levels would have 
dropped below lOx 109/1. within 2 days after the first transfu 
sion (fig. I)" It can thus be concluded that the TPO Ireatment. 
which pre\'t'llled the decline in thrombocyte counts to levels 
lowt'r th~n JOOx JO?/L early in the second week after irradia· 
tion {fig I). also effectively pre\"ented blrroing. 
All association between sTll~lIer platelets and stimulated 
rnegakar)'orylopoiesis has been obs!;'f\'<,d prcviously during 
('xpcriment<ll tilrombocvtojl('lliil induced by antibody. medial 
cd platelet consumption 137.381. and also occu~ in nOflllJl 
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Table 1. Bone marrow cellularity (Xl0'), GM-CfU numbers (Xl0), and BfU·£ numbers (Xl0) per ml aspIrate i SO after TBJ and growth fac, 
tor treatment 
Before 
Cellularity T 65 i 41 
xl0$/ml T,G 103 i 65 
G 62 t 45 
pi 43:t 17 
GM·Cru T 80:t 70 
(Xl0l) HG 137 i 86 
G 85 t 82 
pi 45:t 31 
BfU·E T 32 i 31 
{Xl0~ T,G 66i 46 
G 39 t 41 
~ 21 t 14 
'N[hnol done because of low numbers of cells. 
T: TPO treated monkeys (n = 4). 
T t G: TPO + G·CSf treated monkeys (0=4). 
G: G·CSf treated monkeys (0 = 4) 
pI: placebo treated monkeys (n = 4). 
Day 8 
0.1 iO.3 
0.5 i 0.1 
0.3 t 0.2 
0.6 t 0.5 
ND· 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
nonhuman primates 1391. The mechanism of this association 
\$ not known. The decreases in platelet volume observed In 
this study were similar in all {f(>atment groups and were there--
fore not related either to the stimulation with pharmacologi-
cal concentraUons of TPQ or to the drculaUng platelet mass. 
Platelet fUnction was unaltered in that platelet aggregation 
measurements on the last day of growth factor administration 
did not differ from pretreatment measurements and did not 
vary among the treatment groups. 
TIle effect ofTPQoneaJlyhematopoletlcprogenitorce11sof 
different lineages was unexpected, but Is in line with other 
recent observations 110.40] and consistent with the previous 
finding that the [~ptor for lPO is present on immature pro· 
genitor cells loll]. Because megakaryocytes afe capable of 
releasing various growth factors 142A31, the TPQ effect 
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Fig, 5, Abwtull' numbel- of C034' cells in the bone mar' 
row arter 5·Gy TBt. See figure 1 for an e~p!anation or sym· 
bots_ Data represent arithmellc mean t SO of the varioll~ 
treatment grOllps 
Oay15 Day 22 Day 29 
13 i 23 78 t 61 29 tIS 
27 t 28 136 i 76 38 t 19 
0.5 to.3 41 t 43 43 t 24 
0.3iO.2 4.3 i 2.7 13.2 t 12 
24 i 28 103 i 53 29:t 11 
41 :t 54 84:t 59 24 t 11 
ND 45 t 52 87 t 118 
ND 1 " 15 t 24 
22.5 21 t 11 10 t 7 
21 :t 39 44 i 46 7<2 
ND 12 t 14 3Z t 41 
ND 2,2 ,<7 
observed in Ouf study may be an indirect consequence of stim· 
ulatlon of the megakaryocyte lineage. Alternatively, TPO may 
synergize directly with growth factors such as kit ligand Of flt-3 
ligand to stimulate immature cells. Evidence for such a syner-
gy exists in vitro 144-461. The accelerated recovery of pro· 
genltors cells Is perhaps most cleaJly illustrated by the two-log 
increased reconstitution of Immature C034' cells in the bone 
marrow aspirates of TPO-treated monkeys at the end of the 
second week of treatment. The magnitude of this effect Suf-
pass.cd that of aJly other grO\\1h factof tested In the same ani_ 
mal model. including IL-3 and IL-6 (manuscript in 
preparation). The accelerated fffovery of GM progenitor cells 
may explain the augmented response to G-CSF in the neu-
trophil and monocyte lineages, also reflected by CDllb' cells. 
Apparently G-CSf also stimulated the CD16/C056+ lineage, 
thought to represent natural killer cells originating in the bone 
marrow 147\. Because the G·CSF dosage was supraoptlmal, tile 
augmented responses to G·CSF are best explaIned by Increased 
numbers of progenitor cells. However, in view of the dimin' 
ished platelet response in the monkeys treated Simultaneously 
with TPO and G-CSf, we do not exclude the possibility that 
TrO and G·CSF also compete for a common progenitor cell. 
lPQ also affected the red ceJllineage very early after irradi-
ation, as reflected by the fact that exponential reticulocyte 
regeneration began after the first week of treatment, 10 days 
earlier tllan in placebo- and G-CSF-treated controls. Reticulo-
cytosis was followed by nonllob!astosis. which was accompa 
nled by elevated J.OH serum levels: we aunuute these last two 
findings to rapid and inefficient erythropoiesis. As a result 
hemoglobin concentrations and hematocrit levels stabilized 
earlier at higher levels. However, In TrQ-lreated monkeys, 
signs of a mlcro(yli<:. hypochrollli( anemia became apparent 
after the third week, suggesting depletion of iron stores 
caused by rapid erythropoiesis. In a separate stUdy, the devel-
opment of iron deficiency during ITO tn>allllent was directly 
confirmed, as was its prevention by administration ofprophy· 
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Fig, 6. Elevation of LDHI values In TPO·treated monkeys 
(n:4) after 5·Gy T81. The shaded area represents the 
mean i SO of the lDHl M'rum revels In 14 normal mon-
keys. Measurements marked with· were significantly dif-
ferent from normal (p.:O.05). 
lactic intramuscular Iron /481. We Infer from this that iron sta· 
tus needs to be assessed before. and monitored during. ITO 
treatment. It should be noted that the dosilge of TPO used in 
this study was hIgher than reqUired to normalize platelet lev" 
cis and will likely be unne<:essary for the clinical therapy of 
myelosuppressed patients. It is not dear why nonnob!astosls 
followed reticulocytosis In lPQ-treated monkeys, a pattern 
that runs counter to what has been seen \\1lh other gro\\1h 
factors such as IL-3 [49J and GM·CSF (unpublJshc-d observa~ 
tlon). Since nomlOblastosls was highly reduced in monkeys 
prophylactically supplemented with Iron [481. the pattern 
observed might be related to developing Iron deficiency 
resulting in ineffective erythropoiesis during the course of 
TPO·stlmulated hematopoietic reconstitution. It should be 
noted that the onset of mild normoblastosls In placebo·treat-
cd control monkeys, which did not develop Significant iron 
defiCiency, paralleled the onset of reticulocyte regeneration. 
The present study demonstrates that TPO treatment fol-
lowing cytoreductive treatment prevents thrombocytopenia, 
accelerates platelet and red cell reconstitution, and promotes 
the recovery of immature bone marrow cells. In addition, 
simultaneous G·CSF and ITO treatment alleviates neutrope-
nia more effectively than G·CSF alone, thereby decreil5lng the 
risk of bleeding and infection. which are common compllca· 
tions of Intensive cancer treatment. We Interpret the effect of 
TPO on Immature bone marTOW cells as an Indication that 
this growth factor may playa key role In the design of treat· 
Illent regimens directed at acceleration of both immature 
bone marrow and mature blood cell reconstitution after 
cytoreductive therapy. 
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CHAPTER 3 
Prevention of thrombocytopenia by thrombopoietin in 
myelosuppressed rhesus monkeys accompanied by 
prominent erythropoietic stimulation and iron depletion 
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Prevention of Thrombocytopenia by Thrombopoietin in ~Jyelosuppressed 
Rhesus ~Jonkeys Accompanied by Prominent Erythropoietic Stimulation and 
Iron Depletion 
By Karen J, Neelis, luo Qingliang, G. Roger Thomas, Bob L Cohen, Dan L Eaton, and Gerard Wagemaker 
The effectiveness of thrombopoietin {TPO) in alleviating 
thrQmbocytopenia was evaluated in a placebo·contrQlled 
study involving rhesus monkeys exposed to 5 Gy totel-hodY 
Irradiation (TBII (300·kV x·rays) to result in 3 weeks of pancy' 
topenia. Supraoptimal treatment with human recombinant 
TPO (10 I-Ig/kg/d subcutaneously, days 1 to 21 afferTBI) was 
highly effective in preventing thrombocytopenia, with nadirs 
for thrombocytes, on average, far higher than 100 x 109fl, 
a greatly accelerated recovery to normal values, and no need 
for thrombocyte transfusions. TPO appeared to act selec-
tively in that neutrophil regeneration was not influenced but 
red blood cell lineage recovery was prominently stimulated, 
with reticulocyte regeneration being initiated 10 days earlier 
than in placebo-treated animals. The reticulocytosis was fol-
lowed by a normoblastosls that occurred earlier and was 
more pronounced than in placebo-treated monkeys. The ef-
fect of TPO on the red blood cell lineage was also reflected 
in a less profound nadir for hemoglobin {Hbl and hematocrit 
values than in placebo controls. However, this effect was 
not followed by a rapid recovery to normal velues, due to 
THROMBOPOlETlN (TPO), the ligand for c-mpl, was identified and its gene cloned in 1994.1-3 In vitro and 
in vivo evaluation showed it to be the major regulator of 
thrombocyte production.-l-·7 In vitro experiments also demon-
strated, apart from megakaryocyte colony formation,',·s.9 ef-
fects on erythroid progenitors in synergy with erythropoie-
tin. to.! I In normal experimental animals, thrombocyte counts 
increased to supranormal values without affecting other Iin-
eages.P.12-1S In several myelosuppression models, TPO has 
also been found to stimulate, apart from the megakaryocytic 
lineage, erythroid precursors,lJ,[~,I~,17 expansion of immature 
bone marrow progenitor cells, 18 and, to a lesser extent granu-
locyte-macrophage colony-forming unitS.[~·17 Adverse ef-
fects have not been observed. In the present study, TPO was 
evaluated in a rhesus monkey model for myelosuppression 
to investigate its ability to alleviate thrombocytopenia. The 
monkeys were subjected to 5 Gy x-ray total-body irradiation 
(TBI) resulting in 3 weeks of profound pancytopenia. We 
report here that TPO, apart from greatly promoting thrombo-
cyte regeneration after myelosuppression, also stimulated 
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development of a microcytic hypochromic anemia. Iron 
depletion was demonstrated by measurements of total se-
rum iron and total iron·binding capacity (TIBCI and CQuid be 
prevented by prophylactic Intramuscular (lMllron before TBI 
or corrected by 1M iron after TPO treatment. Rechallenglng 
with TPO in week 8 after TBI demonstrated a homogenous 
thrombocyte response similar in magnitude to the initial 
response, but a greatly diminIshed reticulocyte response. 
This demonstrated that the erythropoietic response to TPO 
administration depends on the hemopoietic state of the ani-
mal and may reflect multiple TPO target cells. It is postulated 
that the extremely rapid erythropoiesis due to TPO treat-
ment in the initial regeneration phase following myelosup-
pression results In Iron depletion by a mechanism similar to 
that seen following erythropoietin treatment in patients 
with end·stage renal failure. It is concluded that protracted 
TPO therapy to counteract thrombocytopenic states may 
result in iron depletion and that the iron status should be 
monitored before, dUring, and after TPO treatment. 
© 1997 by The American Socfety of Hematology. 
erythropoiesis, leading to iron depletion and resulting in mi-
crocytic anemia. 
MATERIALS AND METHODS 
Animals. Purpose-bred male rhesus monkeys (Macaca mulmra) 
weighing 2.5 to 4.0 kg and aged 2 to 3 years were used. The monkeys 
were housed in groups of four to six in stainless steel cages in rooms 
with a reverse-filtered air bmier and nonnal daylight rh)1hm and 
conditioned to 20'C with a relative humidity of 7WL Animals were 
fed ad libitum with commercial primate chow and fresh fruits and 
received acidified drinking water. All animals were free of intestinal 
parasites and were seronegati\'e for herpes B, simian T-I)'mpho· 
trophic viruses and simian immunodeficienc), virus. The housing, 
e.\periments, and all other conditions were approved by an ethics 
committee in accordance with legal regulations in The Nctherlands. 
TEL Monkeys were irradiated with a single dose of 5 Gy TBI 
delivered by two opposing ~·ra)' generators opemling at a tube volt-
age of 300 k" and a current of 10 mAo The half·!ayerthickness wa, 
3 mill c..u. The focus ~kin distance was 0.8 m, and Ihe mean dose 
rate 0.20 to 0.22 Gy/min. During TBI, the animals were placed in 
a cylindril'al polycarbonate cage that rotated slowly (three times per 
minute) around its vertical iL"is. 
Er:perimental procedllre. Two week~ before TBI, the monke}'s 
were placed in a laminar-flow cabinet, and the gastrointestinal tract 
was selectively decontaminated by gi\'ing ora! Ciproxin (Bayer, Mij-
drechl, The Netherlands), nystatin (Sanofi, Maassluis, The Nether-
land,), and polymyxin B (Pfizer, New York, NY). This regimen 
was maintained until Jeukoc}te counts e~ceeded IO"/L. Systemic 
antibiotics were gh'cn when lcukoc)te counts were less than 10"1 
L, in most cases as a combination of Ticarpen lHe.:cham Ph:uma. 
Arnste\veen, The Netherlands) and Zinacef (Gla~o, Zei>t, The Neth-
erlands), as guided by fecal bacleriograms. Dehydr,lIion and ekctro· 
Iyte db-turbanl'es Were trealed by appropriate fluid and electrolyte 
administration subcutaneously. The monkc)'s received irradiated (15 
Gy) thrombocyte transfusions \Ihenever thrombocyte counL<; wcrc 
less than 40 x IO'/L and irradiated packed red blood cells whene\'er 
hematocrits were Ie<-s than 20~'(, and occasiunally. the monkcys 
r.:ccivcd whole blood tramfu>ion~ in l'a'>e of simultanC{lu~ occur· 
rence of both tr,m~fusion criteria. All monkc)'-, were bled for di~g:­
nostic purpo'e~. 7m!. before irradiation. 7 mL I\I!ce weekly during 
38 Chapter 3 
the first 4 weeks, and 3 mL once w~kly thereafter. 1hre.;, milliliters 
of bone marrow was aspir.ued tx-fore irradi~tion and once weekly 
for 6 weeks after TBI. The total blood volume of 3.kg monkeys is 
estimated 10 be 200 mL. 
TI.'51 dn/g. One milliliter \"ia]s containing 0.5 mgfmL nxombi-
nant [ull·length human TPO produced by CHO cells were supplied 
by Genentech Inc (Soulh San Franchco, CAl. The dose used was 
10 J-lglkgld ~ubcutancously once daily [rom day I 10 day 21 after 
irradiation (n = 4). Thre.:. monkeys received the ~ame dose for a 
second period of 7 days from day 52 to day 58 after irradiation. The 
daily doses were diluted 10 a volume of I mL with pho<;phate-
buffered saline (PBS)IO.Ol% Tween 80. Placebo·treated monkeys 
were only given the same volume of diluent (n '" 4), 
Ht'lI1afologic e.wmilwtioIl5. Complete blood cell counts were 
measured daily ming a Sysme.1: F-800 hematology analyzer (Toa 
Medical Electronics Co, Ko~, Japan). The differential of the total 
nuclcated cell, wa~ determined by standard counling after "tay-
Grunwald-Giemsa staining. For reticulocyte mea<;urements, 5 J-lL 
EDTA blood was diluted in I mL PBSIEDTA (5.0 moUL)/azide 
(O.OYl wt/\"ol) and 1 mL of a thiazole orange dilution was added, 
using thiazole in a final concentration of 0.5 J-lgfmL. Measurements 
were made on a FACScan (Becton Dickinson, San Jo>e, CAl and 
analyzed using the Reticount software (Becton Dickinson). 
lroll admillisrrarioll. Three monkey~ received iron supplementa-
tion. One monkey recei\·ed 0.5 mL Imferon (fe{IH) 50 mgfmL; 
Fio;on, Pharmaceuticals, Loughborough, England) for 5 consecutive 
days before irradiation, and two monkeys reeeiwd 3 mL in 10 days 
approximately 3 months after irradiation. Tmferon was given intra-
muscularly. 
Clinical chemis/ry. Serum lewl, of sodium, potassium, chloride, 
glucose, albumin, total protein, aspartate aminotransferase, alanine 
aminOlrunsferase, alkaline phosphata,e, lactate dehydrogenase iso-
type 1 (LOW), -y-glutamyl transferase, total bilirubin, C-re<lctive 
protein, creatinine, urea, and CO, were meawred twice weekly using 
an Elan Analyzer (Eppcndorf Merck, Hamburg, Germany). Total 
serum iron and tOlal iron-binding capacity (TIDC) were determined 
in r<'pre,entative stoTed serum samp\cs, and the percentage saturation 
was calculated. 
Pm/1I10rlt'/il material. As arranged with the e!hics commiltee for 
animal experiments operating at our university, all animals were 
eUlhani7ed at Ihe end of the study. ~Iost of !he animals were eu-
Ihanized at day 43 after iffiidiation by injecting 2 mL Eutha,ate 
(Apharlllo, Affihem, The Netherland,; p:'ntnlwbltal 200 mgfmL) intra-
venously. For two of the TPO·lreated monkeys, Ihe follow-up time 
was prolonged to further evaluate the aHemia, and for one placebo· 
treated monkey for other r<'a,ons. At the time of obduction, organs 
were fixed with 4<;~" paraformaldehyde, and about 24 hours later the 
material was em~dded in paraffin and slides were made stained 
with hematoxylin/eosin. Slides for iron staining were made from the 
paraffin-em~dded material. 
Statistics. If relevant, the mean :!:: SD \\'a~ calculated with the 
assllmption of a normal distribution. The significanc<' of a difference 
wa, calculated by one-way analysis of variance follo\\ed by a Stu-
dent's I-tesl. 
RESULTS 
Peripltemf blood celf COlli/Is. TPO was highly effective 
in alleviating thrombocytopenia after irradiation, and recov-
ery to nonnal values was significantly accelerated (Fig I). 
The dose schedule of TPO was ~upraoptimal, as is clear 
from the increa~e to supranormal thrombocyte counts in the 
third week of treatment. The kinetics of the thrombocyte 
re~ponse strongly suggests that TPO treatment during the 
fir~t week after TBi would have been sufficient for preven-
tion of thrombocytopenia. One week after ces~ation of TPO 
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Fig 1. Neutrophil (AI and thrombocyte (B) regeneration after 5 Gy 
TBI for TPO·tfeated monkeys la, n = 4) and placebo·treated controls 
(O,n=4). 
treatment, thrombocyte counts gradually returned to normal. 
TPO treatment was selectively effective in that neutrophil 
regeneration was not influenced (Fig 1), with values more 
than 0.5 X 109/L being reached at day 20 (range, 20 to 23). 
In addition, TPO had a prominent effect on red blood cell 
parameters. Reticulocyte regeneration, on average, was 10 
days earlier than in placebo-treated controls, and TPO-
treated monkeys developed a normoblastosis that was also 
earlier and much more pronounced (Fig 2). All monkeys 
developed anemia, partly due to diagnostic bleeding. The 
decrease in hemoglobin (lIb) concentration was similar in 
all monkeys until day 14 after TBI (Fig 3). TPO-treated 
monkeys showed less profound nadirs than placebo-treated 
controls, and Hb levels stabilized after the second week. 
However, the earlier stabilization of Hb levels was not re-
flectcd in an earlier recovery to normal values. Instead, TPO-
treated monkeys de\'Cloped a sustained anemia, whereas pla-
cebo-treated monkeys were able to recover 10 subnormal Hb 
levels at the end of lite observation period (6 weeks) (Fig 
3). The anemia ofTPO-treatedmonkeyswasmicrocytic(Fig 
4) and hypochromic (Table I) in nature. The difference in 
mean cell volume (MeV) kinetics is most apparent if the 
data set of each monkey is shown individually. The MeV 
ofTrO-treated monkeys showed an initial increll-~e that coin-
cided with the reticulocyte recovery and was followed by a 
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Fig 2. Reticulocyte regeneration (AI and the appearance 01 nor· 
moblasts t81 after 5 Gy T81 for TPO·t.eated monkeys ,a, n '" 41 and 
placebo·treated controls to, n '" 41. 
gradual decline in the fifth and sixth weeks of treatment, 
whereas placebo·treated monkeys all had an increase in 
MCV values from the third week onward, also coinciding 
with reticulocyte recovery. Mean cellular Hb (MCH) was 
also decreased in TPO-treated monkeys in the sixth week 
after TBI compared with pretreatment values, whereas in 
placebo-treated monkeys MCH values remained constant 
(Table 1). 
TPO redml/eng£' alii! iro1l5l1pplemellfalioll. To examine 
the effectiveness of TPO after myelosuppression without 
limited iron supplies, one monkey was given intramuscular 
(1M) iron during the week before TBI, followed by TPO 
treatment. TIle nadir for Hb and hematocrit was similar to 
those of the four monkeys treated with TPO earlier, but the 
iron-treated monkey had a regeneration of Hb levels much 
earlier than the other TPO-treated monkeys and the placebo 
controls (Fig 3) and did not develop a microcytic anemia. 
Thrombocyte regeneration of the iron-treated monkey was 
in the range of that for the four monkeys treated earlier 
(Fig 5). In an extended follow-up period, two TPO-treated 
monkeys and the single TPOliron-treated monkey were re-
chal!enged with TPO in week 8 after TBI, after which a 
thrombocyte production response similar to that reported for 
normal nonhuman primates occurrt:d '5 (Fig 5). All monkeys 
had a small but significant increase in reticulocyte counts, 
which only in the iron-treated monkey was followed by a 
small increase in Hb levels after an initial decline due to 
diagnostic bleeding. In the other two monkeys, Hb levels 
stabilized. Subsequent 1M iron administered to the latter ani-
mals over a period of 10 days in the third month after TBI 
resulted in a prompt increase of Hb and hematocrit levcls 
(Fig 6) and a correction of anemia. 
Clil/ical parameters and transfusion requirements. The 
number of febrile episodes wa.~ not different between the 
two groups. Normal a,>;illary body temperature in rhesus 
monkeys is 39~C, and fe\'er is defined as a morning tempem-
ture more than 40'C. TPO-treated monkeys had 3.7 :t 2.9 
days with fever, and placebo-treated controls 4.~ :t 3.5 days, 
statistically nonsignificant (P = .76). 
Since iron contained in blood transfusions might confound 
our results, the transfusion requirement of the monkeys is 
also presented. TPO-treated monkeys did not receive any 
blood products during the experiment. All placebo-treated 
monkeys received several thrombocyte transfusions, which 
are not considered to contain significant amounts of iron. 
11rree of four placebo-treated controls received a whole 
blood transfusion at days 15,21, and 26 after TBl, respec-
tively_ This is too late in the time course to account for the 
difference in the Hb nadir occurring in the third week after 
TBI. 
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Fig 3. Hb levets (AJ and hematocrit (8) alter 5 Gy TBI for TPO-
treated monkeys la, n '" 41, ptacebo·treated (ontrols to, n = 41. and 
one Iron-pretreated TPO·treated monkey {AI. 
40 Chapter 3 
A 90 
85 
80 
75 
70 
~ 65 TPO B 60 U 90 ;;; 
85 
80 
75 
70 
65 placebo 
60 
0 7 14 2t 28 35 42 
time (day) 
fig 4. Mev after 5 Gy T81 for lPO-treated monkeys (AI and pia-
cebo·treated controls (B), Each line represents an IndivIdual monkey; 
bold line, Iron'pretreated lPO·treated monkey. 
Clinical chemistry'. TPO-treated animals showed in-
creased serum LDH I levels due to the rapid but insufficient 
erythropoiesis. However, the iron-pretreated monkey did not 
display this elevation in LDH I levels, and the nomlOblastosis 
Tabla 1. Senrm IronfTlBe, Total Serum iron, and MCH Following 
TBI 
Parameter P'ei'radiation Oa), 14 Da)' 2a Day 43 
Serum iron/TIBC (%) 
TPO 27 ± 12 35 :!: 8* 12 :!: 7 6 ± Itt 
Placebo 31 ::': 13 62:!: 11t 30 ± 19 17 ::': 8 
Serum iron lpmoVL) 
TPO 21 ::': 8 28 ± 8* 10:;: 6 5:!:lH 
Placebo 22:!: 8 41 :!: Bt 21 :!: 13 11 ± 4 
Iron/TPO 39' 31 23 
" MCH (amol) 
TPO 1,508.:! 94 1,464 -;;; 141 t,427::': 113 1,210 .:! 255 
Placebo lA37.:! 61 1,393.:! 64 1,471 .:! 67 1,456.:! 75 
TPQ-treated monkeys, n .- 4; placebo-treated monkeys, n = 4; iron! 
TPO (monkey treated with iron before irradiation and TPO after irradi-
ation), n = 1. 
• After iron supplementation. 
t Statistically significantly different from preirladiation, P < .05, 
t Statistically significantly different from time-matched placebo-
treated mon~eys, P < .05. 
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Fig 5. Effect of a rechaHenge with TPO (to 1-'9/kgld) from days 52 
to 58 in th'ee monkeys on thrombocytes tAl, rellculocytes tal, and 
Hb Ie). Two TPO-treated monkeys to, 0) and one iron-pretreated, 
TPO-Ireated monkey Ill}. Black Hnes, duration of TPO treatment. 
seen in TPO-Ireatcd monkeys was also reduced in this mon-
key (data not shown). 
To assess the iron status of the monkeys before and during 
thempy, total serum iron and TIBC of representative stored 
serum samples were detemlined. Iron saturation wa~ 27% ::'::: 
12% hefore irradiation, but decreased to much lower levels 
6 weeks after irradiation (6% ::'::: 1 % for TPO, P = .W; 17% 
::'::: 8% for placebo, nonsignificant). The difference between 
TPO- and placcbo-treated monkeys at week 6 is also signifi-
cant (P < .03; Table 1). Serum iron followed a similar 
pattern in that at day 14 free semm iron was higher, probably 
due 10 diminished iron uti1i7.atioll in the initial period after 
TFH during which Clythropoiesis wa~ profoundly suppressed 
(Table I). In the iron-pretreatcd monkey, lotal serum iron 
also decrea~ed steadily after 'I'm, but not to a degree suffi-
ciently severe to induce anemia. In TPO- and placebo-treated 
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Fig 6. Effect of Iron treatment in two anemic TPO·treated mon-
keys. {AI Hb level; (BI hemetocrit. Iron was administered at the indi-
cated time poInts. (6) Correspond with the monkey representedwi\h 
(01, and (A) with (_I. At the Indicated time poInts, 30 m9 FeUIl) was 
administered. 
monkeys, iron storeS were not detect3ble in bone m3rrO\\' 
slides stained for iron (dat3 not shown). 
DISCUSSION 
TPO wa~ effective in slimulating thromboq1e recovcry 
3fter a myelosuppressive exposure to TBI 3nd fully pre-
vented Ihe development of thrombocytopenia. An efiect on 
neutrophil regeneration W3S not observcd. TPO nlso promi-
nently stimulnted the ef)1hroid lineage, an effect that oc-
curred very enrly nfter irradiation: exponentinl reticulocyte 
regenerntion started after the first week of trentment. 10 days 
earlier than in placebo-treated controls. TIle reticulocytosis 
was foliowed by a nomlOblastosis accompanied by elevated 
LDH serum levels, attributed to the rapid and probably inef-
ficient ef)'lhropoiesis. As a result, Hb levels and hemntocrits 
stabilized earlier at higher levels. However, in TPO-treated 
monkeys, signs ofa microcytic hypochromic anemin became 
apparent after the third week, suggesting depletion of iron 
stores. In this study, the development of iron deficiency dur-
ing TPO treatment was directly confinned, ns was its correc-
tion by Il'vl iron treatment and prevention by prophylactic 
fI\.·f iron. 
111e kinetics of serum iron and TIBC displayed an initial 
increase during the 2 weeks after TBI, which is explained 
by a lack of iron utilization due to myelosuppression. This 
increase is particularly prominent in the placebo-treated 
monkeys, but is a\.so statistically significant in the TPO-
treated monkeys (Table 1). The smaller increase of serum 
iron measured on day 14 after TPO compared with the pla-
cebo control levels is attributed to the early onset of ef),thro-
poietic reconstitution in TPO-treated monkeys. The subse-
quent decline in serum iron and semm ironfTIBC is larger 
in TPO-treated monkeys, resulting in vef)' low levels and a 
state of iron deficiency at the end of the observation period 
of 6 weeks Cfable 1) in TPO-treated monkeys. It is not 
exeluded that the iron deficiency essentially originated from 
a precarious iron balance in rhesus monkeys, similar to hu-
mans, resulting in latent iron deficiency already present be-
fore mdiation exposure. This is more likely. since the MCV 
in the animals before irradi3tion was 75 to 80 and increased 
to 90 in the animal subjected to iron supplementation. The 
latent iron deficiency may then be caused by diet, malabsorp-
tion due to the preirradiation antibiotic regimen, or some 
other process related to iron absorption. 
Three TPO-treated monkeys. two without iron supplemen-
tation and one provided with prophyJnctic 1M iron before 
TBI, were rechallenged with TPO in week 8 after TBI after 
full recovery frol11l11yelosuppression, and showed a homoge-
neous stimulation of thrombocyte production. This indicated 
that (I) the effect of TPO on thrombocytes is independent 
of iron status, since only the iron-pretreatcd monkey had a 
demonstrated nonllal iron status at that time point. and (2) 
the variation of the TPO response following TBI should not 
be attributed to individual sensitivity of the animals to TPO. 
Rather, this should be attributed to a variation in the number 
of residual TPO target cells following TBI, possibly due 10 
individual sensitivity to radiation. The rechallenge experi-
ments also demonstrated a differentinl reticulocyte response 
to TPO early and late after TBI. Although the platelet re-
sponses were similar in magnitude. reticulocyte responses 
were much diminished upon rechallenge (Fig 5). This may 
reflect either multiple target cells ofTPOandlorinvolvement 
of gro\\1h factors olher than TPO in the reticulocyte re-
sponse. TIle magnitude of reticulocytosis upon rechallenge 
was roughly inversely proportional to the Hb level, indicat-
ing an effect codependent on ef)'lhropoietin. 
Iron supplementation to two anemic monkeys proved to 
be effective in treating anemia. Iron prophyla'i:is before TBI 
completely pre\'ented microcytic anemia and lib levels 
quickly retumed to nomlal, further demonstrating Ihe pro-
nounced effect of TPO on red blood cell reconstitution in 
the initial phase after TBI. 
Multilineage effects, including the ef)'throid lineage, of 
TPO have been shown in vitro and in \'i\"o.'''·II·I~.I~ In nomlal 
mice and primates, TPO selectively stimulated thrombocyte 
production. leaving other lineages unaffected. In myelosup-
pression models, multilineage effecLs were mainly of an cr),-
throid nature.I~.I~.19 Since megnkaf)'ocytes an.' capable of re-
Ie'lsing \'arious growth factors,:-"·~I the effect observed may 
be an indirect consequence of stimulation of the megakaf)'o-
cytic lineage. This does not exclude a direct effect of TPO. 
since erythroid progenitors have been shown in vitro to be 
directly stimulated by TPO." The iron depletion of TPO-
42 Chapter 3 
treated monkeys is reminiscent of erythropoietin· induced 
iron deficiency anemia in patients with end-stage renal fail-
ure.n.24 A similar mechanism is proposed for the iron defi-
ciency anemia occurring in the present study. Supplementa-
tion of iron before and careful monitoring during treatment 
proved to be necessary for all patients receiving erythropoie-
tin. It is conduded that TPO therapy to counteract thrombo-
cytopenic stales is highly effective to prevent thrombocyto-
penia, and that its beneficial effect on erythroid regeneration 
may be hampered by iron depletion. Therefore, the iron sta-
tus should be carefully monitored in case of therapeutic TPO 
administration. 
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The Efficacy of Single-Dose Administration of Thrombopoietin 'Vith 
Coadministration of Either Granulocyte/l\!Iacrophagc or Granulocyte 
Colony-Stimulating Factor in l\:Iyelosuppressed Rhesus IVlonkeys 
By Karen J. Nealis, Simone C.C. Hartong, Torstein Egeland, G. Roger Thomas, Dan L. Eaton, 
and Gerard Wagemaker 
Thrombopoietin (TPO) was evaluated for efficacy in a pIa. 
cebo-controlled study in rhesus monkeys with concurrent 
administration of either granulocyte/macrophage colony· 
stimulating factor (GM·CSF) or granulocyte CSF, (G·CSF). 
Rhesus monkeys were subjected to 5 Gy total·body Irradia· 
tion (TBII, resulting In 3 weeks of profound pancytopenia, 
and received either TPO 5 p.g/kg intravenously (lVl at day 1 
(n "" 41. GM-CSF 25 p.g/kg subcutaneously (SC) for 14 days 
(n = 4), TPO and GM·eSF (n = 4), G·CSF 10 Ilg/kg/d se for 
14 days (n = 3), TPO and G-CSF In "" 4), or placebo (carrier, 
n = 4; historical controls, n = 8). Single·dose IV treatment 
with TPO 1 day after TBI effectively counteracted the need 
for thrombocyte transfusions {provided whenever thrombo· 
cyte levels were <40 x 109jLJ and accelerated platelet recon-
stitution to normallevefs 2 weeks earlier than placebo con· 
trois. TPOjGM·CSF was more effective than single·dose TPO 
alone in stimulating thrombocyte regeneration, with a less 
profound nadir and a further accelerated recovery to normal 
thrombocyte counts, as well as a slight overshoot to su-
pranormal levels of thrombocytes. Monkeys treated with 
TPOjGM·eSF uniformly did not require thrombocyte trans-
fusions, whereas those treated with GM-CSF alone needed 
two to three transfusions, similar to the placebo·treated 
I DENTU;lCATION of thrombopoietin (TPO)I.~ as the ma-jor regulator of thrombocyte production~'~ ha~ resulted 
in novel insights into the regulation of immature hematopoi-
ctic cell differentiation,7-9 and has potcntially provided a ther-
apeutic approach to countcmctthrombocytopenic Slates, par-
ticularly those a~sociated with inten~i\'e c)1oreducti\'C 
treatment of malignancies. Its pharmaceutical development 
for the latter application rcquires demonstration of 
efficacy in experimental animal models alone and in COll-
junction with other cytokines. In view of the generally com-
plcx receptor distribution patterns of growth factors,I"-12 in-
teractions resulting from concurrent administration of the 
growth factors are difficult to predict by any approach other 
than detailed experimental animal in vivo studies. We have 
presently focused on growth factors that are likely to be used 
dink-aUy with TPO, ic, granulocytc/macrophage co!ony~ 
stimulating factor (GJ\I~CSFJ and gmnulocyte CSF (G-CSF). 
In previous studies in myelosuppressed mice and rhesu~ 
monkeys, a supraoptimal dose of human Tro with or with-
out concurrent administration of G-CSF was found to pre-
vent thrombocytopenia, accelcrate platelet and red blood cell 
reconstitution, alieviate neutropenia, and promote recovery 
of immature bone marrow celis.I.1·II; The latter observation 
was unexpected, but was consistent with the demomtration 
ofTPOreceptorsonimmaturehematopoietiecells?andwith 
more recent reports on stimulation of immature cells by 
TPO.~'~ TPO abo effectively promoted the nelltrophil rc-
~pome to G-CSF, an effect thought to be mediated by TPO-
stimulated bone marrow progcnitor ccll cxpansion. 
Myelosuppression is a serious complication of current 
chemotherapy regimens, resulting in life-threatening neutro-
penia and thrombocytopenia and hampering fuB deployment 
monkeys, which required, on average, three transfusions. 
Also, reticulocyte production was stimulated by TPO and 
further augmented in monkeys treated with TPO/GM-CSF. 
TPO alone did not stimulate neutrophil regeneration, 
whereas GM-CSF shortened the period of neutrophil counts 
less than 0.5 x 109Jl by approximately 1 week; TPO/GM-
CSF treatment elevated the neutrophil nadir, but did not 
further accelerate recovery to normal values. TPO also auge-
mented the neturophil response to G-CSF, resulting in simi-
lar patterns of reconstitution following TPOjG·CSF and TPOj 
GM·CSF treatment. TPOjGM·CSF resulted In Significantly In-
creased reconstitution of C034+ bone marrow cells and pro· 
genitor cells such as GM·eFU and BFU·E. Adverse effects 
of combining TPO with the CSFs were not observed. It is 
concluded that (1) a single IV administration of TPO is suffi-
cient to prevent severe thrombocytopenia following myelo-
suppression, (2) TPO/G-CSF and TPO/GM·eSF treatment re-
sult in distinct response patterns, with TPOjGM-CSF being 
superior to TPOfG-CSF in stimulating thrombocyte and 
erythrocyte recovery while being equivalent in stimulating 
neutrophil recovery; and 131 TPO significantly Improves the 
performance of CSFs In alleviating severe neutropenia. 
£) 1997 by The American Society of Hematology. 
of anticancer thempy. Both G-CSF and GJ\I-CSF treatment 
have become established therapyI9-2' to alleviate the cytope~ 
nia, particularly the neutropenia resulting from intensive cy-
toreduc6ve treatmenl.11 Although G-CSF and GJ\I-CSF are 
grossly similar in the phamlUceutica[ profile,)j~' G;-'I-CSF 
ha~ advantages in that it also stimulates megakaryoeyto-
poiesis and monocyte differentiation.~~27 In addition, G-CSF 
was found to dampen thrombocyte production. This was also 
observed in a transplant model in rhesus monkeys,"" as wcll 
as after TPO and G-CSF treatment of irradiated mice.l~ The 
beneficial effects of both G~l-CSF and G-CSF on neutro-
penia following c),tor.-:ductive treatment are in JIlost studies 
restricted to approximately a S-day earlier recovery, or less 
in dose-intensified chemotherapy/12,.2" for a total median 
neutropenia of about 20 to 25 days. It is therefore of consid-
From/he Im/i/flteojH<'IIIlI/ofogy. EmmlUS Ullirl'nily ROI/.'rdalll, 
Roltcrdfllll. Th.' N,'lh"r/mli{l: Il1IliWI" of TnIllIpf(lll/(//ioli IIII/JIII/wl-
ogy. Oslo. Nonray: alld GI'I/ell/I'eil Inc. SOIllII Sail FflIllci5co. CA. 
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crable importance to select combinations of growth factors 
that provide optimal costimulatory efficacy. 
TIle study was undertaken (1) to explore the option of 
limiting the total dose of 'fPO, based on previous studies in 
mice3Q showing that a single administration of TPO l11ight 
be sufficient to prevent thrombocytopenia following cytorc~ 
ductivc treatment; and (2) to compare concurrent administra-
tion of TPO and GJ\l-CSF versus TPO and G-CSF, and to 
identify optimal growth factor ther-apy to counteract both 
neutropenia nnd thrombocytopenia. The study involved rhe-
sus monkeys exposed to 5 Gy lotal-body irradiation (TBI), 
which results in a profound pancytopenia for 3 weeks, and 
usc of an optimal do,e of TPO on the first day and G-CSF 
or OM-CSF treatment for the first 14 consecutive days after 
TBI. On-study parameters included, lIpart frum blood cell 
counts, assessment of immature bone marrow cells and mon-
itoring of auvehc effects. 
MATERIALS AND METHODS 
AI/il/wh. Purpose-bred male rhe,us monkey~ (MacaC<l IIm/lll1a) 
weighing 2.5\0 4.0 kg and aged 2 to 3 yeJrs were u,eQ, The monkcys 
were hou,ed in gwups of 4 to (, in stainle~s steel eag<".> in ruoms 
with a re\'erse-filter<"d air bJIrier, normal daylight rh) thm, and eondi-
tionet! to 20'C with a relative humidity of 70~~. Animals were fed ad 
libitum with commerdal primate chow and fre,h fruits and ~ei\'ed 
acidified drinking \\atu. AI! animals were free of intestinal p:lfa,itc, 
and were seronegatil'e for herIX" B, simian T-Iymphotrupic virmes 
llild simian immunodeficiency virus. TIle animal hOll~ing, e~p<'ri· 
menb, and all uther conditions were approvcd by an ethics commit· 
tee in confonnity with legal regulations in Th<" Neth<"rlamk 
TBI. Monkeys were irr"dialed with a single d(\<e of 5 Gy TBI 
delivered by two opposing x-ray generators op<'r:l.ting at a tube volt-
age of 300 kV amI a cumot of 10 rnA. TIle half-Ia)'er !hickne~\ was 
3 mill Cu. The focu, ~kin di,tance WlI'> 0.8 m and the average dose 
rati: 0.20 to 0.22 Gy/min. During TBI, the animals were placed in 
a c)'lindrical pol)'calbonate cage that rotated slowly {three (imes per 
minute) around its lertie-al axi~. 
SlIppvrtil'e mr.'. Two weeks lx-fore TI1I, the monl..eys weri: 
placcd in a laminar·tlow cabinet, and the gastrointeltinaltrad wa, 
selectively decontaminated by admini<;tering oral ciprotlo:»aein 
(Hayer, Mijdrccht, The Netherlands), nystatin (Sanofi, Maas~luis, 
The Netherland~), and polymyxin B (Pfizer, New York, NY). Thi\ 
~ghnen was supplemented with sy,temie antibiotics, in mm! cases 
ticardllin (Beecham Pharma, Amstel\-een, The Netherlands) und ce-
furu~im (Gla.\o, Zeht, The Netherlumh), \\hen leukocyte counts 
were Ie" than IO"/L. Guidcd by fecal bacteriograms, antibiotic'S 
were continued untilleukoc)'te counts incremed to more than IO"/L. 
Deh)'tirJlion and eleclrol),te dilturbances were treated by appropriate 
fluid and clectrolyte admini,tration ~ub<:ulaneously (SC). The nlOn-
keys received irradiat~d (15 Gy y-irrauialion) platelet tran,fu,ions 
l\helleVer Ihromboc}te counh were less than 40 x lo"lL, parl-ed 
red blood l'elh whcnever hematQ(:rit, were leIS than 20~~, and, occa-
sionally, \\hole-blood lransfulions in ca,e of coincldenC<:' of both 
twn~fu,ion criteria. The criterion of IramJusion of thrombocytes at 
counts le>~ than 40 X IO"IL was ~ho~en b.; .. ',lIlle monke)s already 
develup a proponlity 10 potechiae aod other hemorrhage~ at this 
levcl. The,e arc l\,<;ociated \\ith mortality at the midlethal Jose of 
radiation u"ed.-"-" 
. T.'}/ ,Img... Re"'ombinunl full-length rhe,u\ monkcy TPO pro· 
duced hy Chine<,e ham<;\er Olar)' cells \\iJ.~ ~upplietl by G<"n~nte"'h 
Inc (South San FrJIle[,cu, CAl. The dOle uled wa, 0.5, 5, or 50 I,g/ 
kg IV on day I after TBI. The do,e wa, diluted to a volume of I 
ml. with pho,phate·buffered ~a1ine (PBS)f().OI'J, TI\een 20 b.ofore 
administration. Placebo·treated monkeys were only giwn the same 
volume of diluent. Recombinant human G·CSF (Neupogen; Arngen 
InL', Thousand Oaks, CAl \\'a5 administered at a dose of 10 pglkgf 
d SC once daily during days I to 14 after TBI. Recombinant human 
GM-CSF (Leukine; Immune.\ Corp, Se<tltle, WA) was giwn at a 
dose of 25 pglkg/d SC once daily dUling d<lYS I to 14 after TBI. 
The daily dose~ were diluted (0 a ,-oilime of I mL in the solulion 
indicated by the suppliers. 
TPO lel"<'ls. Serum for meao;;urement ofTPOlcvels\,assampled 
from thc monkeys 24 hours after cytokine adminislratiun and stored 
at -20T. A ful! d~scription of the TI'Oenlyme-lillk~d im1l1unosor-
bent a<.~a)' (ELISA) has been reported elsewhue.3-l--'5 Brielly, ELISA 
plates were incubated overnight at.j'C lI'ilh 2 pglmL rabbit F(ab')2 
to human IgG Fe (Jack,on ImmunoRe,earch, West Grow, PA) and 
2 hours at room temperature with conditioned medium containing 
100 ng/mL mpl_IgG. 1 Twofold serial dillilions of samples (starting 
at I; 10) and standards (recombinant full·length human and/or rhesu, 
TPO) were added to wells and incubated for I hoor. Bound TPO 
was detected u,ing biotinylated rabbit antibody to fUll-length human 
TPO (Genenteeh), followoo by p<'roxidll'>e-Iab<'led ~lreptal'idin. The 
range of the assay for rhesus ,erum ,amples is 0.32 to 10 nglmL 
TI'O. Thc a,say preferentially detects aetiw full· length TPO, rhesus 
TPO equally as \\ell as human TPO, and correlates well with a 
bioa"ay u,ing the megakar)'oblastic HU·j cell line. 
S/JIdy grollps. Monkeys wae randomly ;b,igned to lhe treatment 
groups and received either rhelus TPO IV on day [ after TBI at a 
dOle of 5 I'g/kg (n = 4), 0.5 pgfkg (n = 2), or 50 I'g/kg (n '" I), 
G:-'I-CSF at a dus<" of 25 pg/kg/d SC from days I to 14 (n = 4), 
TI'O and GM·(,SP ("fPO/OM·CSF, n = 4), G·CSF at a dose of \0 
pglkgld SC (n = 3), TPO llild G·CSF (TPO/G-CSP, n = 4), or 
placebo (n = 4; hhlorica! controls, n = 8). The TPO dose of 5 pgf 
kg on day I after TBI \\iJ.\ administered to the monkey, Ihnl al,o 
re.:eil'ed GM-CSF or G-CSF SC for 14 consecutive da)',. 
/1ol1e marrow (!5pimle" Bone marrow was <Llpirated under neu-
roleptic ane,thesia using Keta!ar (Aphanno, Amhem, The Nether-
lands) and Vetranquil (S~nofi, Ma:l.<;~lui\, The Netherlands). Small 
bone marrow ~pirates for analytical purposes were taken from the 
shaft of Ihe humeros u,ing podiatric spinal needles and collccted in 
bott!cI containing 2 mL Hanks bufiered HEPES solution (HHHS) 
\\"ith sodium hep3rin 200 IU mL (Leo Pharmaceutical Products, 
Wee-lp, The Netherlands). Low.densit)' cells were isolated uling 
Fil"oll ,eparation (den,ity '"" 1.077; N)'t"omed Pharnw, Oslo. Nor· 
way). 
C%nyassays. Cells were plated in 35·mm dish~s (Becton Dick-
inson, Leiden, The Netherlandl) in I Ill!. u·D:-'IEM (GlBeO, Gaith-
er,burg, MD) containing O.8~-i-, methykellulo,<", 5~< fetal calf ~erull1 
(FCS), llild additives as d~scrib~d prel'iOll\I)'.~'-" For bllrst-fOflning 
units-erythroid (I1FU·Ej, culturc~ wefC supplemented with hemin (2 
x 10 'mollL), humm r<"combinant el)'thropoietin (4 Uillll; Behring, 
G~mlany), and Kit ligand (\KL) 100 ng/mL; kindly provided by 
Dr S. GiIIi" Immune:», Scaltle, WA). For gmnulocyte/macroplwge 
colony. fanning units (GM-CFU), cultures were supplemented with 
recombinant hUllwn GM-CSF (5 ng/mL; Behring), recombinant rhe-
sus monkcy interlcukin·3 (30 ng/mL) produad in Bat'll/ItS Nelll'lIi-
jan!lis and purified as desc'ribed pre\'iou,!y,H.~) and KL. Low·density 
cells were plated al 5 x 10' por di,h in duplicate. (,olony counts 
were calculuted per milliliter of hone marrow a<.pirated ming the 
recowry of cel1\ owr the Heol! density gradient. Colony numlx-rs 
repre,ent the mcan :!: SD of bonc marrow ~ampl<,,~ of individual 
monkeys . 
Heillatolugic £.WlllillaliullS. Cumplete blood cell counts were 
measur<"d daily u>ing a Spllle:>; F-SOO hematology an~l)7er (Toa 
Medical Eltttronics Co, Kobe. Japan). The differentisl of the nude-
ated cells \\as d~tenllined by '<;I~ndard counting after ~la}'.GriJnwald­
GieJl1~a ~Iaining. For reticuloc)te mealurement~, 51'L EDTA blood 
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FIg 1. Thrombocyte counts after 5 Gy TBI (day 0) for monkeys 
treated with TPO 5 /19 ,a, n .. 4), TPO 50 1'9 IOJ. TPO 0.5 1'9 10, n 
= 2), and the concurrent placebo treatment Ill, n '" 4), Th& lower 
shaded area represents Iha mean::': SO of 12 conlrol monkeys; the 
upper shaded area Is the mean .:t SO of 4 monkeys treated with 
human TPO for 21 days after Irradiation. Data represent the arithme-
tic mean ± SO of the yarlous treatment groups. The horizontal line 
defines the level of thrombocytopenia 140 x to',ll below which 
thlOmbocyte transfusIons are given. 
lIas diluted in I mL PBSIEDTAialido- and I mL [hiamle orunge 
dilUTion wa~ added. u,illg thiuzole at II final concentration of 0.5 pg/ 
mL. Measurements were made on a FACSran (Be<.:lOn Dkkin,on, 
Leid~n, The l\'Nhaland,) and ;malYled u,ing: th~ Reticoun! softwar ... 
'\/{'mllrenlent of ,\llrjr/(t' /111/('1,'1/1. Once weekly, it FACScan 
liIlalrsi~ IVa, made on peripher,.t\ blood and bone mnrrow ~al\lple, 
on the folluwing ~urface antigens: CDS, Cf)·J, C020, COllb, C056, 
COI6, and CDll Directly labded monocional antibodies (~loAbs) 
\\'~re ll>ed for CD8, CO..!, CD20, C056, and COl6 (Leu 2a·FlTC, 
Leu 3a-PE. Leu 16-PE, Leu 19-I'E, and Leu I JaflTC IBe.:ton Did:-
inson], res~ctively). For CDllb, the "loAb "!OI·RTC (Coulter 
Immunology, Hialeah, FL) was used. and for CD34, un MoAb 
again,t human C034 (MoAb 566) that had been fiuore,ceinated 
with rITe (Sigma, St Louis, ,\10) according to ~tnndard procedures. 
Whole blood or bone marruw (a.S mI.) wa~ \)"ed in 10 mL I) sing 
solution (8.26 g ammonium chloride, 1.0 g potil."ium bic.lrbon~te, 
ami OJJ31 g EDTA pN liter) for 10 minute~ at 4'C. After Jy~i~, the 
<'ell .. were \\a.,hed twice \\ith HHBS containing 2'1 FCS und O.OS~( 
(\\1/\'01) sodiulll azide (HFN). The cell, wcre rcsu,pended in 100 
ilL HI'N containing 2~}, normal monkey ~erull1 to prevent "'ipecific 
binding of the MoAb,. MoAbs were added in a \'olume of 5 ilL liIld 
ilieubJted for 3U minute, on ke. After two wa.,he" the <:<,11> \\'<'f<' 
measur<,d on the flow cytometer. Ungated list· mode data were col-
lected for 10,000 events and an~lyzed u,ing the Lysis II softwJre 
(Becton Dickinson). 
Statis/ifS. Standard dc\-iations \\ere calculated and are presented 
in the text and figures on the assumption of a nomlal distribution. 
The significance of differences wa, c~1cuJated by Fisher's exact test 
for categorical data, and for continuous dutu by a one· way an31ysis 
of vari~nec followed by a nonp~ired Student's /·test. 
RESULTS 
Dose of rhesus monkey TPO alld pl/llem of thrombocyte 
recomlilllfion. Based 011 data in normal monkeys~! and ex-
tnlpolation of doses used in mice,") as well as the supraopti-
mal dose of 10 pglkg human TPO in a previous study ,I~ a 
single IV dose of 5 pglkg rhesus monkey TPO at day I after 
TBI was considered optimaL TIle thrombocyte regeneration 
of four monkeys treated in this way is shown in Fig J in 
comparison to placebo controls and the previous data on 
human 'fPO administered for 21 consecutive days at a dose 
of 10 flglkg/d. TIle data for the four concurrent control mon-
keys have been included in Fig I in addition to Ihe eight 
historical controls; significant differences wer~ nOI observed 
in the regcnemtion patterns of any of the blood cell lineages 
between these !lroups of controls, The single·dose treatment 
was effective in that the four TPO-treated monkeys needed 
only two thrombocyt~ tmn~fusions (one in each of two mon-
keys), as opposed to the four concurrent placebo controls, 
which needed a total of 13 transfusions (mean, 3; ran!le, I 
to 6) since their thrombocytes had decreased to less than 40 
x 1O~1L; this is statistically significant (I' < .0..\; Table I). 
In addition, TPO-tr~ated monkeys displayed a dearly lICCel-
crated thrombocyte reconstitution and reached normal 
Ihrombocyte levels 2 weeks before the placebo·treated con-
trols (I' < ,03). 
To validate the choice of Ihe dose of 5 pglkg IV further, 
one monkey was trealed with a IO-fold higher dose lind two 
monkeys with a lO-fold lower dose. The results are also 
presented in Fig I. Rhesus monkey TPO at the single dose 
of 50 pgJkg IV was effective in preventing thrombocyte 
tran~fusions, with a nadir for thrombocytes of 75 x lO~/L 
at day 13. Thrombocyte reconstitution following this dose 
precisely coincided with the mean values for monkeys 
trented with the 5-pg/kg dme, on which basis we considered 
thai the latter dose provided the maximal stimulation to be 
expeded from a single admini~lration of TPO I day after 
TBI. Monkeys treatcd with 0.5 pglkg both had nadirs lower 
Table 1. Transfusion Requirements and Blood Cell Regenerallon Alter 5 Gy TBI and Growth Factor Treatment 
Trootmonl 
TPO 
TPa + GM-CSF 
TPO + G·CSF 
GM·CSF 
G·CSF 
Placebo 
/10. of 
Monle'/> 
3 
4 
No_ 01 
lran,fusTons 
0:0/1/1' 
O:O,'{J,'O' 
OiOJ1iO~ 
3.'21'l12 
t/2/t 
3/6/3/3 
Data for individual monhys or the mean::': SO are shown. 
Thrombocyte, 
>40 x 10",1. (d) 
NA 
NA 
NA 
t3.2.!. 1.7 
13.3::': 1.5 
19.5:':: 7.0 
Abbreviation: NA, not applicable, ie, level <40 x 10'{l not reached In the majority of monkeys. 
'Statistically significantly different from placebo·treated monkeys (P < .05). 
Retkulocyte, Neutrophil, 
>1%(d) >05:0< 11)'/L(d) 
14.2 .!. 3,6' 21.5 .!. 2.4 
10.5::': l.r 14.5::': 2.6' 
13.2 ;I: 2.6' 14.2::': 1.2' 
16.2::t 2.5' 17.7:':: 2.2' 
17.3.:':: 0.6 19.7 .!. 3.2 
20.5::': 2.1 22.5::': 2.4 
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than 40 x 109/L, and needed one and two thrombocyte trans-
fusions, respectively. providing a further validation of the 
dose of 5 Jlglkg as being close to the minimum required for 
a maximal response. 
TPO lel'els. TPD levels were measured in serum col-
lected 24 hours after cytokine administration (day 2 after 
irradiation), and for some monkeys also in samples taken 
later in the first week after irradiation. Leyels measured were 
1.9 :!:" 0.5 nglmL for TPO-treated monkeys and 2.5 :!:: 0.4 
for monkeys treated with TPO and G-CSF or GM-CSF; this 
difference is not significant. TPO levels were not different 
for monkeys treated simultaneously with either TPO/G-CSF 
or TPO/GM·CSF. Levels at day 3 or 4 were just above the 
detection limit of the assay (31.2 pglmL in a 1:10 dilution) 
at about 0.4 ng/mL in some monkeys, and below the detec-
tion limit in others. 
Comparisol/ of peripheral blood cell COl/illS ill monkeys 
treated with TPOIGM·CSF and TPOIG·CSF. In contrast 
to monkeys treated \\'ith TPO alone, of which two needed a 
single thrombocyte transfusion, monkeys treated with TPO/ 
GM-CSF remained completely transfusion·free and showed 
an even more elevated nadir, with two of four monkeys 
never reaching thrombocyte levels less than 100 x J09/L. 
GM·CSF 
G·CSF 
time (day) 
fig 2. Thrombocyte counts alter 5 Gy TSI (day 0) for monkeys 
treated with TPO (., n = 41. TPO/GM·CSF [~, n = 4), or GM·CSF to, 
n = 4) In the upper panel and TPO/G·CSF /"1, n = 41 or G·CSF to, n 
= 3) in the lower panel. Data represent tha arithmetic mean:': SO of 
the various treatment groups. The horizontal line dafines the level 
of thrombocytopenIa {40 x 10~/ll below whIch thrombocyte transfu· 
slons are given. 
time (day) 
fig 3. RetiCUlocyte regeneration after 5 Gy Tal {day 0). Symbols 
are as In fig 2. The horizontalHne defines the level 01 !'Yo, a regenera· 
tion marker. 
Recovery to normal \'alue~ was w.:celerated by 23 days com· 
pared with placebo-treated monkeys (P < .003), and an 
overshoot to supranornlal \'alue.~ was apparent, which re-
turned to normal values after cessation ofG~t·CSF treatment 
(fig 2). Monkeys treated with TPO/G-CSF had a thrombo-
cyte regeneration pattem identical to that of the monkeys 
treated with TPO alone, and one of the fOllr monkeys needed 
a thrombocyte tmn~fusion. Monkeys treated with GM-CSF 
or G-CSF alone all needed one to three tr.lIl~fu~ions. Al-
though there wa.~ no significant difference versus the pla-
cebo·treated controls in the nadir and transfusion require· 
ment, the subsequent thrombocyte regeneration wa~ faster 
than that of the placebo controls for both G-CSF- and G~I­
CSF-treated monkeys (Fig 2). 
Reticulocyte regeneration to values more than i<;'c. oc-
curred approximately I week earlier in TPO·treated monkeys 
than in placebo-treated controls (P < .()3) and showed a 
hiphasic response (Fig 3). Again, TPO/G-CSF wa~ similar 
to TPO alone, whereas TPO/GM·CSF was more effective, 
further accelemting the reconstitution by 4 days. G~I-CSF 
alone also slightly accelerated reticulocyte regeneration by 
4 da),s (P < .0-1) and G-CSF alone hy 3 days (Fig 3). This 
pattern wa.~ also reflected in the rccovery of red bloud cell 
counts after the initial decline, which is largely due to diag-
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Fig 4. Neutrophil regeneration after 5 Gy TSI {day 0). Symbols are 
as in Fig 2. The hOlizontal line defines the level of 0.5 )( to'/t. 
no~tic bleeding, with TPO/GM-CSF monkeys being the fast-
est to recover (data not shown). 
Neutrophil reconstitution for TPO-tre;lted monkeys was 
within the range uf that for placebo-treated monkeys, with 
recovery to levels more than 0.5 lO~/L occurring at about day 
21 (Fig 4). Both TPO/GM·CSF and TPO/G·CSF treatmeot 
elevated the neutrophil nadir, reflecting an accelerated reco\'-
er), to reach levels more than 0.5 X IO"/L I week emlier 
than TPO and placebo treatmeot. Recovery (0 Donnal values 
wa~ slightly more pronounced in monkeys treated with TPO/ 
G-CSF versus TPO/OM-CSF, but the difference did not 
reach statistical significance. Monkeys treated with O-CSF 
alone and OM-CSF alone had ~imilar neutrophil recovery 
pallems, reaching levels more than 0.5 x IO~/L 5 days befof<~ 
placebo-treated monkeys (P < .03, Fig 4). Treatment with 
CSFs resulted in a ~Iightly earlier but not detectably le~~ 
profound neutrophil nadir. 
Tnm~fu~ion data and regcncmtion parameters are summa-
rized in Table I, which shows that the TPO, TPO/OM-CSF, 
and TPO/G-CSF monkey group~ arc all significantly differ-
ent in transfusion flxjuirements Versus the placebo controls. 
In addition, the TPO/OM-CSF group differed signifieantly 
from the OM-CSF group in tmmfusion requirement (/' < 
.003), hut not from the TPO-tn:ated group (P = .13). 
II'hilt' h/lllld ('ell .~lIbscI5 me(/I/m'd by jfOIl' (~)'/IIII/dly. 
Row cytometry W<L~ pcrfunlled Iln lysed peripheral blood 
cell ~amples to assess regeneration of ~everal ~ubscls of 
white blood cdls. CDllb+ cells, representing gnmulocytes 
and l1lonoc}'tes, showed a pattem similar to neutrophil regen-
eratbn, in which both TPOIO-CSF- and TPO/GM-CSF-
treated monkeys had a higher nadir and an accelerated recov-
ery to normal values. Placebo-treated monkeys recovered to 
the lower range of ba~e1inc levels at day 28, ,[PO-treated 
monkeys at day 21, TPO/O-CSP-treated monkeys at day 
14, and TPO/GM-CSf-treated monkeys at day 17_ O-CSF-
alone- and GM-CSF-alone-treated monkeys recovered 
similarly to TPO/o,\I-CSF-treated l1lnnkeys, bt1l had a more 
profound nadir. TIlC difference between TPO-alone and pla-
cebo-treated monkeys could be attribt1led to a more mpid 
monocyte regenemtion (data not shown) and not to differ-
ences in neutrophil regeneration (Fig 4). 
CD8+ lymphocytes recovered to nonnallevels within the 
observation period of 6 weeks in alJ treatment groups without 
significant differences. All animals had subnomlalle"e1s of 
CD-l' T lymphocytes and CD20+ B lymphocytes at tlle end 
nfthe observation period. 'tbese Icvels were not significantly 
different between the various treatment groups (data not 
shown). 
ROlle II/orrol\' cellularity alld pmxt'lIi1or cell cOlllelll. 
Bone marrow a"pirations were perfomled before TBI and 
once weekly thereafter. Cellularity was very low in the first 
week after TBI in all monkeys, not yielding suflicient num-
bers of cells to perform colony assays. Two weeks after 
irradiation, both TPOJO-CSF and TPo/OM-CSF monkeys; 
slmled to show repopUlation of the bone marrow. Three 
weeks after TBI, all treatment b'TOUPS except for placebo-
treated monkeys had nomlal bone marrow cellularity. Pla-
cebo-treated monkeys; did not have near-nonnal cell numbers 
until week 4 after TBL TIle stimulating effect of the single 
administration of 5 pglkg TPO on bone marrow cellularity 
and CD34+ cell and clonogenic progenitor cell recoyel)' WlIS 
considerably Jess prominent than reported in the previous 
TPOJG-CSFsludy using the same myelo_~uppression model!.' 
for the human TPO dose of 10 pglkg/d administered for 21 
cnnsecu!ive days after TBL This is understandable, since the 
total TPO dose is much lower. Since the variance of this 
type of data is inevitably large due to variations of boae 
marrow cnntent at the puncture site and admixture with pe-
ripheml blood cells, we present only the m('~t relevant data, 
ie, those nbtained in the TPO/OM-CSF group of monkeys 
for CD34' cells at day 15 and for OM-CFU and llFU-E at 
day 22 after TBI (Fig 5). At day 15 after TBI, C034' cell 
numbers significantly exceeded those of placebo controls in 
the TPOJOi\I-CSF (P < .03; Fig 5) and G~CSF (P < .01; 
nol shown) treatment groups. For OM-CFU, only the TPOI 
G~I-CSF group significantly exceeded (/' < .01) the placebo 
cuntrob by approximately I log at day 22 after TBI (Fig 5). 
The TPO/GM-CSF group wa~ also richer in GM-CFU than 
animals treated with OM-CSF alone (P < .04), underscoring 
the ~ignificallt impact of TPO if combined with OM-CSF. 
As for UFU-E, similar patterns were observed, with only the 
TPOlG~I·CSF treatment group doing significantly (P < .02) 
better than the placebo controls (Fig 5). 
Olhl'r SIIII(V f/llmmelns (l1II1/duill' t'pisllill'.I-. No abnor-
malities were obser\'Cd for most nfthe senllll dinical chemis-
try. Albumin cnllcentralions were stable at about 40 giL, 
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except for OM-CSF monkeys, which developed edema (vide 
infra). Electrolyte disturbances due to gastrointestinal radia-
tion damage were minor during the first week after TBI. The 
liver enzymes alkaline phosphatase, ALAT, and ASAT also 
showed only minor changes. The number of febrile episodes 
(axillary temperature >4Q'Cj wa~ 5.3 :!:: 3.4 days, with no 
significant differences between the various treatment groups, 
although TPO/Gl\t-CSF and TPOIG~CSF monkeys tended 
to have more febrile days. There was no association brtween 
febrile episodes and C reactive protein (eRP) levels. 
Ai/I'Nse effeCIS of growth jactor Irea/melll. Two of four 
GM-CSF-treated monkeys developed generalized edema 
a~cribcd to capillary leakage, which resolved following dis-
continuation of GM-CSF. In comparison to the other 26 
consecutive monkeys that did not receive GM-CSF, the phe-
nomenon proved statistically significant (P = .02, Fisher's 
exact test). None of four TPOIGM-CSF-treatcd monkeys 
developed edema; the difference with the GM-CSF-treated 
monkeys is statistically nonsignificant. Apart from slight lo-
cal irritation at the injection site of GM-CSF and to a lesser 
extent at that of G-CSF. other ad\'erse effects were not ob-
served. 
DISCUSSION 
The present preclinical evaluation demonstrates that a sin-
gle IV dose ofTPOadministered I day after a myelosuppres-
sive dose of radiation that results in 3 weeks of cytopenia 
in placebo-treated controls is sufficient to virtually prevent 
the need for thrombocyte tram,fusions and to accelerate 
thrombocyte reconstitution to nonnal levels by 2 weeks. Fur-
thermore, the re~ults demonstrate that TPO/GM-CSF and 
TPO/G-CSF treatment display distinct response patterns 
CD34+ 
day 15 
GM-CFU 
day 22 
BFU-E 
day 22 
Fig 5. Bone marrow CD34+ ceUs and GM·CfU 2 and 3 weeks after 
5 Gy TBI, respectively !arithmetic mean :t. SE). Since the variance of 
this type of datum is inevitably large due to variations of bone mar-
row content at the puncture site and admixture with peripheral blood 
ceUs, In addition to possible variations In radiation sensitivity and 
exponential reconstitution, the other gloups did not show significant 
differences versus tha placebo contiOls, 
among three major peripheral blood cell types. Coadminis-
tmtion of TPO/G;\l-CSf augmented thrombocyte, red blood 
cell, and neutrophil production over either of the individual 
growth factors alone, wherea~ in the TPO/G-CSF group only 
neutrophil reconstitution appeared to benefit from the combi-
nation of growth factors. 
The observation that a single IV dose ofTPOshortlyaftcr 
intensive cytoreductive treatment is ,',ufficient to ~ignificantly 
alleviate the cour~e of thrombocytopenia is of considerable 
pmctical and clinical importance. TIle finding is comistent 
with the data in mice,") with the kinetics of TPO-stimulated 
thrombocyte reconstitution in nonhuman primates indicating 
a very early action of 11'0, l'.ll and with the decline in re-
sponse when TPO administration is delayed. ll These studies 
all point to a critical time phase early after TBI during which 
11'0 has to be administered to achieve an optimal response. 
TIlis could be explained by a decline in the numbcr of bone 
marrow TPO-responsive target cells as a function of time 
after irradiation, possibly due to the absence of sufficiently 
high concentmtions of TPO. This may be due to either pre-
vention of physiologic death or apoptosis in the presence of 
TPO similar to that identified for erythropoietin and red 
blood ccll progenitors,~~·-l-I or protection of TPO-responsive 
progenitors from mdiation-induced cell death by 11'0. Eluci-
dation of ~uch mechanisms not only will provide further 
insight into the physiologic function ofTPO, but also will be 
of considerable importance to achieve the maximum clinical 
benefit of its therapeutic usc. Altho'ugh the data show that 
a single IV dose of 5 pglkg TPO is suflicient to prevent 
thrombocytopenia at the level of myelosuppres~ion chosen, 
this finding docs not preclude that clinical cytoreductive ther-
apy requires a more intensive TPO treatment regimen. 
A central issue ofTPOtreatmentispreventionofbleeding 
as a consequence of myelosuppression. Our pulicy to trans-
fuse donor thrombocytes at a level of 40 x IO~/L coincides 
with the first appearance uf petechiae and other bleeding, 
and was chosen to prevent undue deaths due to hemurrhage. 
For obvious reasons, this level is higher than used for human 
patients where instnlctions Clm be given to the patients and 
sensiti7.ation to nlloantigens should be avoided. However, 
as can be extrapolated from the postirradiation decrea,e in 
thrombocyte counts after the first week and the first a<;-
cending counts in the third week after TBI in placebo-treated 
monkeys, without transfusions, thc thrombocytes would 
have decreased to levels less than 10 x 1O~/L within 2 days 
after the first transfusion (Fig I). It can thus be concluded 
that TPO treatment that prevented the decline of thrombocyte 
counts to levels less than 40 X 10~/Lcarly in the second week 
after irradiation also effectively pre\'cnted the propensity to 
bleeding (Fig I). 
Administration of TPO/GM-CSF proved to be superior to 
all other growth factors or combinations of growth factors 
studied for stimulating thrombocyte reconstitution. G;\I-CSF 
alone did not influence the thrombocyte nadir or significantly 
reduce the need for thrombocyte transfusions. However. it 
was as effective as the ~ingle administration of TPO alone 
in stimulating po~t nudir thrombocyte production. The aug-
mented thrombocyte reconstitution of the TPO/GM-CSF 
monkeys ma)' refleel synergism of the two growth factoTS, 
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since the initial recovery of both thromboc)'tes (Fig 2) and 
reticulocytes (Fig 3) in the TPO/GM-CSF group exceeded 
the sum of those in the monkeys treated with either of the 
growth factors alone. A .'>timulatory action of G:>.t-CSF on 
megakaryocytes resulting in increased thrombocyte produc-
tion has been described in normal nonhuman primates,1I'A~ 
although the results of in vivo treatment with GM-CSF on 
thrombocyte reconstitution after cytotoxic insult to the bone 
marrow ha\'c always been heterogenousM--4,! and, in retro-
sprct, m<1}' h<1\'e been codependent on variations in endoge-
nous TPO levels. From TPO levels measured 24 hours after 
injection, we could not conclude that there was a major 
change in Tro pharmacokinetics due to coadministration of 
GM-CSF as a basis for the augmented recovery of thrombo-
cytes. The same observation wa~ made for G-CSF. Surpris-
ingly, the IO-pglkg/d dose (for 2 weeks) of G-CSF also 
appeared to stimulate thrombocyte production to a certain 
extent, in contra.~t to the 5-pglkgld dose (for 3 weeks), which 
wa.~ u'ied in a preVious .'>tudy in the same nonhuman primate 
model, l.' but the result is consistent with that in a similar 
model in whil:h 10 pglkgfd wa.>;; also used.!~ We previously 
observed, in the same myelosuppression model as used here, 
a dampening effect of G-CSF on 'fPO-stimulated supmnor-
mal thrombocyte production. u This wa>;; also seen in mice.!6 
Meanwhile, in a transplant model in rhesus monkeys involv-
ing 8 Gy Till followed by infusion of highly purified stem 
ceils, protnlcted thromhoeytopenia significantly related to G-
CSF treatment wa~ encountered in a few cases.2i\ The re-
ported effects of G-CSF on thrombocyte production are am-
biguous: most reports mention no effects at all,I~A9"! some 
a positivc effect,'l and others a negative cffeCt.~1.-~\ The 
camcs of the variahle reaction of thrombocyte\ to G-CSI' 
treatment are not elucidated and may be governed by com-
plex mechanisms; it should be noted that G-CSF receptors 
are present on thrombocytes.5-'> We conclude provisionally 
that combining TPO and G-CSF treatment may have a vari-
able, as-yet-unpredictable, and occ[L~ionally adverse out-
come. 
TPO augmented the ncutrophil recon~titution stimulated 
by G~f-CSF as well a.~ G-CSF, which might be of consider-
able clinical significance, since in the reported clinical trials 
the effects of the CSFs in general have been modest,2LL, .. N 
similar to the re~ults presented here in a preclinical nonhu-
man primate Illodel. In particular, the neutrophil nadir ap-
peared to be greatly improwd in TPOICSF-Ireated animals. 
G-CSF or GM-CSF treatment alone did not appreciably in-
fluence the neutrophil nadir, but accelcrated regeneration 
afterward with a time course .~imilar to that for clinically 
acceptable neutrophil counh. We attributed the advanta-
geou~ effect of TrO 10 expamion of immature cells along 
llIultiple hematopoietic lineages,n.I"1 thus making more G-
or GM-CSF target cells available for myelopoiesis. From 
the kinetic:. of neutrophil rccon~tjtllti(ln, it is ;llso apparent 
that the effect originate~ from stimulation at an early stage 
after TBI (Fig 4). 
The slightly more rapid recon~titution of neutrophils fol-
lowing TrO/G-CSF admini~lration ~hould be weighed 
again\t the reported dampening effect of G-CSI' treatment 
on thrombocyte recovcf)', 1l.!5 although this efff'''j \\',L~ nllt 
apparent in the present study. However, the greater target cell 
range of the TPOiG;'I,[-CSF combination should be balanced 
against the slightly higher incidence of reported adverse ef-
fects of GM-CSF,l1 13 as also seen in the present study. The 
development of edema in two monkeys treated with GM-
CSF was an unwanted adverse erfect of the C)1okine treat-
ment, a rare event that has been previously reported, albeit 
only at higher doses of GM_CSF.2L2'.s~ For as-yet-unex-
plained reasons, edema wa~ not obseryed in monkeys treated 
with TPO/Q,\I-CSF; however, this dificrence is not _~tatisti­
cally .'>ignificant. Apart from stimulation of thrombocyte pro-
duction, a prominent feature of TPO adrninistmtion is the 
accelerated reconstitution of immature bone marrow cells, 
consistent with the presence of Tro receptors and stimula-
tOf)' effects in vitro.7.') Accelerated recovery of bone marrow 
cellularity, CD34+ cells, and c1onogenic progenitor cells 
Mlch as GM-CFU and BFU-E following supmoptimal TPO 
treatment has been reported previously.l.l.!~ The present study 
with a much more limited Tro dose confirmed these data 
and demonstrated that the effect is reinforced by combining 
TPO with GM-CSF. This places TPO alllong the few b>TOwth 
factors that can presently be safely used clinically to promote 
the recovef)' of immature bone marrow cells in an carly 
stage after cytoreducth'e therapy without notable adven-e 
effects. As a direct implication, the future development of 
TPO treatment regimens in the clinic should be directed not 
only at optimal thrombocyte recovef)' but also at the most 
optimal reconstitution of immature bone marrow cells. 
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Abstract 
The efficacy of recombinant human thrombopoleUn (,[PO) 
and recombinant human granulocyte colony stimulating fac~ 
tor (G·CSF) in stimulating platelet and neutrophil recovery 
was evaluated In a placebo-controlled study involving trans· 
plantation of limited numbers (I~3x IOl/kgl of highly puri· 
fied autologous stem cells (CD34++/RhLA_DRduIlj Into rhesus 
monkeys after the animals were subjected to 8 Gy of total 
body irradiation (TBI) (x-rays). The grafts shortened profound 
TBT·lnduced pancytopenia from 5 to 6 weeks to 3 weeks. Daily 
subcutaneous (sc) IQJectlon of TPO (10 pg/kg/day, days 1~21 
after TBI) did not stimulate platelet regeneration after trans-
plantation either alone or In combination with G-CSF (5 
pg/kg/day sc, days 1~21 after TBI). G-CSF treatment failed to 
prevent neutropenia in the monkeys and did not stimulate 
recovery to normal neutrophil levels. Simultaneous adminls· 
tration of TPQ and G-CSF did not Innuence the obseryed 
recovery patterns. To test the hypothesis that the limited 
number of cells transplanted or the subset chosen was respon-
sible for the lack of effectiveness of TPQ. three additional 
monkeys were transpJanled with 101/kg unfractionated autol· 
ogous bone marrow cells. Two of these animals received T1'O 
and the other served as a controL In this setting. as well, 11'0 
treatment did not prevent thrombocytopenia. This study 
demonstrates that treatment with TPO does not accelerate 
platelet reconstitution from transplanted stem celis after hlgh-
dose TBI. These findings contrast with the rapid lPO-stimu· 
lated platelet recovery in myelosuppression induced by 5 Gy 
of TBi In rhesus monkeys: we conclude from this that the 
clinical effectiveness of the TPO response depends on the 
availability of Tro target celis In the first week after TBi, that 
is. before endogenous TPO levels reach the saturation point. 
In addition. protracted Isolated thrombocytopenia was 
observed In two G·CSF·lreated monkeys, one of which also 
received TPO. Furthermore. TPO treatment for 7 days in the 
6th week after TBJ during severe thrombocytopenia in one 
monkey produced prompt clinical improvement and an 
Increase In platelet counts. 
Key words: Thrombopoletin-Bone marrow transplantation 
-Total body irradlaUon-CD34' stem cell 
subset-Rhesus monkeys 
Introduction 
Thrombopoletin (TPQ), the ligand for the receptor encoded 
by the protooncogene c-mpJ. was first identified and Its gene 
cloned in 1994 1i~3J. Since blood TPQ levels are Inversely 
related to platelet counts [1-3]. and mice lacking either the 
receptor for TPO or Ule ligand are severely thrombocytopenic 
[4.5J. TPO Is considered the major regulator of platelet pro· 
ductlon. Administration of recombinant TPO to normal 
experimental animals has shown it to be a potent throm-
bopoletic agent 12.6,7J. TPO has also been tested In several 
myelosuppression models in mice [6.8.91 and shown to be 
effective in accelerating platelet reconstitution as well as In 
preventing morbidity caused by bleeding. TPQ was not effec-
tive after myeloablative treatment and bone marrow trans· 
plantation (EMT) In a syngeneic mouse model. whereas 
marrow from donors pretreated with TPO showed augmented 
regeneration of platelet numbers 1101. 
One of the likely clinical uses of TPQ will be as a stlmula· 
tor of hematopoietic reconstitution following autologous or 
allogeneic BMT. It Is hoped that TPO will accelerate early 
reconstitution as well as counteract protracted thrombocy· 
topenla, which Is especially common in patients subjected to 
prior chemotherapy for leukemia. The use and efficacy of 
granulocyte colony·stimulating factor (G·CSF) as a single 
growth factor to stimulate neutrophil rccovery has been 
described extensively In several animal models and has been 
confirmed by clinical trlals 111-151. 
Preclinical evaluation of TPO and other growth factors 
reqUires testing in large animal models such as rhesus mon-
keys. In the present study we examined the simultaneous 
ildministration of TPQ and G·CSF to assess their synergistiC 
efficacy and possible stimulatory andlor adverse interactions. 
The setting chosen involved transplantation of limited num· 
bers of the Immature RhLA·DRduIl subset ofauto!ogous CD34' 
58 Chapter 5 
[1G,17[ cells fo][owing 8 Gy orTB! in rhesus monkeys. A stem 
cell graft of this small size after hlgh·dose T8I allows investi· 
gators to determine the lower limit of residual hematopoietic 
stem ceil numbers. which permit stimulation of blood (<,II 
formatIon by hematopoIetic growth factors 1181. as well as to 
test for the capacity of a growth factor to accelerate peripher-
al blood cell recomtitution from immature hematopoietic 
stem cells. The dose of TPa was chosen based on previous 
dose finding studies in mice and experiments In normal 
monkeys (19], and because it proved highly effective in pre-
venting thrombocytopenia after radiation-Induced myelosup-
pression In rhesus monkeys [201. The latter study also 
showed that TPQ treatment augmented the G·CSF response 
and accelerated immature bone marrow cell recovery. In the 
present study we attempted to extend these previous findings 
and to further define the potential efficacy ofTPOtherapy in 
the clinical setting. 
Materials and methods 
Animals 
Purpose. bred male rhesus monkeys (Maraca mu/atta). weigh-
Ing 2.5 to 4.0 kilograms each and aged 2 to 3 years were used 
In this study. The monkeys were housed in groups of 4 to 6 In 
stainless steel cages In rooms equipped with a reverse-filtered 
air barrier. provided with normal dayIJght rh}·thm. and coruli· 
tioned to 20'C with a relative humidity of 70%. Animals were 
allowed free access to commercially avallable primate chow, 
fresh fruits. and acidified drinking water. All animals were free 
of Intestinal parasites and seronegative for herpes B, simian T· 
Iymphotrophic viruses (STLV), and simian immunodeficiency 
virus (SI\[). Housing. experiments. and all other conditions 
were approved by an ethics committee in accordance with 
legal regulations in The N"etherlands. 
Tout body iFTadi;ftion 
After aspiration of bone marrow. monkeys were Irradiated 
with a sIngle 8-Gy dose TBI delivered by two opposIng x-ray 
generators operating at a tube voltage of 300 kV and a current 
of iO mAo The half· layer thIckness was 3 nun Cu. The focus 
skin distance was 0.8 m and the average dose rate 0.20 to 0.22 
Gy/mlnute. During TBL the animals were placed in a cylindri-
cal polycarbonate cage which rotated slowly (three 
times/minute) around its vertical axIs. 
SuppMiye Cdfe 
Two weeks before TB!. the monkeys were placed in a laminar 
flow cabinet and their gastroIntestinal tracts were selectively 
decontaminated by administration of oral clprofloxacln 
(Bayer, MiJdrecht. The Netherlands). nystatin (Sanofi BV. 
l\faassluls, The Netherlands). and polymyxin B (Pfizer. New 
York. NY). When leukocyte counts dropped below i09 /L. this 
regimen was supplemented wIth systemic antibIotic medica· 
tions. in most cases a combination of tlcarcll!ln (Beecham 
Phanna, Amste!veen. The Netherlands) and cefufuxlm 
(Glaxo. Zelst. The Netherlands): this antibiotic regimen. 
which was guided by fecal bacterlograms. was continued 
until leukocyte counts rose to levels> i09/L. Dehydriltlon and 
electrolyte dIsturbances were treiltoo by appropriate sc fluid 
and electrolyte injection. The monkeys received Irradiated 
(15 Gy) platelet transfusions whenever platelet counts 
reached values below 40x i09/l and irrildiated pack('d red 
cells whenever hematocrIt levels declined below 20%: In 
those in5tances in which platelet counts ilnd hematocrit lev· 
els \\erc found to be sillluitaneously decreased. whole blood 
tramfusions were administered. 
Test drugs 
One-milliliter vials containing 0.5 mg/mL recombinant 
human TPO were supplied by Genentech Inc. (South San 
Francisco. CAl. The dosage used was iO J.lglkglday. ildminls-
tered by sc Injection once per day from day I to day 21 postir-
radiation. The dally doses were diluted to a volume of 1 mL 
wIth phosphate-buffered saline (PBS)/O.OI%Tween 80. Place-
bo·treated monkeys were given the same volume of diluent. 
Recombinant human G·CSF (Neupogen. Amgen. Thousand 
Oaks. CAl was administered at a dosage of 5 J.lg/kg/day sc. 
once per day from day I to day 21 postirradiation. The daily 
doses were diluted to a volume of I mL In the solution recom· 
mended by the manufacturer. 
Study groups 
The monkeys were treated sequentially at intervals of I week 
with a break every 4 to 5 weeks to thoroughly clean and 
decontaminate the Isolation facility; the study was completed 
in a total of 7 months. Animals were randomly assigned to 
study groups. Results from one historic control that did not 
receive gro\\1h factors are included in the graphs. Four mon-
keys were treated with TPO alone. two simultaneously wIth 
TPO and G·CSF, three with G-CSF alone. and two with place-
bo. Two monkeys that did not receive a transplant served as 
irr<ldiatlon controls. Three additional monkeys were trans-
planted with unfractlonated bone marTOW grafts: two of these 
received TPO. and the other sef>'ed as a control. 
Bone m.UTOW aspirates 
Bone marrow was aspirated whHe the animals were under 
anesthesia using ketalar (Apilarmo. Arnhem, The Nether· 
lands) and vetranquil (Sanofl. Maassluls. The Netherlands). 
For transplantation. bone marrow WilS aspIrated from the 
shaft of both femurs into bottles containing iO mL Hanks' 
buffered Hepes solution (HHBS) and 250 IU sodIum hep' 
arin/mL (Leo Pharmaceutical Products. Weesp. The Nether, 
lands). Erythrocytes contained in the aspirate were returned 
to the monkey after two washings with 0.9% NaCI and fIItra· 
tlun to remove bone fragments. eIther before irradiation or 
as irradiated (I5 Gy) blood product after TBI. Small bone 
marrow aspIrates were obtained for analysis from the shafts 
of the humeri usIng pediatric spinal needles. Low.denslty 
cells were Isolated using Ficoll (density 1.077: Nycomed 
"hanna AS. Oslo. Norway) separatIon. 
CO/onyassays 
Cells were plated in 35·mm dishes {Becton Dicklmnn. San 
Jose. CAl in )·mL enriched Dulbecco'5 medium (Gibcn. 
Gaithersburg, MD) containing 0.8% methy1cellulose. 5% frtal 
calf serum (FCS). and ilddilives. <IS described previously 
[2 I -23]. For burst-forming units-erythroid (BFU·E). cultures 
were supplemented with hemin (2x 10 4 moUl). human 
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recombinant erythropoietin (Epa; 4 U/ml; Behrlngwerke AG, 
Marburg am tabn. Germany) and Kit ligand (KL; 100 ngfmL; 
kindly provided by Dr. S. GIllis. Immunex. Seattle, WA). For 
granulocyte/macrophage colony formlng·unlts (GM·CFU). 
cultures were supplemented with recombinant human GII.I· 
CSF (S ng/mL; Behring). recombinant rhesus monkey IL·3 (30 
ng/mL) produced by B. /icJlen/{ormis and pUrified as describ€d 
previously {24,2SI. and KL Low-denslty cells were plated at 
5x 101 cells per dish and sorted cell fractions at rol per dish 
in duplicate. Colony numbers represent the mean ± standard 
deviation of bone marrow samples from Individual monkeys. 
Stem cell IsolatIon and lranspfanlatkm 
To enrich for progenitor cells. buffy·coat cells were subjected 
to a discontinuous bovine serum albumin density gradient 
{26.271. Low·denslty cells were collected and CD34' cells Iso· 
lated by immunomagnetic separation using an IgG2A anti· 
body against CD34 (mAb 561; from G. Gaudernack and T. 
Egeland. RlkshospltaleL Oslo. Norway) that was noncova-
lently linked to fat antl·mouse IgG2A beads (Dyna!. Oslo. 
Norway). CD34' cells devoid of the antl·CD34 antibody were 
recovered using a polyclonal antibody against the Fab part of 
the antJ·CD34 antibody (Detachebead. Dynal). Purified cells 
were Incubated with a monoclonal antibody (mAb) against 
human CD34 (mAb 556; from G. Gaudernack and T. Ege-
land) that had been conjugated with fluorescein Isothlo-
cyanate (FITC: Sigma, St. Louis. MO) and simultaneously 
with a phycoerythrin (PE).coqjugated mAb against human 
HL\·DR that reacts with rhesus monkey RhLA-DR antigens 
(Becton Dickinson. San Jose, CAl. Control cells were stained 
with each mAb separately to allow proper adjustment of flu· 
orescence compensation. CelJ sorting was performed using a 
FACS Vantage flow cytometer (Becton Dickinson) with the 
argon laser set at 48B nm (100 mW). CD34t:<~h[/RhLA_DRdull 
cells {I?I were sorted in the normal C mode and re.malyzed 
for purity. The sorted cells were transplanted at a dos(' of lA 
to 3x 101/kg body weight and returned to the monkey on 
the same day. 
Hemal%gJcal examInations 
Complete blood cell counts were measured daily using a Sys-
mex F-800 hematology analyzer (Toa Medical Electronics, 
Kobe. Japan). The differelllial of the total number of nucleat· 
ed cells (TNCs) was determIned by standard coullling after 
1\!ay.Grilnwald.Glemsa staining. For retIculocyte measure-
ments, 5 pl ethylene diamlne tetraacetic acid (EDT!\) blood 
wa~ diluted In I mL PBSfF:DTA {0.5 M)/a;dde (0.05% \\1/\'01), 
and I ml of a thlazole orange dilution was added at a final 
concentration of 0.5 pg/mL. l\leasurements were done on a 
FACScan (Becton Dickinson) and analyzed using Retlcount 
software (Becton Dickinson). 
MeasulMlfflls of wtface antigens 
Once per week FACScan analysis was performed on PB and 
BM samples on the following surface antigens: COB. CD·t, 
CD20. COl lb. CDSO. and CDI6. Directly labeled monoclo· 
nal antibodies were used for CDB. CD4. CD20. CD56. and 
CDIG (Leu 2a·FITC. Leu 3a-PE. Leu 16·PE. leu 19·PE. and 
leu Ila·FITC (Becton Dickinson). respectively. CDllb anti-
gens were detected by the FITC·conjugated monoclonal anti-
body MOl (Coulter Immunology. Hialeah. Florida). Red 
blood cells were removcd by incubation of 0.5 mL whole 
blood or bone marrow In 10 ml lysing solution (8.26 g 
ammonium chlorlde/1.0 g potassium bicarbonate. and 0.037 
g EDTAlL) for 10 minutes at 4'e. After lysing. cells were 
washed twice with HHBS containing 2% PCS (vollvol) and 
0.05% (wt/vol) sodium azide (UFN). The cells were resus· 
pended In 100 pl HFN containing 2% (vol/vol) normal 
monkey serum to prevent nonspecific binding of the mono-
clonal antibodies. Monoclonal antibodies were added In a 
volume of 5 pl and Incubated for 30 minutes on Ice. After 
two washes. the cells were measured by flow cytometry. 
Ungated list mode data were collected for 10.000 events and 
analyzed using Lysis II software (Becton D!cklnson). 
Clinical chem/slsy 
Serum concentrations of sodium, potassium, chloride. glu· 
cose, albumin. total protein. aspartate-amino transferase. ala-
nlne·amlno transferase. alkaline phosphatase. lactate 
dehydrogenase (LDH). gamma-glutamyl transpeptidase, total 
bilirubin. C reactive protein. creatinine. urea, and bicarbonate 
were analyzed twice per week using an Elan Analyzer (Eppen· 
dorf Merck. Hamburg. Germany). 
TPOkrels 
Plasma fOf measurements of levels of TPO was sampled from 
the monkeys Just before cytoklne administration twice per 
week and stored at -80'e. A full description of the TPa 
enzyme-linked Immunosorbent assay (ELISA) is given else· 
where 128.29J. Briefly, ELISA plates were Incubated overnight 
at 4'C with 2 pg/mL rabbit F(ab')2 to human IgG Fc ijac\(5on 
ImmunoResearch. \Vest Grove. PAl and 2 hours at room tem-
perature with conditioned medium containing 100 ng/mL of 
mpl·lgG [31. Twofold serial dilutions of samples (starting at 
1:10) and standards (recombinant full length human andlor 
rhesus TPO) were added to wells and incubated for I hour. 
Bound TPO was detffted using blotlnylated rabbit antibody 
to fulI.length human TPO (Genenlffh), followed by peroxi-
dase·labeled streptavidln. The range of the assay for rhesus 
plasma samples Is 0.32 to 10 ng/mL TPO. The assay preferen· 
tlally detects active full· length TPO with equal accuracy in 
rhesus monkeys and humans. and correlated well with a 
bioassay using the megakaryob!astlc HU-3 cell line. 
HefT/(lsU$ls p,uamefers 
Plasma for measurements of fibrinogen. prothrombin time 
(PT). and activated partial thromboplastin time (APlT) was 
collected twice per week and stored at -80'e. Measurements 
were done on an Automated Coagulation Laboratory·IOO 
(ACl-IOO; Instrumentation Laboratory. I\tilano. haly). A 
commerCially available kit was used for fibrinogen measure-
ments (fibrinogen· test. DiaMed AG. Cressier sur r..torat. 
Switzerland). thromborel S (Behringwerke AG. Marburg. Ger-
many) was used for the PT. and platelin LS (Organon Teknika 
Corporation. Durham. NC) for the APTf. Platelet aggregation 
tests were done before treatment and at day 21 using a whole 
blood luml aggregometer (Chronolog. Havertown. PAl using 
5x 10.5 M ADP (Sigma, SI. Louis. MO). 5 U/mL thrombin 
(Central Laboratory of thl;' Blood Bank. Amsterdam. the 
Netherlands). or 5 J-lg/mL collagen (Sigma). 
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Table 1. Regeneration parameters after 8·Gy leland 5tem cell transplantation 
Number of 
Cell fratlion monkeys Growth factor 
C034 .. /RhLADR ..... TPO 
TPO + G·CSF 
G-CSf 
placebo 
None noM 
Unfraetionated ITO 
Unfrac!i0fJ3ted placebo 
S/dUstics 
If relevant, standard deviations were calculated and are given 
in the text, the figures. and the table on the assumption of a 
normal distribution. The statistical slgnlfic<lnce of differences 
was calculated by Fishe(s exact test for categorical data. and 
by one-way analysis of variance followed by a Studenfs t lest 
for continuous data. 
Results 
Characterization of stem cell transplants 
To assess the effiCiency and enrichment potl"ntial of the 
selection procedure used for stem cell isolation. cell numbers 
were counted for each cell fraction. colony assays were per-
formed, and a FACScan analysis was done for C034 antigen 
expression. Tota[ cell recovery for the C034 selection step 
using the Oyna\ immunomagnetic beads was 76.4 ± 15%, 
with an average of 8.6 ± 3.5% of the cells In the positive frac-
tion. Calculated as percentages of the aspirated bone marrow 
cells. C034'"'lRhLA·ORdo!l cells represented 0.03% of the total 
cell number. Recovery of GM·CFU numbers during the CD34 
selection stage was 50.6.± 24.1%. with 41.9.± 23% of the GM-
CFUs recovered In the CD34' cell fraction. Recovery of BFU-E 
was 82.8 ± 52.5% durIng the C034 selection step. with 56.6 ± 
38.9% found In the posItive cell fraction. Recovery of the 
C034"/RhlA_ORdutl fraction. compared with the C034+ cell 
fraction of GM-CFU and BFU-E. was 8.1 ± 5.9% and 1.3.± 
1.6%. respectively. reflecting a depletion of more mature pro-
genitor cells. which are segregable from Immature cells on 
the hasls of f{L\-OR expression 1171 in this subset. FACScan 
analysIs revealed a recovery of C034' cells of 38.0 01; 15.8%. 
with 24.9 01; 13% found In the poslti\'C cell fraction. and a 
purity of C034' cells of 43 01; 18%. The C034"/RhLA_ORd~1I 
cells represented 3.4 01; 2.2% of the C034+ cell fraction. The 
cell dose transplanted was on average 2.7x lOl/kg (range 
IA-3x 1011kgl. 
Hematopcf~fjc reronstitutlon 
Based on previous tramplantaUons In this setting 130]. the 
reticulocyte regeneration was found to be the best parameter 
to quanUfy the engri'lftment pOlentt<11 of a BMT. BCCilliSe 
TPQ has been found to influencE' reticulocytE' regeneration 
after myelosuppression 1201. this parameter is less reliable In 
TPQ-treated monkeys. but In placeho. and G·CSF·treilted 
monkeys regeneration was very homogenE'olls. i.e .. 21.7 .± 
Ret1culocytes Neotrophils > 0.5 Pit> 40 
>l%atday 101/ml at day 10~/ml at day 
20 i 2 21 t 2 21 :t 5 
23;17 25;15 32;15 
21 :I: 2 19 ± 3 57;24;18 
23 ± 0 23 ± 2 24:t 1 
27;27 32;30 37;34 
11;19 17;20 15;17 
20 
" 
24 
1.7 days after TSI (n=6). The monkey transplanted with 
iOI /kg unfractionated bone marrow celis and treatE'd with 
placebo had greater than 1% retlculocytes at day 20. similar 
to historic controls 130]. Comparison of the regeneration 
times of the unfractlonated transplants and those of the 
stem cell transplants yielded an enrichment In repopulating 
c<lpacity of approximately 30G·fold for the latter. IBI with· 
out transplant resulted In a 5· to 6·\Veek period of pancy· 
topenla. A CD34"/RhlA~DRrl"1l transplant without growth 
factor treatment resulted In a three week period of profound 
pancytopenia (Table I). All monkeys were dependent on 
platelet transfusions and antibiotic treatment during the 
recovery phase. 
Peripheral bIcod celllXHJtd$ 
Platelet regeneration after bone marrow transplantation was 
not influenced by TPQ treatment. The nadir for platelets was 
not alleviated by TPQ. <lnd the time needed for normalization 
of those values was not shottened (FIg. I). TPO·treated mon-
keys needed 3 to 6 transfusions compared with 4 to 5 for 
placebo-treated animals. Qf monkeys treated with TPQ and G· 
CSF (I1"'2). one needed only 2 transfusions and reached a 
transfuslon·free platelet level at day 15. whereas the other 
required 10 transfusions and did not reach transfusion Inde-
pendence until day 32. Tn G·CSF·treated monkeys (n=3). the 
data were also heterogeneous. Two monkeys showed <I [E'gen· 
eration pattern for platelets similar to that of placebo·treated 
controls. whereas the other developed protracted thrombo-
cytopenia. requIring 22 transfusions <lnd reaching transfusion 
Independence on day 57 after irradiation. The monke~ s with 
G'CSF-associated protractE'd thrombopenia will U£' discussed 
separalCly hide in(r'"l). 
Reticulocyte regeneration. defined as the day on which the 
percentage of reUculocytes exceeded 1%. occurred 3 days ear-
lier In IpQ·treated monkeys than in placebo·trealCd controls. 
although this dIfference was not statistically sIgnificant. G· 
CSF had no effect on reticulocyte regeneration. and for TPQ 
plus G·CSF results were variable (Table I). Neutrophilic granu-
locytes regenerated In placebo-treated controls and TPQ·treat-
cd monkeys In a similar way (Fig. I). The reco\'ery of 
neutropenia In monkeys treated 5imultaneollsly with Ira 
and G·CSF (n=2) was <lIsa heterogenous. The first one had 
neutrophil [e'le[s higher than 0.5x 109 /L by day 25 and the 
other by day 15. For the three G·CSf·treated monke}s these 
le\"('[s were attained on days 17.22. and 19. resp€<ti\"{'I\" 
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lime (day) 
Fig. 1. Mean peripheral blood counts after a·Gy TBI and 
Hem cerr tramplantation. lhrombocytes (upper panel), 
rellculoeytes (middle panel), and neutrophils (tOwel"" panel) 
for lPO (open squares, n=4), lPO and G·CSF (half filled 
square~, n=2), G·CSF (black squares, n=3), and placebo· 
treated monkeys. (open cIrcles, n=3). Horizontal lines define 
degree of cytopenIa, 40:-:10'1l for lhrombocytes, 
0.OS>·10' I/l for retlculocytes and 0.5" t09/l for neullophils 
Urrfractronafed bone IrIdrTOW franspf.Jn/$ 
To examine the ~ffcct of size and cellular composition of 
the graft on lPO-stimulated platelet regeneration, three 
monkeys received an autologous unfractionated bone mar 
row tr<lmplant at a cell dose of WI/kg body weight. Two of 
Ihr5e monkeys received TPO <It thE' S<lllle dme as the strlll 
crll-tramplanted monkeys <lnd one of these received piace. 
bo treatment. TPO treatment dId nol prevent the plate!pt 
oadir and did not Significantly ~Ii!llulau> recovery towMd 
normal values (Fig. 2). Days to reticulocyte regeneration 
>1% were It, 19, and 20. respectiyely. and days 10 neu· 
trophll reg<'neration 17.20. ilnd 24. resprctively. in these 
thn'<, animals (Table I). In Figure 2. tilE' mean plall.'l('\ 
regeneration in the unfraCiionated transplanls is compared 
& 
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Fig. 2. Comparison of the erf~t of lPO following trans· 
plantatIon of purified stem cells and unfractionated bone 
marrow. In the upper panel the mean thrombocyte 
counts of 4 lPO·treated stem cell-transplanted monkeys 
(filled squares) and 3 placebo·treated stem cerr-trans-
planted mon~eys (fiUed circles) are plotted. The tower 
panel dIsplays the mean of two TPO·treated unfraellonat· 
ed marrow transplanted monkeys (half·filled squares) and 
the unfractlonated marrow-transplanted control monkey 
(filled triangles). lhe dose and route of lPO were the 
same for all monkeys (tOflg/kgfday, sc, days 1-21). Tile 
shaded areas represent means i SDs of thrombocyte lev. 
els of 5·Gy Irradiated monkeys after TBI; the lower shaded 
area represents 8 placebo·treated controlS, the upper one 
4 TPO·lreated monkeys. 
with that in the 5tem cell transplants. illustrating the ~im[­
larity of reSpOn5l' 10 TPO hetween th<' 1\\"0 groups. Figure 2 
also displays Ihr fPO respollSe in the S·Cy irr<ldlatcd mono 
keys 1201, showing Ihat the transplants resulted in pl<ltelet 
reconstitution at a level siln!iar to that In Ihe placebo con-
trols following myelosuppression induced by S.Cy of irradl· 
ation, and illustrating the virtual lack of a TPO response In 
the transplanted monkeys. 
White blood cen subsets me.JSured by now c,1omefry 
A profound nadir was obs<'l"'·ed for al! surface markers lesled 
in the prriphrrai blood. Regellrratioll patt<'fIls did not differ 
belwl'en different tr('<llment group,>. The number of CD20' 
cells did not rc;'coW'r to pretreatment le\"Cls during tile obsl'f-
\'<ltion pniod (6 we<'ks) and neli\tcr dId the number of cor 
celis. eDllb' (elis followed the same pailI'm as tilE' neu 
trophils sh{mn in Figure!. CDS' c<,11 numbers reac\ted pre 
tn'<lll1lrnt lewis during the sixth weck. 
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Table 2. Bone marrow celrularitic~ (x to'), GM-CFU nmnbers (xtO'), and 6fU-E numbers (xtOI}.t SO per ml aspirate after a·Gy TSI and stem 
ceil transplantation 
Treatment Before Week 1 Week 2 WeekJ Week 4 
Cellularity xlOi/ml T 39 t 7 0.1 ± 0.2 0.'1 t 0.3 3.9:t 3.4 28.7 t 48.9 
T. G 26;53 0.02;0.03 0.14;1.0 Q.8;ND 5.2;6.5 
G 22.t 5 0.2 ± 0.2 0.6 i 0.5 14.3.t 20.7 4.1 ± 4.8 
pI 20;23 0.14;0.0 0.26.t 0.0 1.1;1.5 19 ± 8 
GM-CFU )(101 T 10.t 32 NO NO ,>4 36.t 72 
T.G 45;12 NO NO O;ND 0;2 
G 28 t 10 NO NO 15 t 25 0.3 ± 0.1 
pI 39;54 NO NO 0.3;0.1 6;5 
6fU·E )(10
' T 11 t 6 NO NO 0.91'.1.7 17 t 30 
T.G 16;26 NO NO O;ND 0;0.6 
G 9.t 0.4 NO NO 5.6 t 9.7 0.5 t 0.6 
pI 9;11 NO NO 0;0 0.7;2 
ND '" not done b!Xiluse of klw ceif numbers; TPO; IpQ·treated monkeys (0=4); T + G: IPQ· + G·CSF-treated monl\eys (n=2); G: 
G·CSf·treated monkeys (n=3), pi: placebo-treated monkeys (n",2). 
/kr1e marrow cellularity and progenitor r:eI1 content 
The bone marrow cellularity of the aspirates used for trans· 
plantation was 30.9 ± 11 x IOG/mL and served as a control 
value. In all treatment groups, cellularity at days 8 and i5 was 
too low to allow performance of colony assays (fable 2). G· 
CSF-treated monkeys showed greater marrow cellularity at 
day 22 but with wide variations. At day 28 no differences 
were ohSNved between the tre<llment groups. The progenitor 
cell content of the bone marrow, expressed as colonies per 
milliliter of aspirate. was also subject to wide variation and 
showed no trend favoring a gro\\ th factor regimen. 
TPOlereis 
Pretreatment TPQ levels were below detection level (320 
pg/mL) in all but one s<lmple. varied from 2438 to 25,143 
pg/mL in samples taken from TPQ-treated monkeys from day 
3 to day 21 after TB!. and became vel)' low again at days 24 
and 28 (Fig. 3). in animals treated with G-CSf alone or place-
bo, elevated levels wew ml'<l5ured in samples taken at days 7. 
10, 14. 17.21. and 28. consistent with the thrombocytopenia 
present in those animals at those times (fig. I). These mdoge-
nOlls TPQ levelsvaricd from 314 to 1627 pglml. which was In 
the low range compared with TPO·treated monkeys. but clear-
ly elevated cornpared with baseline values. These elevated 
TIO levels should probably be considered relatively moderate 
elevations because the animals In this group were given 
platelet transfusions whenever their platelet levels dropp€d 
below 40X J09/l. 
Clinical cMmistly and hemostAsis p.1ramefers 
Abnonnalitles were not ob>Cfvoo for most parameten. Minor 
electrolyte disturbances were observed during Ihl' first week 
after TBI bec<luse of gastrointestinal radiation damage. Some 
monkeys had a short period of hypalbuminernia. No differ-
ences were found between APIT. PT. and fibrinogen levels 
among the different treatment gwups. and these levels did 
not nuctuate dmlng the postirradiation period. Platelet aggre-
gation tests scheduled for day 21 after TBI were not always 
fl'asible because of the low number of platelets; the tests done 
In 6 animals revealed no differences attributable to gro\\·th 
factor treatment (data not shown). 
G·CSF assocl.1fed thrombocrtopenla 
Two monkeys developed protrac.ted thrombocytopenia. One 
had been treated with G-CSf alone. the other with TPO and 
G-CSF. Platelet counts for those monkeys are shown In <l sepa· 
rate graph (fig. 4). The clinical condition of the G·CSf·treatoo 
thwmbocytopenlc monkey became very severe. Including 
dependence on almost daUy transfusions and abundant 
petechiae and other hemorrhages. At this stage. local regula. 
tlom demanded either euthanasia or emergency trc<ltment. 
We elected to kill one monkey and treat the other with TPO 
(10 jJglkg/day sc. from day 37 to day 43). After a lag phaS(' of 
10' 
"8 
'" 
104 
-'" 
" > -'l 103 
0 
'" 1-< 
10' 
0 7 14 2i 28 
time (day) 
Fig. 3. TPO levels In p!asma mea$ured by [USA. for 
e~p!anation of symbols see figure 1. The $haded sqllare$ 
represent TPO·lIcatoo llnfraclionatoo boll(! marrow lIans· 
plants. Samples were taken before lIealment and at days 
J, 1, 10, 14, 11, 21, 24, and 28. Data not Shown We/e 
below dete<;t1on level (320 pg/ml). 
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Fig. 4. Thrombocyte counts in lhe monkey treated with 
G·CSF alone (upper panel). and of the monkey treated 
with TPO and G·CSf (lower panel) that developed pro· 
tracted thrombopenia. The blatk line indieates the level of 
40Xl0'/llhrombOtytes under which tramfuslons were 
given. The black arrows Indieate the tramfusions given to 
the monkeys. the closed ones represent thrombocyte 
transfusions, and the open ones Whole blood transfusions. 
approximately 1 week, platelet counts rose sharply. Increased 
slowly ther('after. and reached normal values by the tenth 
week after Irradiation (Fig. 4). The petffhlae and hematomas 
[('solved within days 
Discussion 
In this study TPQ and G·CSF were combined to evaluate their 
effects after transplantation of highly purified stem cell con· 
centrates into Irradiated rhesus monkeys after TBI at a duse of 
8 Gy. TPO alone did not prevent thrombocytopenia and did 
not significantly stimulate regeneration to normal platelet 
values. With the possible exception of retlwlocytes. other 
cell lineages were not Infiuenced either. Simultaneous treat· 
ment with TIQ and G-CSF (tested in two monkeys) showed 
variable results. In one monkey. neutrophil regeneration was 
enhanced (>O.5x109/L at day 15) whereas in the other It 
regenerated at the same rate as that obsl'rYed in placebo· 
treated controls. Platelet and rellculocyte regeneration was 
augmented In the monkl'Y whose neutrophils regenerated 
faster, whereas the other monkey developed protracted 
thrombocytopenia. Treatment with G·CSF alone did not 
stimulate neutrophil regeneration or affect the red cell lin-
eage. and In one of three monkeys profound and long·last· 
Ing thrombocytopenia developed. To test whether the size or 
cellu!,lf composition of thl' graft w~ responsible for the lack 
of efficacy of TPQ. three monkeys were transplanted with 
unfractionatl'd bone marrow cells at a cell dos(' of \07/kg. 
TPQ treatment In this setting ag,lln did not prevent thrombo-
cytopenia. and recovery to normal platell't values was only 
slightly accelerated. 
In monkeys that were irradiated with 5 Gy TSI without 
receiving a transplant, TPQ (to !--Ig/kg/day) exerted a highly 
stimulatory effect on platelet recovery. as renected hy much 
Iw; profound platelet nadirs as well as an accelerated recovery 
to normal values. resulting in full prevention of thrombocy. 
topenla In these anImals 120] (Fig. 2). Since the duration of 
thrombocYLOpenia and the platelet recovery pattern Wl're the 
~me for the placebo-In'ated monkeys in both llIodels. the dif-
ferent responses to TrQ arc a significant feature. In princlpk. 
thl' difference between the efficacy of TPQ in the stern cell 
transplant model and In the JlIyelosuppr('s~ion model may be 
attributed to the dose of TPQ chosen. the difference In radia-
tion dose. which may have caused more ~troll1al damage In 
the stem cell transplant mooel. or the composition of the cell 
populations in which hematopoietic reconstitution originated . 
The dose and dose schedule of TPQ were based on pilot 
do~e·find!ng experiments In normal mice and rhesus mono 
keys 1191 and were found to be supraoplimal. The dose 
schedule chosen was also fount! to be supraoptimal In the 
myelosuppression mode! in that very high levels of platelets 
were reached within 2 weeks. Apparently. the elevated 
endogenous TPQ lewIs measured In the placebo.treated can· 
trois (Fig. 3). which were more than one order of magnitude 
lower than those obtained with exogenous TPQ. were suffi· 
cient for full platelet reconstitution. Therefore. It Is unlikely 
th~t the Ineffectiveness of TPQ In the transplant model was 
attributable to the dose or dose schedule used. 
It is equally unlikely that the difference between S Gy and 
8 Gy IBI resulted in Significantly Increased stromal damage 
aft('{ the latter dose. and hence Impaired platelet rffonstltu· 
Hon. This is because. in the placebo (oIllrol monkeys, the 
kinetics of platelet reconstitution were very Similar. if not 
Identical. in both models. Furthermore. stromal damage 
resulting In slgn!f1cantly impaired hematopoiesis has only 
been observed following Illuch greater doses of radiation 1311 
than those used In this study. 
lhe composition of the reconstituting cell populations Is 
most likely til(' dechive determinant of a clinically relevant 
response to IPQ. In the S·Cy myelosuppression Illodel. the 
residual cells were depll'ted of stem ceUs and progenitor cells 
by less than 2 orders of magnitude and remained In their 
normal stromal environment. It Is also cle,1r from the kinetics 
of the TIQ respome In this model that Its effectiveness was 
determined in the Initial pbase after TBI. a conclusion that 
has been corroborated by the diminished response to delayed 
administration of TPQ 1321 as well as by the obs('fvation 
made In mice that a single initial Iv injection of TPQ was suf-
ficient to prevent profound thrombocytopenia 133]. In the 8 
Gy model. on the other hand. Iherl:' was a greater than 3.log 
5tem cell depiction. and the hematopoietic reconstltutlun 
pattern observed was dependent on Infused. hIghly purified. 
and progenitor cl'lI-depleted stem cells. which needed to 
horne Into the hemalOpoietlc sites. It is conceivable that in 
this situation Initial hematopoietic reconstitution cannut be 
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stimulated by TPO alone. but needs to be either boosted by 
othrr growth factof5 or stimulated b .. fore TrQ treatment to 
generate IPQ·responsive progenitor cells_ Since the r("ponst' 
to TPa was also severely diminished in the unfractionated 
bone marrow recipIents compared with the 5-C}' myc!osup--
pressed monkeys. \\hfch had platelet recomtltlltloll kinetics 
similar to the placebo. treated control monkey. the inefficacy 
of TPQ and G·CSF cannot be atlrltlU(ed solely to the deple-
tion of progenitor cells: It may also be a result of poor 
engraftment of the responsive progenitor cells. finally. our 
results Indicate a steep decline in TPO and G-CSF responses 
with increasing radiation doses, a phenomenon that has also 
been observed for growth factors such as GM·CSF 1341 and fL· 
3 1351. Thus. although it is possible to accelerate hemato· 
poietic reconstitution after high·dose TBI by gh'ing either a 
stem cell graft or unfractionated bone marrow. exogenous 
gmwth factors add lIule to the reconstitution because of the 
relative lack of progenitor cells [18,341. 
There is a strong <lnd justified tendency in treating a 
majority of patients to replace bone marrow transplantation 
with cytokine-mobllized peripheral blood stem cell trans· 
plantation. because the latter have significant advantages in 
terms of stem cell procurement and the number of cells that 
can be harvested. As a consequence of the rapid hemato-
poietic reconstitution observed In recipients following trans-
plantation of mobilized peripheral blood cells. It is difficult 
to justify the use of growth factor stimulation to further 
accelerate blood cell production. Indeed. thrombocyte regen-
eration may well be complete within apprOXimately 2 weeks 
136-38]' making It unlikely that growth factors such as TPa 
will signtf1camly enhance this response. Therefore. the pres· 
ent data apply only to clinical conditions in which limited 
numbers of Immature hematopoietic cells are av,]i!able for 
transplantation. In spite of advances made. the relative lack 
of these cell~ will continue to be observed in a minority of 
autologous transplantation cases after intensive chemo-
therapy or in gene tran~fer protocols. This lack of stem cells 
will also continue to be seen follOWing allogeneic transplan-
t,]tlon. which requires more stem cells than used In autolo· 
gous recipients because of the histocompatibility barriers 
and because the number of donor cells available for procure· 
ment. especially when matched unrelated donors arc 
involved. Is necessarily limited. Similarly. allogeneic trans-
plantation following ~uboptimal Immunosuppression. such 
as occurs in whole body radiation aceldent vlahns and in 
some of pediatric recipients treated for hereditary denclen-
des. may resulL in significant loss of stem cells through 
rejection. For those cases it remains necessary to develop 
growth factor treatment regimens that both accelerate short· 
[crill hematopoietic regeneration and promote sustained 
reconstitution. The present study shO\~s that this cannot be 
easily accomplished. 
Our finding that two of five G·CSF·treated monkeys 
de\'Cloped protracted thrombocytopenia. one despite treat· 
ment with TPO. suggeHs that in situations in which limited 
numbers of ceUs are available for lu:,matopoietic flxonstitu-
tiOrl. G·CSF treatment may prove detrimental to platelet 
reconstitution. The association in our study between pro· 
tracted thrombocytopenia and G-CSF was statistic,]lly signifi· 
canl (p < 0.03. Fisher's exact test) when the resuits are 
compared with those oblained In 2~ monkeys exposed to 
~imilar doses of TBI and shn!lar numbers of transplanted 
CD3~' cell, (induding the 6 monkeys not treated with C· 
CSF in the present study). in which protracted thrombocy. 
topenia was not observed (manuscript in preparation). 
Thrombocytopenia Is an occasionally reported side eff!.'o of 
G·CSF treatment [11.39.401. A[though delayed thrombocyte 
recovery, as well as dampening of TPO-stlmulated thrombo-
cyte production by G-CSF treatment. has been observed in 
recent animal studies [4 [,421. no animal model has been 
developed thusfar for the study of protracted isolated throm-
bocytopenia after BMT. A model exists In normal dogs treat-
ed with canine GM·CSF in which consistent 
thrombocytopenia develops [43,44J. but its mechanism may 
be different from that of post-B~1T thrombocytopenia. We 
took advantage of the G·CSF·associated. isolated thrombocy-
topenia to examine the effect of TPO treatment for 7 days 
(10 [Jg/kg/day sc) in one of the monkeys, using the other, 
le~s severely thrombocytopenic monkey as a control. After 1 
day of TPa treatment. the severely thrombocytopenic mall' 
key's clinical condition improved. with a rapid disappear· 
ance of petechiae and hematomas. Platelet counts started to 
rise after a week and the monkey became transfusion inde· 
pendent 6 days after the start ofTPOtreatment. The kinetics 
of the increase in thrombocytes was similar to that seen in 
unirradlated TPO-ueated monkeys [71: After discontinuation 
of TPO. the further rise in platelet counts slowed down and 
an additional 3 weeks elapsed before normal values were 
restored. Although this case report remains anecdotal, the 
pattern observed suggests that TPa will be benenclal In pro-
tracted isolated thrombocytopenia following stem cell trans· 
plantation andlor B~IT. 
The present study demonstrates that. after high·dose total 
body irradiation and transplantation of limited numbers of 
bone marrow cells or highly purified stem cells. TPa and G· 
CSF are ineffective in accelerating platelet and neutrophil 
reconstitution. respectively. although they both enhance 
recovery from radiation· Induced myelosuppreSSion. These 
findings may be explained by the composition of the cen 
populations in which hematopoietic reconstitution origi-
nates: they may also indicate that TPO and G·CSF targets In 
transplanted BM are either few in number or difficu[t to 
transplant because of poor engraftment. which became espe-
cially apparent in this study after transplantation of the lim-
Ited cell numbers used. The study further defines the 
limitations of effective growth factor therapy following 
intensive cytoreductive treatment. 
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CHAPTER 6 
A single dose of thrombopoietin shortly after 
myelosuppressive total body irradiation prevents 
pancytopenia in mice by promoting short-term 
multilineage spleen-repopulating cells at the transient 
expense of bone marrow-repopulating cells 
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A Single Dose of Thrombopoietin Shortly After iVlyelosuppressiye Total Body 
Irradiation Prevents Pancytopenia in 1\'1ice by Promoting Short-Term 
.Muitililleage Spleen-Repopulating Cells at the Transient Expense 
of Bone 1\'Iarrow-Repopulating Cells 
By Karen J. Neelis, Trudi P. Visser, Wati Dimjati, G. Roger Thomas, Paul J. Fielder, Duane Bloedow, Dan l. Eaton, 
and Gerard Wagemaker 
Thrombopoietin (TPO) has been used In preclinical myelosup· 
pression models to evaluate the effect on hematopoietic 
reconstitution. Here we report the Importance of dose and 
dose scheduling for multitineage reconstitution after myelo-
suppressive total body irradiation (TBI) in mice. After 6 Gy 
TBI, a doseofO.31-l9TPOtmouse (12I-lg/kg) intraperitoneally 
UP),O to 4 hours after TBI, prevented the severe thrombope-
nia observed In control mice, and in addition stimulated red 
and white blood cell regeneration. Time course studies 
showed a gradual decline in efficacy after an optimum within 
the first hours after TBI, accompanied by a replacement of 
the multillneage effects by lineage dominant thrombopoletlc 
stimulation. Pharmacoklnetic data showed that IP injection 
resulted In maximum plasma levels 2 hours after administra-
tion. On the basis of the data, we inferred that a substantial 
level of TPO was required at a critical time interval after TBI 
to Induce multifineage stimulation of residual bone marrow 
cells. A more precise estimate of the effect of dose and dose 
timing was provided by Intravenous administration of TPO, 
which showed an optimum immediately after TBI and a 
sharp decline In efficacy between a dose of 0.1l-lg/mouse (4 
I-lg/kg; plasma level 60 ngtmll, which was fully effective, 
and a dose of 0.03 I-lg/mouse (1.2 ,...g/kg; plasma level 20 
ng/mLI, which was largely ineffective. This is consistent 
THRO~IBOPOIETIN (TPO), the ligand for the cytokine receptor C-lIIp!, ha~ been cloned nnd characterized in 
19941.3 and shown to be the physiologicnl regulntor of platelet 
production by generating mice deficient for either TPO or 
c-mpl.-I5 Admtnistnltion of phannacological doses of TPO to 
normal mice and nonhuman primates resulted in dose-
dependent increases in platelets, far exceeding that observed 
aCler administmtion of other growth factors.I.V;,1 These observa-
tions have led to the phamlaceuticill deyelopment of TPO as a 
therapeutic to counteract thrombopenic states, such as those 
resulting from myelosuppression due to cancer treatment. In 
myelosuppression models, TPO effectively alleviated the nadir 
for platelels and accelerated reeowry to normal values.6 .1l-1i In 
several of those models, daily administration during the pancy~ 
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with a threshold level of TPO required to overcome initial 
c·mpJ-mediated clearance and to reach sufficient plasma 
levels for a maximum hematopoietic response. In mice 
exposed to fractionated TBI (3 x 3 Gy, 24 hours apartl, IP 
administration of 0.3 ,...g TPO 2 hours after each fraction 
completely prevented the severe thrombopenia and anemia 
that occurred in control mice. Using short-term transplanta. 
tion assays, ie, colony.forming unit-spleen (CFU-S) day 13 
(CFU-S-13) and the more Immature cells with marrow repopu-
lating ability (MRA), it could be shown that TPO promoted 
CFU-S-13 and transiently depleted MRA. The initial depletion 
of MRA in response to TPO was replenished during long-
term reconstitution followed for a period of 3 months. Apart 
from demonstrating again that MRA cells and CFU-S-13 are 
separate functional entities, the data thus showed that TPO 
promotes short-term multilineage repopulating cells at the 
expense of more immature ancestral cells, thereby prevent-
ing pancytopenia. The short time interval available after TBI 
to exert these effects shows that TPO is able to intervene in 
mechanisms that result In functional depletion of Its multl1in· 
eage target cells shortly after TBi and emphasizes the 
requirement of dose schedullng of TPO in keeping with these 
mechanisms to obtain optimal clinical efficacy. 
:[) 1998 by The American Society of Hematology. 
topenic phase re'iUlted in an overshoot in platelet counts to 
supranonnal \'alues.~5.1(\.11 Although in nom13l experimental 
animals the response to TPO was dominant along the megakaryo-
cytic lineage, in myelosuppression models multilineage effects 
have been shown Sllch as stimulation of erythroid recov-
ery, 8.11·1-1 accelenltion of immnture progenitor cell reconstitution 
in bone marrow,S.15 and augmentation of the responses to 
granulocyte-macrophage colony-stimulating factor {GM-CSFJ 
and !,'Tanuloc}·te colony-stimulating factor (G_CSF).8.16 We and 
others have shown that a single dose of TPO administered 24 
hours after total body irradiation ('fBI) WilS as effedive in 
alleviating the nadir for thrombocytes as daily dosing, D.I6-I~ 
thercby reducing the need for thrombocyte transfusions in 
myelosuppressed nonhuman primates and accderating recovery 
to normal platelet counts. The effects on rcd cell regeneration 
and immature bone marrow progenitor cells were retained with 
single dosing of TPO.Ll.16 These results showed that the more 
conventional dose schedules that have come into use for growth 
factors such a.~ G:-'\-CSF and G-CSt-: werc less appropriatc for 
TPO. 
Careful design of growth factor treatment protocols requires 
preclinical experiments to gain insight into the mechanbms of 
action and in the optimal dosc and dose schedule to achieve 
maximum therapeutic benefit and reductions in the occurrence 
of side effects. a.~ well a.~ tn prevent unne<.:e~sary tn:atment. 
thereby reducing co,t ... Hecau,e a dclay in the administration of 
TPO lifter <:yton::du<.:Iivc Irealment proved to he detrimental III 
its etlicacy.!~·I'" we examined in Jel,lil the time de~nden..:c of 
TPO eflkaey in the initial 12 hOUf:- after mydllsupprc,sivc TBI. 
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with special emphasis on the response of inunature bone 
marrow cells and their progeny, to rewal mechanisms ofTPO 
action on immature repopulating cells important for efiteacy. 
MATERIALS AND METHODS 
Allimais. Female (C57BL X CBA)Fl (BeBA) mice, apprm:i· 
maldy 12 \\e-eks of age, were bred at the E'p<'rimen!~l Animal Facility 
of Erasmus Unin'n.ily (RouerJ.lnl, The Netherlands) and maintained 
under spcdfic pathogen· free ~onditi0ns. Housing, <,.'penment" and all 
other conditions were approW-d bY:ln ethical committee in accordanc,) 
Wilh lega! r<'gulations in The Netherbnd" 
ETpnime/llll! design TBI was administered at da} 0 using two 
oppo,jng 137Cs sources (GaffiffiJcell 40; ,\tomie Energ>' of Canada., 
Onawa, Canada) al a do,e rate between 0.92 and 0.9-1 Gy/min as 
described."') Doses u~ed were 6 Gy for single dose irradiation and a 
fractio[]ated do,e of 9 Gy in thrcc cqU:ll dOles \Iith 24·hour inter.·als. 
Mice were bled only once; for each data point a random expaimenlal 
group of three mice wa, kiHe.l. All parameters Were c()!le.;ted for 
indivjduallllice. 
7(jt dnlf? Re.;;()mbinant full length murine TPO produccd by 
Chinese hlIlliter ovary cells (Gencntcch Inc. South San I'ranci>co, CAl 
was used throughout the ex~rilllents, diluted in phosphate-buffered 
salinelO.OI~t 1\lwn 20, and administered intra~ritoneall)" OP} Dr 
intr,m~nOUlly (lV) in a volume of 0.5 rn1.. The dose ofTPOu,ed\\'a, 
OJ pglrnouse (12 )1g/kg, based on a mean body weight of 25 g at the 
lime of irradiation) unle~s otherwise indicatoo. We haye previously 
shown that this dose \Ia, effectil·e ill a similar model for rnydosuppre,-
sion.\J 
HrmatoloRiC" e.wmiH(lliolls. After ether·ane~thc~ia, the mice were 
bled by retro-orbital puncture and killed by ce,,·ical dislocation. Blood 
W.l' collected in EDTA tube,. Complete blood cell count, were 
measurcd using a Sy,mex I'-SOO hematology ;mal}"ler (ToJ. ~ledic,ll 
Ekwonics Co, LID, Kobe, Japan). 
I'hel1ot)pic ol1(1/JJi~ 0/ white blood cdk For phcl10typic anal)',i, 
blood wa, collected in EDTA tub<",. Samples from three mice that 
recei\'ed the sanlC treatment were pooled 10 yield sufficient number, of 
c~!!<;. Rcd blood cd!, \\ere remo\'ed by incubating 'Ihole blood in 
lysing solution (8.26 g ammoniUlll chloride/l.O g pO[a<,sium bkarbonate 
and 0.OJ7 g EDTAfL) for 10 minutes at 4T. After lysing, cells were 
washed twice \\ith Hank~' buffered Hepes ~olmiol\ (millS) containing 
0.5~t (\'ol/ml) bovin!.' .,,"-'rum albumin (BSA; Sigma, St Loui" MO), 
O,OY~ (\\t/yol) sodium aLide, and (lA5';} (wt/vol) gluco,e (~krck, 
DJ.IIl1<;tadl, Germany) (HBN). The cdl_ were rew'pended in 50 pL 
HBN CDntaining 4% (\'oJfml) normal mome ~erurn to preyent nOI1'pe-
rifle binding of the monoclonal antibodies (MoAb<,). To detet.·t neutro-
philic gr,;nulo.:)te<; and monocyte, the MoAh ER·~IP20 (mt IgG.!..)!1 
\1<1> added in a mlulTIc of 50 flL. ER-~IP20 bright cell<. are monoc) le<; 
(corre,pnnding with Mac-l-po,ill\'e cell,1!) and ,·ells ~taining illlerme-
diate \\ith ER·~IP20 are gr,.Ir1UIIl<:)WS (co='ptlnding with Gr-I-
pmili\'c cdl,)!). To deted I)'rnphoc)te~ the anti-CD-J ~loAb YTS [91 
and thc anti-CDS :"lnAh YTS J(,9?_1 (a kind gift from Dr 11. Waldmann, 
Department of pJthnlogy, Canlbritlge Uniyel>ity, UK) were added at a 
com·entr~tion of 2 pglmL. Celh ;md "'loAb, were in,·ub~ted for )U 
minute, 011 icc. After two \\<I,h .. , the cdls were in,·ub~ted with a 
tluore<,(dn·!Jbded goat-anti-r.lt MnAb. After another two lI'a<;heo;, the 
cdf<, were labeled with pl1!pidium iodiue and rne,l<;ured by now 
C}\f1llJctry. UngaltlJ lil\IlHll.k dJta wCfccoJle<.:ted fm In,UOOnenh ,lOt.! 
iinJlyzC'd u,ing Ly,h II ~oftll'J.Ie (BC'ctnn Didio,,)n, Mountain Vkw, 
C;\). 
TI'O In-d<. D~ta for characterit<dinn pla.S()lJ TPO phJrma;;(lkinet-
ie .. ,Iere "enerat~d at Gencnl""h Inc '" prel'iou,Jy de\cribed.~~ In '[lOrt. 
mke "eft' inje~t~d IP \Iith 1~\I-rmTPO eith~r with a .. ingle d",e of 0.9 
pg/m"u,e (3/', pg/kg) nr I,ith three o.I",c, nfO.3 )Jgfmnu,e (12 J-l.?J1g) 
separated by 2-l- hour,;. Citrated blood I,as collected immediately :lfter 
dosing and at inter'ials thereafter (n = 3 mice p"r time point), ceotri-
fUged at 2,950g for 10 minute" plasma obtained, :lnd TCA-precipitable 
radioactivity determined. Phamlacokinetic parameters were estimated 
:lfter converting trirhloroa,·etic acid--il!ccipitab1e cpm/IilL and fitting 
the data of concentration '-ersus time to a two·comp~rtment model ,lith 
first l'fder ablo/ption using nonline:lT leaq-squares regres<.ion anJ.lysis 
(WIN-NONLlN; Statistical Comultants, Le;l;ington, KY). Area under 
the concenlr~tjnn time cu,,·cs, ma:umum concentration, terminal half· 
lives, and cleJ.rance (mlJhlkg) were l.'a1cuJated using coefllcient<; and 
e~ponents obtained from thc model fits. 
Colony (lSj:(IJJ. Sef1Jl11-freC' mcthylcellulo,e culturcs were used in 
this study.ll-11 Appropriate numb-ers of bone m3JTOI\' cells were 
suspended in Dulh.xco's modified Eagle's medium obtained from 
GIBCD (Life Te.:hnologie;; LTD, P.lis1ey, S,·otiand) supplemented with 
the amino acids L-~1anine, L-alparagine, L-asp~rlk add, L.cy~teine, 
J.. .. glutamic acid, and L-proline (Sigm3); ,-itamin B11, biotin, Na-
pyruvate, glucose, NaHCO .• , and antihiotics (penicillin and streptomy-
cin) at an osmolarity of 300 mD.,m/L; 5uppkmented with I '.t, BSA 
(Fraction V, Sigma), 2 X 10- 6 mollL iron·saturJted hUr)l!lll transferrin 
(intergen COIllI-'!lllY, New York, NY), 10-7 mollL NazSeOj (Men:k), 
10"4 moUL Il·men::apto-ethanol (Merck), linoleic acid (Mcrd.:), aDd 
cholelterol (Sigma), both ;It a final conccntration of 1.5 X 10-5 mollL 
~nd 10' j gIL nucleoside, (q-lidine, adenosine, uridine, guano,ine, 
2' -dwx),<?ytidinc, 2'dcoxyadenosine, thymidine, and 2'deoxyguano;ine 
obtained from Sigma) and 0.8% methykdlulose (Methocel A4M 
Premium GrJde; Dow Chemi,'al C(I, Barendrccht, The Netherlands). 
The culture" were plated in 35-mrn Falcon lOOS Petri dishe, (Becton 
Dickinson Labware) io j-mL aliquots.15 
Gnmul<xyte/maCfophage colony fonnation was stimulated by a 
saturating concentration of macrophage colony .. stimulating factor (M-
CSF) purified from pregl1ant mOllse uteri extract as de>cribed be-
fore,l"-.:'! supplemented with 100 nglmL murine stem eel! fador (SCI'; 
Immunex Corpor.ltion, Seattle, WA) and 10 ng/mLmurine interkukin·3 
(lL-3; R&D, Minneapolis, ~m). GrJnuh:,.;ytelmacrophage colony-
forming unit (G:"l-CFU) colonies were counted after 7 days of culturc. 
Burst-forming unit---el)'throid (BFU-E) gru'llh was stimulated hy 100 
nglmL SCI' and 4 UlmL humID ef)'thwpoietin (EPO; Behringwerk, 
~Iarburg, Gennaoy), titmted to an optim~1 concentration. Colonie, were 
counted after 10 day, of culturc. The culture medium of the el),throid 
progenitors al\o contained hcmine (bovine, ty~ I; Sigma) at a 
concentration of2 X 10 -~ moUL. 
Megakaf),oc)'te progenitor edls (CfU-:\leg) were cultured in OJ75<J. 
agar culture,. Colony forma1ion was stimulated by 100 nglmL SCF, 10 
nglmL IL-3, and 10 nglmL murine TPO (Genentech Inc). After 10 d~y" 
the cultures were dried, ,tained for acctykhllline<;terasc.positi\"e cells, 
and coumC'd.-")-l~ AI! cuI lure, were grown in dUplicate at 37'C in a fully 
humidified atmosphere with 10% COl in the ~ir. Colony numt>ef'\ are 
e_\prc<;o;cd as a number per femur or ~r ~ple.:'n ~l1d represent the 
mean..! SD of individu,d mice. 
771,· _'pfCt"1l colollY aHay. Thi, a<;~ay was perfllmled a, dcscrib.:'d by 
Til! and McCulloch.)) Brieny, mice werc injected with one fifth of the 
cell content of a femur in HHBS one dJ.y after TB!. lllirtcen days I~ter, 
mke were kilkd, and splt"<'n'> were e\cj<;ed and fixed in Tellyesniczly's 
solutiun (f>l~i ethanol. 5\'\- acetk ;)dd. ~nd 2% form~ldeh)'de) in 1i,0. 
Colony number;; lIerc cxpre ... ~ed ii' a numb.:r per dunor femur ± SD. 
The celh giving rhe to thc spleen colonie_<; wcrc dnignated as day 13 
CFU·~pken (CRJ·S), ~hortl)" CfU-S-13, 
MarrOn" ,,'populating allilil)' (JIRA). Bnne ll1:mu\\" from micc 
irrJuiated with 9 Gy TBI (in 3 equal fr.lctions. ea,-h ~~par.l[ed hy 24 
hours) wa' l'olkned 24 hOUT> after the la<;t fr.lction \If TBI, and !O 
Ieth"lIy irradiated rccipil'nt mke were injected with the cellular content 
(If <me remur of control mke <lr mice tr~ated \,ilh 0.3 pg ofTP02houI> 
aft~rcJlh fraction ofTB!. After 13 days the bone I1lMroll' nfre.:ipient 
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mice were assayed for the pre,ence ofG)t.I-CHJ.J-I )t.1RA is express~d as 
the number of GM·CFU p"r recipkut femur. Data from two indepen~ 
dent experiments \\ith similar re,:,ult, were pooled. AI the lime points of 
I and 3 months and for nonllal mice, the standard number of lOS bone 
marrow (eils was injected. 
Statistics. SD, \\<'re calculated and are gh'en in the text and the 
figures on the assumption of a norma] distribution. The significance of a 
difference was calculated by one-way analysis of vallance fOllowed by a 
nonpaired Student's /-telt using StatView (Abacus Conc<'plS Inc. 
Berkeley, CAl. The SD ofCFU·S·13 \y,Js(akuJatcd on the assumption 
that (rude colony (ounts are Poisson distributed. Differences in 
repopulating abilitiel were evaluated uling Fisher's e~act test. Ail 
colony a"ays were p<'lfoml<,d in duplicate for indiyidual mice. The 
results of the colony assays are e~pressed as the mean ± SD pa femur 
or spleen for atlea~tthree mice per group. 
RESULTS 
Efficacy ojTPO after 6 Gy TBI. Exposure of mice to a TBI 
dose of 6 Gy resulted in severe bone marrow suppression and 
impaired blood cell production for a period of about 3 weeks. 
The nadir for thrombocytes occurred around day 10 (Fig 1). A 
single dose of TPO administered 24 hours after TBI was 
effective in alleviating the thrombocyte nadir. Plateletcounl~ 10 
days after irradiation were 465 :!: 142 X J09/L (n = 15) 
compared with 144 :t 62 X 109/L for control mice (n = 14), 
(Fig 1 and Table I). TPO injected 2 hours after exposure was 
significantly more effective, thrombocyte levels 10 days after 
TBI being 739 ± 165 X 109/L (n = 15, P < .0001). White 
blood cell regeneration was not influenced by TPO adminis-
tered 24 hours after TBI; counts at day 10 were 0.4 ± 0.1 X 
109/L, similar to 0.4 ± 0.1 X 109/L for control mice (Table 1). 
However, if TPO was administered 2 hours after TBI, white 
blood cell counts 10 days afterTBI were 1.1 ± 0.4 X I09/L. For 
red blood cells the results were: 7.2 :t 0.5 X JOH/L for control 
mice, 7.5:t 0.5 X 1012/L for the 24·hollrmice, lllld 9.0 ± 0.6 X 
IOH /L for mice Ire,1ted 2 hours after TBI (Table I). Ckarly, 
administration earlier than 24 hours after TBI resulted in an 
accelerated multilineage peripheral blood reconstitution in 
7 14 
time (days) 
Fig I. RegeneratIon pattern of platetets In mIce Irradiated with 6 
GV TBt and treated with 0.3 ,.g/mouse ofTP024hoursafterT81(0),2 
hours after T81 (_" or placebo to), data from one representative 
experiment, n '" 3 per data point. The shaded area represents the 
mean platetet counts ±SD of 19 normal mtce (1123 ± 89). ·P< .0001 
compared with control mlce;'P < .0001 compared with mice trealed 
24 hours after TBI. 
Table 1. Major Peflpheral Blood Cell Counts 10 Davs After 6 Gy T61 
and IP TPO AdminIstration 
lime RedB'ood White Broad 
R~I"t<v" TPOO<>se Ceils Ce'~' Platelets 
(oTBt I~\ll jXl0",1-1 {x1(t>.l) (xtD'.'L1 
14 7.2 ± 0.5 0.4.± 0.1 144 ± 62 
+24h 0.' 16 7.6:!: 0.6 0.4.± 0.1 465 .± 142' 
+2h 0.' 15 9.0.± 0.6't 1.1 ± O.4't 739 ± 165't 
-2h 0' 9.0'± 0.2*t 0.7.± 0.2't 533 ± 55'* 
-2h 30.0 9.0 ± 0.3't 0.8.± 0.2'1 718 ± 86't 
Normal mIce 19 10.2 :!: 0.6 5.3:!: 1.9 1,123 ± 89 
'Significantly different from control mice. 
tSi9nifitantiv different from mice treated 24 hours after TBI. 
tSignificantly different from micolreated with 30 Vg TPO 2 hours 
before T61 IP = .03). 
contra,t to the lineage domin~nt effect of TPO when adminis-
tered 24 hours after TBJ. As is well known from previous 
observations in mice and nonhuman primates,9.15 the multilin-
e~ge effects originated from accelerated reconstitution of pro-
genitor ceJls along the neutrophil, erythroid, and megakaryo-
cytic lineages measured in bone marrow of mice 7 days after 
irradiation. Femoral GM·CFU, BFU-E, and CEU~Meg reached 
consistently higher numbers in the treatment group compared 
with the placebo conlrols. (Fig 2). The results in the 24~hour 
treatment group were in b<:tween those of the 2-hour and control 
groups, although the differences were significant only for 
G~t~CFU due to the large variance as a result of exponential 
reconstitution of progenitor cells at this time inten'al after TBI. 
The higher number of femoml G;\t·CfU in the 24-hour 
tr<'atment group compared with control numbers was not 
reflected in Hcce1emted leukocyte regeneration 10 days after 
TBI (Fig 3), which is consistent with our previous obsen'ation 
in rhesus monkeys that the TPO effect on GM progenitors may 
20.----------------, 
15 
10 
5 
o 
Fig 2. The effect of 0.31-'g TPO 24 hours or 2 hours after TBI on the 
regeneratfon of bone marrow progenitors after 6 Gy T611n mIce. GM, 
GM·CFU; E, BFU·E; and Meg, CFU·Meg per femur at day 7 after T61 
(means ± Sf). The open bar to) represents control mIce (n '" 6). the 
IIghtlV shaded bar (O) represents mice treated with TPO 24 hours 
afterTBI In '" 6), and the dark shaded bar lliI! represents mice treated 
with TPO 2 hours after T61 In'" 6). 'Sign!flcal1l compared with 
conlrol mIce (P < .03), 'significant compared with mice treated with 
TPO 24 hours after Irradiation {P < .03\. 
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FIg 3. The effe<:t of th",lIme of admInistration of 0.3 "9 TPO IP on 
perIpheral blood (:eU counts 10 days after 6 Gy TSL Values are 
means ± SD. Shaded areas repff:lSent the mean ± SD of 14 control 
mIce. The closed squares (_j are counts from mice tfeeted with 30 fig 
of mTPO 2 hours before Irradiation. 
require administration of G- or G~t-CSF for peripheral blood 
manifestation.S.t6 
To establish the optima! lime point for TrQ administration, 
mice were injected IP with a single dose of TPQ at various 
intervals before or after 6 Gy 1BI. Based on Fig I. the lime 
dependence of the effect of TPO treatment was evaluated 10 
days after TBL The effect of TPQ was consistently optimal if 
TPO was administered IP 0 or 2 hours after TBI (Fig 3). 
Progressively lower counts were observed when TPO wa~ 
injected at later time points; platelet counts at day !O after TBI 
did not significantly differ between miee treated 6 hours or later 
after TBI, whereas the difference between later !,.'TOUpS amI the 
O~ and 2-hour groups were highly significant (P < .003). 
A !>imilar time dependence wa~ observed for white and red 
hlood cell counts. For the white blood cells, TPO administration 
!O hours or later after TBI resulted in counts not significantly 
different from control mice while being significantly lower than 
thc 0- and 2-hour treatment groups. The effect on white blood 
cell regeneration could be attributed to differences in neutro-
philic granulocytes and monocytes. Flow cytometric analysis of 
peripheral blood ce!Is 10 days after irradiation performed in two 
cxperimenL~ rewaled a major increase in the numbers of 
ER-MP20-positive granulocytes and monocytes in the TPO 
treated mice, whereas the number of CD4/CD8-positive T cells 
was similar in TPO treated mice compared with controls (data 
not shown), thus showing the myeloid nature of the white blood 
cell response. Also for red blood cells a gradual decline in 
effectiveness of TPO with later administration of TPO was 
observed. We noted that there was no difference between the 
effects of TPO administration at 0 hours and at 2 hours after 
TBI, whereas TPO administration 2 hours before TBI resulted 
in consistently lower levels of platelets and white blood cells at 
day 10. The hypothesis that phannacologieal levels of TPO in 
the first hours after TBI are required was initially evaluated by 
administration of a very high dose of TPO before TBI to 
examine whether an efficacy could be reached similar to that 
obtained by TPO early after irradiation. Administration of 30!1g 
TPO IP2 hours before TBI was as effective as 0.3!1g IP2 hours 
after TBI (Table I and Fig 3). The dose of 0.3 !1g!mouse IP 2 
hours before irradiation was significantly less effective com-
pared with the 30-!1g dose in alle"iating the thromboc}'te nadir 
(/' = .03) (Tablc 1 and Fig 3). 
The improved efficacy ofTPOwhenadministeredearlyand 
the decline in the efficae), at time points later than 4 hours after 
TBI led us to speculate that relatively high levels ofTPOinthe 
first 2 hours after administration would be of decisive impor-
tance for its eflicacy. A pharnmcokinetic analysis of plasma 
levels after IP injection of 0.3 !1g TPO revealed that peak levels 
of 29 nglmL were reached 2 to 2.5 hours after administration, 
with a terminal half-life of 35 hours and a clearance of 27 
mlJhJkg. After the ma."ILimum value, there wa~ an initial steep 
decline followed by a slower wash-out phase (Fig 4). On the 
basis of these data, in combination with those of Fig 3, we 
postulated that the multilineage emeacy ofTPO was dependent 
on a threshold Icvel ofTPOwithinthe first few hours afterTBl. 
The time course and the plasma level required were accurately 
assessed using rVadministration ofTPO(Table2andFig5).IV 
administration also showed that early treatment (0 ond 2 hours 
after TBI) wos considerably more effecti\'e in stimulation of 
platelet le\'el regeneration than treatment 24 hours after TBL 
The multilineage effecL~ seen with early lP treatment were also 
obsen'ed with early TV administration, and were similarly lost if 
TPO was administered 24 hours after TBI (TobIe 2). Lowering 
the dose ofTPOtoO.1 rlg!mouse did not affect the results, but at 
0.03 jJg/mouse or lower ellieaey was lost, thus demonstrating a 
threshold TPO level required to aehicve optimal multilineage 
efiieacy (Fig 5). 
Efficacy of TPO after fraclimwted irradiatiol/. To enable 
a~sessment of immature hematopoietic cells by short·term 
lransplantotion o~says, which is technically not feasible shortly 
after 6 Gy TBI due to the vcI)' low frequency of residual 
immature cells, we amplified theTPO response by adjusting the 
model by fractionation of a total dose of9 Gy TBI in three equal 
doses separ,lIed by 24 hours. This regimen induced a slightly 
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Fig 4. Plasma level of TPO after IP administration of 3 doses of 0.3 
Itgfmouse separated by 24 hoUis each Idotted lines}, and of a single 
dose of 0.9 jigfmouse {solid line}. For explanation, see text. 
more profound pancytopenia Ihan the single dose of 6 Gy TBI 
(Fig 6). Fractionated TBI would also more closely resemble the 
protracted cytotoxic insult administered to chemothempy pa· 
tients. Groups of mice receiwd either no TPO, or were treated 
with 0.9!-1g TPO 2 hours after the last fraction ofTBI, O.3]Jg 
TPO 2 hours after each fraction ofTBI, or 0.9 !-Ig TPO 2 hours 
before the first fraction of TBL Pharmacokinetic analysis of 
repetitive lP administmtion (three doses of 0.3 ~Ig/mouse, each 
sepamted by 24 hours) did not re,·eal accumulation of TPO 
plasma levels. The dose ofO.91-lg/mouse resulted in higher peak 
plasma levels (151 ng/mL) without affecting the temlinal 
half-life or clearance (Fig 4). TPO administered 2 hours after 
each fmction of radiation completely prevented thrombopenia 
(rIg 6 and Tnble 3). This schedule did not prevCI\t the severe 
reduction in neutrophils, but accelerated their recowry to 
nonnal values. Platelet counts and red and white blood cells 
were significantly lower in the group treated with 0.9!-1g TPO 2 
hours after the last fraction compared with 0.3 pg TPO 2 hours 
after each fraction. Administration of TPO 2 hours before the 
first fraction in a dose of 0.9 !-Ig/mouse was largely ineffective. 
The effeet ofTPOonbloodcellregenerationwasulsoreflected 
at the level of progenitors of different blood cell lineages (Fig 
7). Placebo mice and mice treated with 0.9 !-Ig/mouse 2 hours 
before TBI displayed very low levels of progenitors even at day 
\3 after TBI, before progenitor cell reconstitution resulted in a 
Table 2. Major Peripheral Siood Cell Counts 10 Days After 6 Oy TBI 
and IV TPO Administration at Different limepolnts After TBI 
Time 
"" 
Re<lSiood While Blood 
ReTat"·., Do" CerTs ceils Platelets 
toTSI t~gl txl0",1l Ix1O',l) 1,,1O',t) 
14 7.2:<:: 0.5t 0.4:£ 0.1t 144:<:: 62t 
0 0.3 12 8.7 :!: 0.5' 1.0:<:: 0.2' 838:<:: 116' 
2 0.3 6 8.8 ± 0.5~ 1.0 ±O.P 765 ± 119· 
4 0.3 6 8.2 :!. 0.5~ 0.7:!. O.Pt 658:!. 140·t 
0.3 6 8.3:<:: 0.3" 0.5:<::0.Pt 691 :<:: 77't 
B 03 6 7.8:<:: 0.3't 0.5:<::0.1f 504:<::SS'f 
24 0.3 7.5 ± 0.2t 0.3 ± 0.1t 424;:';- 143't 
Normal mice 19 10.2 ± 0.6 5.3 ± 1.9 1,123 ± 89 
·Significantty different from control mice. 
tSignificanlly different from the O-hour treatment group. 
large overshoot, especially manifest in the spleen 3 weeks after 
TBI. In contrast, the schedule optimal for blood cell regenera-
tion (2 hours after each fraction) also led to a rapid nOnllaliza· 
tion of progenitor cells in the spleen without the characteristic 
large overshoot in the placebo controls (P = .01 at day 17) and 
in the mice treated with the suboptimal TPO dose schedule. In 
the fractionated radiation model, administration of 30 !-Ig of 
TPO 2 hours before the first radiation fraction was as effective 
as TPO administered 2 hours after each dose of radiation (Table 
3 and Fig 6). 
Because the progenitor cell data of irradiated TPO·treated 
mice in this fractionated TBI regimen indicated a prominent 
effect ofTPOon immature bone marrow BM cells, CFU·S·13 
were enumerated, the MRA of bone marrow of the TPO-treated 
mice assessed, and progenitor cells assayed 24 hours after the 
last TBI fraction (Table 4). The numbers of CFU-S-13 of mice 
treMed with TPO 2 hours after each dose of irnldiation were 
approximately 14·fold those of the placebo control mice (Table 
4). The progenitor cell content of the bone marrow 24 hours 
after TBI was also significantly increased (Table 4), G;\J-CFU 
numbers per femur approximately 4·foid, BFU·E numbers 
65-fold, and CFU-Meg 20-fold those of placebo control mice, 
which grossly cQrresponds to the efticacy of TPO treatment 
along those lineages. The I\IRA ofTPO-treatedmice,definedas 
secondary GM·CFU in Ihe bone marrow of lethaJty irradiated 
recipients, was more than one order of magnitude reduced in the 
TPO·treilted mice compared with placebo· treated controls (Fig 
S). TIlis result showed that Ihe TPO-stimulated increase of 
CfU·S-13 and progenitor cells occurred at Ihe expense of the 
more immature MRA cei!s, which were proportionally depleted. 
Although day \3, which is the time of Ihe peripheral blood 
count nadirs at which white blood cells were undetectable in 
both groups of lethally irradiated recipients, is not the lIIost 
suitable time inter\'al 10 study the impact of this shift among the 
immature bone marrow cells on peripheral blood cell reconstitu-
tion, the difference in repopulating ability was nlso clearly 
reflecled in the erythrocyte as well as the thrombocyte counts of 
the lethally irradiated recipients used for the MRA assay 
(measured in one of the two experiments fro\\\ which the upper 
panel of Fig S was derived). The 10 recipients of bone marrow 
from TPO-treated mice re.lchcd erythrocyte counts all exceed-
ing 4.4 x J012/L{4.7 ~ 0.3), and all but I reached thrombocyte 
eounts of more than 10 X JO~/L, as opposed 10 the 8 (of 10) 
st!r\·iving recipients orbone marrow from placebo-trc,ned mice 
that had ef)1hroc}'te counts of 3.4 ~ 0.9 X [ot~/L and 
thrombocyte counts of 5.5 ..:+:: 2.8 X JOq/L. These differences are 
highly significant (P = .002 and P = .006, respectively: Fish· 
er's exact test), thus illustrating the importance of spleen-
repopulating cells in early reconstitution of peripheral blood 
counts in mice. Beciluse 1\ depiction of immature stem eells, 
such 3-'i measured by the MRA assa)', could be potentially 
deleterious in the clinical setting, the effect of TPO on bone 
marrow progenitor cells was also evaluated after a more 
prolonged interval. Peripheral blood count and progenitor cell 
content of both spleen lII1d femurs were e\'(liuated I and 3 
months after the 3 X 3 Gy irradiation protocol. Peripheral blood 
eounts did not differ ~tween TPO· or placebo· treated mice at I 
and 3 months, and also the femoral and spleen content of 
GM·CFU. BRJ-E, and CFU-Meg was not different hetween 
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both groups at either time point (data not shown). At these time 
intervals, we also measured the MRA of the bone marrow of the 
TPG· versus placebo-tre.1ted mice (Fig 8). MRA cells were 
similar in both groups of mice at I month after irradiation 
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Fig 6. The effect of TPO on hematopoIetic regeneration after 9 Oy 
TBllo mite. The mice \vere Irradiated with three fractions tTl of 3 Gy 
with 24·nour intervals. In the upper panel platelet regeneration Is 
depicted, In the mIddle panel red blood cell regeneration Is shown, 
and In the lower panel white blood cell regeneration is shown. !OI, 
mIce treated with three doses of O.3ltg/mouse of mTPO If 2 hours 
after each fraction oITBI; ((;jjJ), mice treated with 0.9 Itg If 2 hours after 
the last fraction ofTBI (dayO): (_), mice treated with 0.9"g If 2 hours 
belore the first fraction of TBI; (0), control mice. Data are 9iven as 
means ± SO, three mice per data point per group. The closed 
triangles (A) are counts Irom mice treated with 30 "g of mTPO If 2 
hours before irradiation Cn '" 3). 
aCthough still depleted compared with normal levels. At 3 
months after irradiation, MRAcells in both groups had returned 
to subnormal !e\·els,. again without a difference between the 
recipient groups. On this ba..~is, we concluded that the initial 
Fig 5. Dose-response curves for the multilineage effll(:t of TPO admln· 
istered IV immediately after 6 Gy TEL Peripheral blood cell counts 10 days 
after 6 Gy TSI. Values are means ± SO, n '" 6 fot the doses of 0.01, 0.03, 
and 0.1,,9 and n '" 12 for the dose 0.3 J..Lgfmouse. The vertical line In the 
upper panel represents the dose level of 0.15 J..Lg/mouse, whlctJ results in 
50% saturation 01 c·mpton platelets. The placebo control/evels coincide 
with the level at which the horizontal axis is set 
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Tabla 3. Major PeliphelalSlood Cell Counts 10 Days After 9 GyTSI 
{3 x 3 Gy, 24 Hours Apart) and IP TPO Administration 
Time ''0 Red Blood .... hite B!ood 
Relative 00>" Celi. Cen. Platelet. 
t<>TBI I~g) ()(lO".l.) ()(10'.1.) (x 10'.1.) 
, 5.8:!: 0.8 0.26:!: 0.05 51 :!: 25 
3x + 2h 0.3 6 8.6::': 0.2' 0.93::': 0.23" 883:!: 163' 
+2h 0.' 3 6.6:!: 0.7 0.43:!: 0.06~ 527 ± 135~ 
-2h 0.' 3 7.2::': 0.2" 0.47 ::': 0.06~t 215:!: 80·t 
-2h 30.0 3 8.4 ± 1.0' 0.90:!: 0.10' 792::': 157" 
Normal mice 19 10.2 :!: 0.6 5.3:!: 1.9 1,123:!: 89 
3x + 2h, three doses of 0.3 f-lg TPO 2 hours after each dose of TSI; 
+2h, 0.9 f-lg TPO 2 h<>urs after the last dose ofTBI; -2h, 0.9 or 30 f-l9 
TPO 2 hours before the first dose of TBL 
'Significantly different from control mice. 
tSignificanUy different from mice treated with 30 jJ9 TPO 2 hours 
before TBI. 
depletion of MRA of TPO·treated mice became replenished 
during long-term hematopoietic reconstitution from cells with, 
by definition, long-tenn repopUlating ability. The protracted 
nature of MRA reconstitution, which has not been documented 
before, is noteworthy. 
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Fig 1. Regeneration of progenitor cells in bone marrow {upper 
panel) and spleen !lower pane)) at 7, 10, 13, and 11 days after the last 
fraction of TBiln mice irradiated with three fractions of 3 Gy with 24 
hour Intervals. (.j, GM·CfU per femur or spleen; (0), SFU·E; (0), 
CFU·Megs per femur or spleen. Placebo, control mice; TPO·2h, mice 
heated with 0.9 jl9 TPO 2 hours before the lirst fraeUon of TSI; TPO+ 
2h, mice treated with 0.9 ].1g 2 hours after the last fraction of TSI; 
IP03x+2h, mice treated with three doses of 0.3 jlg/mouse 2 hours 
after ~ach fraction of IBl, three mice per data point. SDs wefe 
calculated for the sum of the individual colonies per mouse. ~Sign1fl· 
cantiy different from time matched controls {P < .05), • '{P < .005). 
Table 4. Effects of TPO Treatment After 9 Gy TSI {3 x 3 Gy, 24 Hours 
Apart) on CFU·S·13 and Progenitor Cell Content of Bone Marrow 24 
Hours After the Last Dose of TSI In Mice Treated With TPO IP 2 HOllrs 
After Each Dose of TSI Versus ContrOl 
CFU·S·13 
(Co!onies GM-CFUI BFU-Ef CFU·Meg' 
Treatmen! pet femur) Femur Femut Femur 
Placebo 2::':2 597:!: 229 8.3::': 3 22 ± 10 
TPO 3 x 0.3 21 :!: 6' 2026:!:131" 558::': 282' 430:!: 135' 
'Significantly different from placebo. 
DISCUSSION 
The present analysis shows that a single administration of 
TPO is capable of counteracting radiation·induced pancytope~ 
nia mediated through its effect on immature multilineage 
repopulating cells and their direct progeny, thcreby promoting 
peripheral blood reconstitution of thrombocytes, erythrOC}1es, 
and granulocytes. Multilineage efiicacy wa~ critically depen~ 
dent on time relati\y to TBI and a relatively high dose ofTPO. 
In particular. the first few hours after Tm nppeared to be 
important to elicit the muitilincnge response to TPO. Mecha-
nisms im'olved included prevention of depletion of multilineage 
cells during the first 24 hours aner TBI, a preferential stimula-
tion of spleen-repopulating cells with short-tenn peripheral 
blood reconstituting ability at the transient expense of marrow-
repopulating cells, and 1I threshold dose of TPO to overcome 
initinl c~lIIpl-mediated clearance. 
The mechanism by which TPO makes multilineage cells 
available for accelerated hematopoietic reconstitution remains 
to be further elucidated, as does their apparent functional 
depletion as a function of time after TSI in the absence ofTPO. 
Muitilineage TPO responsiveness declined sharply as a function 
of time after TBI, leaving a lineage dominant thrombopoietic 
response when administered 24 hours after TSL This indicates 
that in the absence ofTPO,multilineageTPOresponsh'ecelis 
are rapidly depleted or become inaccessible. The loss of the 
Illultilineage TPO response may have diverse and complex 
causes, which include apoptosis or radiation· induced cell death, 
differentiation along other hematopoietic lineages, inhibition 
mediated by cytokines produced in response to radiation injury, 
or inaccessibility of the immature cells for TPO due to stromal 
reactions 10 radiation. TPO has been shown to prevent apoptosis 
of immature hematopoietic cells>" and this might be a prime 
candidate mechanism to explain the short time inlerval a\'ail-
able for optimally effective TPO intervention. In vitro, TPO 
does not confer a proliferative response to immature hematopoi-
etic cells, but docs so strongly in the presence of suitable other 
factors, eg, Kit ligand.·1H2 The mechanisms involwd might 
therefore also include activation of one or more cofactors 
required for the strong proliferative response observed in the 
present study. We also do not exclude that the effect of TPO on 
muitiline.lge cells is augmented by the relea~e of various 
cytokines by megakaryocytes-l JA-t subsequent to stimulntion by 
TPO, although the time frame obsen'ed makes such a mecha-
nism not likely. 
TIle lack of a leukocyte response 10 days after 6 Oy TBI in 
Ihe presence of significantly more a:-'l·CFU at 7 days in the 
24-hour treatment group is noteworthy. The neutrophil response 
to TPO has been variable throughout the reported stud· 
ies.~·q·!!.-I"·~5 We observed in a myelosuppression model in 
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fig 8. Marrow repopulating abltity: GM·CFU, ranked in ascending 
order, on day 13 in femurs of recipients of bone marrow of mice 
treated with 0.3 1-19 TPO If 2 hours after each fraction of 3 Gy T8I (III) 
In comparison with thoss of recipients of control mauow {OJ of mice 
that did not receive TPO. Upperpanef: a total 0125 mice were Injected 
with bone marrow (lha content of 1 femur, 24 hours after TBI) of 
TPO·treated mice ofwtdcfl only 5 mice had more than 10 GM·CFU per 
femur, and 17 (survivIng of 20 injected) mice with bone marrow 01 
placebo-treated mice of which 10 had mora than 10 GM·CFU per 
femur. Results from two experIments. This difference Is highly 
slgnfficant {P '" .01. Fisher's exact test}. Upper middle panel: 10 mlee 
were InJecled with the standard 10~ bone marrow cells from each of 
the groups 1 month afterTBI, ofwhleh in each recipient group 9 mIce 
survived and 5 mIce had more than 10 GM·CFU per femur. lower 
middle panel: 10 mice were injected with the standard 10; bone 
marrow cells from each of the groups 3 months alter TBI, of which In 
the recipient group of the TPO·treated mice 1 mouse dle& before day 
13 and 1 mouse had less than 10 GM·CFUlfemur. lower panel: 20 
mice were inJected with the standard 10; bone marrow ceUs from 
normal, untreated donors for comparison. 
rhesus monkeys that TPO-stimulated GM-CFU reconstitution 
was not reflected in an increase in peripheral blood granulocytes 
which, howewr, could be brought out by coadministration of 
G- orGM_CSF.~t6Thus, without exogenous CSFs, the myeloid 
progenitor cell effect of TPO after myelosuppression may 
remain unnoticed at the peripheral blood cell level, to which the 
short sun'ival of circulating neutrophils might also contribute. 
These obsen'ations are fully consistent with the mouse data 
presented here. It is not inconceivable that some myelosuppres-
sion regimens may result in sufliciently high endogenous CSF 
lewIs for a significant neutrophil response to exogenous TPO 
alone. as has been obsen'ed in some studies.9.11A5 
To establish the TPO dose level needed. a dose titration was 
performed using IV administration immediately after irradia-
tion. The dOSeS of 0.3 and 0.1 /lg/mouse (12 and 4 /lg/kg. 
respectively) gave identical results, whereas 0.03 (1.2 /lglkg) 
and 0.01 /lglrnouse were largely ineffective. This obsen'ation is 
interpreted as evidence for a threshold level ofTPOrequiredfor 
optimal efficacy. It was previously shownn.l~ that IV injection 
of 125I-rm11'O into mice results in an initial sharp decline in 
plasma levels, followed by steady state clearance approximately 
3 hours after IV injection.14 A lower dose does not influence the 
terminal half-lifc.B After IV bolus injection, the initial rapid 
decline in plasma TPO levels is due to binding ofTPOtoc-lIIpl 
on platelets and on ceJls in the spleen,2~ whereas the slower 
terminal decline is likely related to uptakc and clearance by 
c-mpl on platelets, spleen cells. and megakaryocytes, as well as 
nonspecific mechanisms.2H7 Thc initial binding and uptake of 
11'0 to c-mp! is concentration dcpendent and becomes saturated 
at higher doses, leading to greater plasma TPO levels.~s This 
relationship between TPO pharmacokinetics and c-mp! levels 
has recently been studied in nonllal mice, which showcd that an 
IV dose of approximately 6 /lg/kg (",,0.15 pg/mouse) was 
needed to obtain an occupancy of 50% of c-mp! sites (indicated 
in Fig 5). Doses greater than 6 /lg/kg began to saturate this 
specific clearance mechanism, whereas lower dOSeS failed to 
reach 50% receptor occupancy.~s This is consistent with a 
threshold level of TPO needed to overcollle initial c-mp!-
mediated clearance and to result in sufficient plasma TPO levels 
to achieve a maximal hematopoietic reSponse. Doses larger than 
6 /lg/kg (0. J 5 /lgfmouse) lllay not provide any greater cllicacy. 
These data are consistent with the findings presented in Fig 5. 
showing that the hematopoietic recoveries after IV doses of 0.3 
and 0.1 ~Iglmouse (12 and 4 vg/kg. respectively) were not 
different. whereas a dose of 0.03 /lglmouse (1.2 ~Ig/kg) was 
suboptimal in preventing myelosuppression. Based on the 
previous IV pharmacokinetic data comparing TPO plasma 
levels in c-mplknockout and normal mice.2~ it was inferred that 
40% of the exogenous TPO binds to c-mp! on platelets and 60% 
is availablc as free TPO in the plasma. Assuming a plasma 
volume of I mL in a 25-g mouse. the suboptim[l] dose of 0.03 
/lglmouse results in a ma'\imum level of 20 ng/mL and the 
cffectivc dose oro. I /lglmouse in 60 nglmL. Consequently, the 
minimum effective or threshold plasma level is in between 
those levels. 
Fractionation of the dose of mdiation and appropriate dosing 
of TPO was thought to amplify the TPO effect on immature 
cells to enable short-term transplantation ass[lYS. Such an 
appro[lch would [liso be more represent[llive of clinically used 
mdiation regimcns anti of the protnlcted nature of cytoreductive 
treatment by means of chemotherapy. Also after fmction[lted 
TEl (3 x 3 Gy. 24 hours apart), the optimal dose and dose 
scheduling of TPO derivcd from the 6 Gy experiments. ie, 0.3 
/lglmouse, 2 hours after each TBI fraction, prewnted thrombo-
penia and promoted erythrocyte and leukocyte reconstitution. 
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We noted that also the femoral and spleen progenitor cells (Fig 
7) nomlaliled rapidly and lacked the late overshoot in the 
spleen characteristic of the placebo controls. Because the range 
of stimulation by TPO was not lineage specific, we postulated 
that the effect was mediated by stimulation of multilineage 
cells. After transplantation of bone marrow into lethally irradi-
ated recipients, the number of CPU-S-13 is a measure for 
relati\'e1y immature repopulating stem cells,49 associated with 
the initial, short-tenn wave of hematopoietic reconstitution, 
which lasts for several months.50 By this assay it was shown that 
the mul!ilineage effect ofTPOadministered2hoursafterTBIis 
mediated through stimulntion of these immature cells and is 
already manifest 24 hours after the last fmclion of TBI. The 
number of secondary in vitro clonogenic progenitors in the bone 
m:mow of such recipients is a measure of the MRAofthe gmft, 
the primary cells being closcly associated with those that 
provide sustained hematopoiesis after bone marrow trunsplanta-
tion.34 MRA, measured by enumerution of GM-CFU numbers 
in the bone marrow of mice injected with cells from TPO treated 
mice, was one to two orders of magnitude less than that in 
control mice. The incre.1Se of CRJ-S-13 and the concomitant 
decrease of cells with MRA mostlikcly indicates recruitment of 
multilineage short-tenn repopulating cells from a more imma-
ture ancestrul population. This is the more conceivable from the 
magnitude of this effect (14-fold for CFU-S), which suggests 
three to four cell doublings. Because these occurred during the 3 
days that elapsed from the first TPO administration to the time 
of the measurement, 24 hOllrs after the last fruction ofTBI, this 
would be in close agreement with tbe doubling time established 
previollsly21 for sucb immature cell populations during bemato-
poietic reconstitution. The decline in marrow-repopulating cells 
wilh Ibe concomitant increase of spleen-repopulating cells 
could also be considered as a shift in homing pattern among 
these immature ceUs. To date, there is no evidence to suggest 
that such a shift may occur without cell divisions, whereas the 
ancestral position of the marrow-repopulating cells relative to 
the spleen colony-fomling cells has been well documented.3-I.51.52 
The depletion of MRA ceUs in the TPO-treated mice, 
measured 24 hours after TBI, was tmnsient. Peripheml blood 
cell regenemtion I and 3 months after three fractions of 3 Oy 
wa~ not different in mice treated with TPO compared with 
controls and neither were the femoral and spleen in vitro 
colony-forming cell numbers. Assessment of the !\.IRA at tbe 
same lime intervals also did not show differences between the 
TPO-treated mice and the placebo group. We interpret these 
observations as replenishment of the MRA cells from a more 
ancestral cell population with, by definition, long-teon repopu-
lating ability, consistent with a model in which MRAcells are a 
transitory population intermediate to stem cells with long-ternl 
repopulating ability and the spleen-repopulating cells measured 
by tbe CRJ-S-13 assay. To date, the effcct ofTPOtreatmenton 
long-term repopulating cells has nut been quantilativcly docu-
mented. Recently, it was reported that transplantation of bone 
marrow from TPO-treated, 3.5-Gy irradiated donor mice facili-
tated the 90-day survival of the recipient mice;~-' Howe\'er, this 
sun'ival effect had become established already at the short-Ienn 
hematopoietic reconstitution parameter of 30-day sUTvival (in 
pmctice already within 17 days), closely a~sociated~O to the 
CFU-S-13 a~say used in the present study. Using such an 
experimental design to establish TPO effects on long-tenn 
repopulating ceUs would require a genetic marker capable of 
distinguishing between donor and recipient cells along multiple 
hematopoietic lineages. 
In addition, we showed that TPO is effective if administered 
at a very high dose shortly before myelosuppressive TBT. The 
dose used, 30 fJgfmouse (1.2 mglkg), suprasaturates the c-mpl-
mediated clearance mechanism (which makes phamlacokinetic 
measurements futile) and is not recommended for clinical use. 
We did not so far establish empirically the minimum effective 
dose required for prophylactic TPO administration, but such a 
dose could be derived on the assumption of maintaining plasma 
TPO levcls of approximately 60 ngfmL in the first hours after 
TBl as calculated abo\'e. However, the obsen'ation has rel-
evance for the further development of emcacious dose and dose 
scheduling regimens, especially in conjunction with chemother-
apy, as well as in the area of radiation protection. The present 
study did not address propensity to hemorrhage and prevention 
of mortality, but rather was directed at mechanisms important to 
optimize emcacy. The benefit of TPO treatment shortly after 
much rugher ("supralethal") doses of TBI on survival and 
prevention of bleeding will be published separatel}'.~ 
In vivo studies on TPO eBicacy have yielded various resuits, 
in that in normal animals usually only a platelet response was 
obtained,6,7.~5-59 whereas in myelosuppressed animals muhilin-
cage responses was the prevailing patkm,S_9.11-n_!5.1("~H,,).61 and 
tlfter transplantation of limited numbers of stem cells no 
response was obtained ut all.{o! On the basis of this heterogene-
ity, it can be llssumed that the response to exogenous TPO is 
determined by multiple factors. We already pointed out the 
import(lnce of cotreatment wilh G-CSP or GM-CSF to make the 
TPO effect on GM-CFU reconstitution manifest in neutrophil 
numbers in the peripheral blood. The present study also 
identifies time relative to myelosuppression and dose of exog-
enous TPO as pi\'otal factors. In addition, the difference 
between normal and myelosuppressed animals indicates that tbe 
TPO response of immature cells might be dependent on tbe 
presence or activation of one or more coraclors. As already 
pointed out, TPO by itself does not induce in vitro a prolifera-
tive response in immature bone marrow cells, but does so 
strongly in synergy with. eg, Kil ligand.-1.6-11 Identification of tbe 
cofactor(s) which operate in irradiated or otherwise myclosup-
pressed animals to generate a proliferative response to TPO 
administnltion might therefore be highly relevant as well to 
impro\'e the clinical TPO response. 
Irrespective of the mechanisms involved, the optimal efttcacy 
of TPO if administered within 2 hours after cytoreductive 
treatment places emphasis on the importance of dose and dose 
scheduling in clinical protocols of cancer treatment and/or ufter 
bone marrow transplantation. Indeed, the initial clinical experi-
ence did not demonstrate a major effect similar to those 
obsen'ed in the experiments described here.~:w:.61t is concluded 
that dosing similar to what has become conventional ba~ed on 
the G-CSF and Gl\-I-CSF experience is 1I0t optimal forTPO and 
that its eftlcacy can be substantially improved by achieving 
relatiYely high TPO levels shortly after cytoreducti\,e tre::Jtment. 
This was attributable to the dual target cell nature of the TPO 
response. of which the important multilineage component is 
functionally depleted sbemly after radiation exposure, and to the 
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identified threshold plasma level ofTPOrequired to overcome 
its initial c-lIIp/-mediated clearance. 
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7.1 INTRODUCTION 
The cloning of the gene for thrombopoietin and the subsequent production of various 
fonns of the protein have led to extensive research directed at the physiological role, 
mechanism(s) of action, regulatory mechanisms and potential clinical applications ofTPO. 
The experimental work described in tlils thesis supports the hypothesis that the cytokine 
regulating platelet production might have therapeutic applications in counteracting 
induced thrombocytopenic conditions. In prcclinical experiments in rhesus monkeys, the 
efficacy of TPO after myelosuppression and after bone marrow transplantation was 
investigated, and in studies with myelosuppressed mice the administration schedule was 
improved and the cellular basis of the multilineage effects further elucidated. 
Evaluation of TPO in a myelosuppression model is clinically relevant since many 
oncology patients become thrombocytopenic as an adverse effect of anti-cancer 
treatment. This may lead to complications such as bleeding and often results in treatment 
interruptions which are unfavorable for probability of cure. (l-5) Prevention of 
thrombocytopenia therefore would reduce morbidity and decrease the number of 
thrombocyte transfusions needed. This is also beneficial in view of the occurrence of 
allosensitization in response to platelet transfusions which should be avoided, especially 
if an allogeneic bone marrow or stem cell transplantation is contemplated, and in view of 
infection risks related to the use of blood products. Since thrombocyte transfusions 
account for a considerable part of treatment costs, thromhopoietin therapy might also 
reduce those. 
Severe myelosuppression as occurs with certain chemotherapy regimens, or 
myeloablation in the treatment of hematologic malignancies, require a hematopoietic stem 
cell transplant to ensure hematopoietic reconstitution. However, reconstitution following 
transplantation is often impaired, and protracted thrombocytopenia is a well known 
problem, especially in patients subjected to prior chemotherapy. (6-tO) Patients would 
benefit from adjuvant or supportive treatment modalities to enhance blood cell 
reconstitution. For this reason, the efficacy of TPO to stimulate platelet regeneration was 
also evaluated in a model for purified stem cell transplantation. 
TPO greatly promoted thrombocyte regeneration after a myelosuppressive dose of 5 Gy 
TBI, which results in severe pancytopenia for a period of approximately 3 weeks. TPO 
when adnilnistered alone also cnhanced red blood cell reconstitution. Combining TPO 
with either of the two myeloid growth factors registered for clinical use, G-CSF or GM-
CSF, was even more efficacious; the stimulating effect on platelet regeneration was 
maintained while TPO acted in synergy with the CSF's to enhance neutrophil 
regeneration. The effects outside the megakaryocytic lineage were originally not 
anticipated and could be demonstrated to result from accelerated mullilineage B M 
progenitor cell regeneration. However, despite the promising results in the 
myelosuppression model, TPO was ineffective after 8 Oy TBI and transplantation of a 
highly defined stem cell subset. 
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A separate set of experiments was carried out in myelosuppressed nlice to adjust the dose 
schedule of TPO in order to maximize the multilineage response. An optimal effect could 
be achieved if TPO was administered within the first few hours after TBI. Furthennore, 
the origin of the multilineage response was investigated by determining the effect of TPO 
on immature hematopoietic cells, i.e., day 13 spleen colony-forming cells (CFU-S-13) and 
cells with marrow repopulating ability (MRA). 
A comprehensive model to explain both the ill vitro and the ill vivo results obtained 
with recombinant TPO is emerging. In line with expectations, TPO was shown to be the 
physiologic regulator of platelet production. Mice genetically engineered to be deficient 
for either TPO or its receptor are severely thrombocytopenic (11-13), demonstrating the 
importance of TPO in maintaining ill vivo platelet levels. In vitro, TPO is a powerful 
megakaryocyte colony stimulating factor and also supports the maturation of 
megakaryocytcs. (14-16) Injection into normal experimental animals induced a striking 
thrombocytosis and increased numbers of megakaryocytes in the bone malTOw. (14.16-
18) TPO levels appeared to be simply regulated by a c-mpl mediated clearance 
mechanism and therefore, since c-mpl is present on platelets, predominantly by platelet 
mass, 
Contrary to initial expectations of lineage dominance, TPO was also shown to be an 
early acting cytokine. Apart from expression throughout the megakaryocytic lineage 
(19-21), the TPO receptor is present on multilineage hematopoietic precursor cells in both 
mice and humans. (21,22) Effects exerted on those early cells include suppression of 
apoptosis of immature cells. (23-26) Also, TPO stimulates ill vitro colony formation from 
those cells in synergy with other growth factors such as SCF and IL-3. (22,27-32) Tllis ill 
vitro dependence of TPO on other cytokines for a proliferative etIect on immature 
Illultilineage cells is reflected hl vivo by the difference in effects of TPO in 110nnal and 
myelosuppressed animals. In normal animals the effect is mainly thrombopoietic whereas 
after myelosuppression multilineage effects have been demonstrated. (this thesis and (33-
36) After myelosnppression, a variety of cytokines is upregulated and endogenously 
produced that could act as the required co-factors. (37-40) It is, in addition, possible that 
the effect of TPO on multilincage cells ill vivo is augmented by the release of various 
cytokines by megakaryocytes (41,42) subsequent to stimulation by TPO. To obtain an 
optimal ffillltilincagc effect in mice it is important to administer TPO early after TBI in a 
dose sufficient to overcome initial c-mpl mediated clearance. The precise mechanism of 
action should be clarified to extrapolate these findings to an optimal clinical efficacy. 
In this chapter the data presented in this thesis will be discussed against the background 
of the expanding literature all the etJects of TPO in preclinical settings. A final paragraph 
will review the clinical data available to date. 
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7,2 EFFECTS OF TPO ADMINISTRATION IN NORMAL ANIMALS 
Before a cytokine can be used in clinically relevant models, experiments in nonnal 
animals arc needed to investigate the dose range needed for effectiveness, the 
mechanism of action and potential adverse effects. The dose of human TPO used in the 
experiments described in the first chapters was based on dose titration experiments 
carried out at Genentech in normal rhesus monkeys and rodents and was set at I 0 ~g/kg. 
This is in the range of doses used by other groups (14,16-18) resulting in foUl'- to ten-fold 
increases in platelet counts in normal animals. (14,16-18) Preceding the increase in platelet 
numbers, an increase in the numbers of CFU-Meg in the bone marrow (17,18,34,43) and in 
the volume and ploidy of megakaryocytes was observed. (18,34) Although incrcases in 
the number of bone malTOIV BPU-E (33,34) or CPU-GM (33) have been reported, 
increases in peripheral blood reticulocytes, erythrocytes or leukocytes were not 
observed. (16-18,33,34) 
Those results are consistent with the hypothesis that additional cytokines are necessary 
to produce mature end cells of other lineages than the megakmyocytic. In steady staty 
bone marrow the pharmacological doses of TPO only stimulate the proliferation of 
megakaryocyte progenitors, the maturation of megakaryocytes and the production of 
platelets, resulting in thrombocytosis, whereas stimulation of more immature cells may 
lead to a certain expansion of bone manow progenitors of other lineages without the 
produclion of mature blood cells. 
The only adverse effect reported is the development of cross-reacting antibodies in 
normal dogs to human TPO. (44) TillS results in thrombocytopenia approximately 2 
months after the start of TPO administration, accompanied by decreased numbers of bone 
marrow megakaryocytes. Also in sublethally irradiated dogs, sensitization to human TPO 
followed by thrombocytopenia has been reported. (45) Thrombocytopenia dne to the 
development of antibodies after TPO administration has not been published for other 
species so far. However, patients treated with TPO should be carefully monitored, 
especially if TPO will be used in otherwise healthy people, such as donors of allogeneic 
transplants. 
The presence of TPO receptors on platelets indicates that TPO might have a function 
beyond the maturation of thrombocytes, such as modulating hemostasis. Although 
activation of platelets has been observed in vitro (46-48), platelet aggregation only 
occurred in the presence of other agollists. (46-48) The physiologic meaning of this 
observation is not clear, and thrombotic events have not been reported in animal models. 
(49) Other adverse effects have not been observed. also not due to the vel)' high 
thrombocyte counts induced by TPO treatment. 
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7.3 EFFECTS OF TPO ADMINISTRATION AFTER MYELOSUPPRESSION 
In the first part of this thesis the results of TPO administration to myelosuppressed rhesus 
monkeys are described. A conventional growth factor dose schedule consisting of daily 
dosing for 21 consecutive days, starting the day after TBI, was used. Results were very 
promising in that thrombocyte reconstitution to normal values was accelerated by t \vo 
weeks, with an improvement of the thrombocyte nadir and a complete prevention of the 
need for thrombocyte transfusions. The effect of TPO was not restricted to the 
megakaryocytic lineage. FACScan analysis revealed much greater numbers of CD34+ 
cells in the bone marrow of TPO treated monkeys. Using progenitor cell assays of 
regenerating bone marrow it was shown that also OM-CFU and BFU-E recovery was 
accelerated. This was reflected in an enhanced red blood cell nadir and, with co-
administraton of G-CSF, enhanced neutrophil reconstitution. Similar results on 
thrombocyte regeneration after myelosuppression have been obtained by other groups. 
(35,43,50.51) The effect of TPO on elythroid precursors and red blood cell regeneration 
after TBI has also been demonstrated in mice (34), as was the regeneration enhancement 
of bone marrow CFU-GM. (33) In our experiments, and in carboplatin treated mice (50), 
an effect of TPO alone on peripheral blood neutrophil reconstitution was not 
demonstrated, although in simiIm' experiments in myelosuppressed mice and rhesus 
monkeys, some efficacy along this lineage was observed. (35,43.52) 
The combination of TPO with G-CSF leads to various results in different settings. In our 
experiments, the combination of G-CSF and TPO counteracted the thrombocyte 
recovery induced by TPO, as was similarly reported in a chemotherapy model in 
baboons. (52) In normal mice, G-CSF down-modulated the effect of TPO on the ploidy of 
megakaryocytes. (53) However, in 6Oeo irradiated rhesus monkeys and in mice 
myelosuppressed by irradiation and carboplatin this adverse effect was not seen (35,36), 
or even enhanced thrombocyte regeneration compared to TPO alone was reported. (51) 
For neutrophil regeneration the effect of the combination of TPO and G-CSF is also 
heterogenous. We found a synergistic or additive effect as did certain other groups 
(35,36,51), whereas in chemotherapy treated baboons such effects were not observed. 
(52) The reason for these discrepancies could relate to differences in the production of 
endogenous cytokines due to variations in the induction of myelosuppression. or 
diffcrences in the dose of exogenously administered G-CSF. 
The effects of TPO on erythrocyte regeneration and BM progenitor cell recovery after 
myelosuppression. fit with the concept of lllultilineage stimulation by TPO. The 
difference between the effect of TPO on hematopoiesis in Honnal and myelosuppressed 
animals likely results from the change in the cytokine environment that occurs following 
myelosuppressive therapy. During the pancytopenic state cytokines are produced which 
are normally below detection level. This could for instance explain the differcntial effect 
of TPO on erythroid cell production in normal and myelosuppresscd animals. It has been 
demonstrated that the erythropoietic effect of TPO is dependent on the presence of EPO 
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(32,54,55), and the TPO receptor has been demonstrated on cultured human erythroblasts 
(J 9) and on the early erythroid progenitor cell BFU-E, (56) In normal animals, 
administration of TPO leads to increased numbers of erythroid progenitors, but because 
in steady state hematopoiesis levels of EPO are very low (39), an increase in red cell 
numbers is not observed. After cytoreductive treatment, the animals progressively 
become more anemic, which will induce a rise of EPO levels. Synergism between EPO 
and TPO leads to increased numbers of CFU-E and reticulocytes. The increased 
production of red blood cells elevates the hemoglobin nadir and, in the presence of 
sufficient supplies of iron, accelerates reconstitution of normal Hb levels. (Chapters 2,3 and 
4) Similarly, the increase in white blood cells in response to TPO administration in 
Illyelosuppressed animals Illay be the result of the synergistic effect of TPO and 
endogenously increased other eytokines, such as G-CSF and GM-CSF. 
In experimental animal models for myelosuppression, TPO was initially administered for 
prolonged periods of time after the cytotoxic insult, starting 24 hours after irradiation or 
chemotherapy. Delayed administration in rhesus monkeys and mice was significantly less 
effective than administration early after TBI. (57,58) It has been shown recently that a 
single dose of the molecule is as effective (58-61) as repetitive administration to achieve 
the main goal of treatment: elevate the nadir for thrombocytes to reduce the need for 
thrombocyte transfusions and accelerate reconstitution to nonnal thrombocyte counts. 
Also in normal mice the effects of single dose administration of TPO on platelet counts 
(50,61), megakaryocyte numbers, size and ploidy (62) in the bone marrow, are quite similar 
to those seen in animals to which repetitive doses were administered. The fact that a 
single dose of TPO produces a platelet rcsponse that is sustained several days explains 
why the dependence of the response on repetitive doses of TPO is not very striking. 
After a first injection ofTPOadditionalinjectionswill not add much to the magnitude of 
the platelet response. 
In principle, stimulation of blood cell regeneration after myelosuppression by 
hematopoietic growth factors is either due to increased numbers of progenitor cells 
activated to produce end cells, or to accelerated cell divisions, resulting in a shorter 
doubling time. If growth factor stimulated production only occurs from a larger number 
of progenitor cells, the doubling time will be unaltered, resulting in regeneration patterns 
in the exponential phase of reconstitution that will be similar in both groups, be it that 
the growth factor stimulated curve occurs earlier. However, if cell mu1tiplication is 
accelerated, the regeneration patterns will be different in the stimulated versus the 
placebo treated group. Thrombocyte production is a special case, since platelets are 
membrane fragments of cells driven by endomitosis to mature. Platelet production is 
therefore directly related 10 ploidy and size of megakaryocytes. TPO stimulates 
endomitosis, increasing the ploidy and size of the megakaryocytes. (14·16,63) 
From the data obtained in the rhesus monkey model for myelosuppression the doubling 
time for the number of thrombocytes during the exponential phase of regeneration could 
be calculated at approximately 3 days for monkeys treated with TPO, whereas it was 
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more than 8 days for placebo treated monkeys (Fig 1). Apparently TPO treatment 
decreased the doubling time for platelets. Since doubling time is the resultant of 
thrombocyte production and destruction, the underlying assumption is that the life span 
of the produced thrombocytes is similar in the TPO stimulated and the placebo treated 
group. The life span of platelet produced in response to TPO treatment in nOlmal 
baboons is not altered compared to unstimulated platelets. (I8) 
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Figure t. Analysis of regeneration patterns of thrombocytes and reticulocytes in 5 Gy irradiated 
rhesus monkeys. The upper panel represent thrombocyte regeneration in response to TPO (10 
~g/kg/day, SC, days 1-21, n=4, squares); or in response to TPO/G-CSF (TPO 10 flglkg/day, sc, days 1-
21 and G-CSF 5 Jlglkg, sc, days 1-21, n=4, triangles); or in placebo treated controls (11=12, circles). 
The lower panel represent reticulocyte regeneration in reponse to 'fPO (10 /lg/kglday, sc, days 1-21, 
11=4, squares); or in placebo treated controls (0=4, circles). Regression lines were calculated for the 
exponential phases of reconstitution, as indicated by solid symbols. This was done using the 
exponential curve fit analysis in Cricket Graph III (Computer Associates International Inc.) Doubling 
times for thrombocytes and reticulocytes were calculated using the equation 10" =2, in which the a.x 
was provided by Cricket Graph. 
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It should be noted that in this period thrombocyte transfusions were given to placebo 
treated monkeys whenever platelet counts dropped below 40 x 109JL (from day 10 to 
29). This might have influenced the thrombocyte reconstitution pattern in two ways. The 
transfused platelets increase thrombocyte counts at the time of the nadir and cause the 
curve to be more shallow than it would have been without transfusions. The calculated 
platelet doubling time for placebo treated monkeys could therefore have been shorter in 
undisturbed regeneration. Binding of endogenously produced TPO to transfused 
platelets might have influenced platelet production in a more indirect way. 
Extrapolation of the regression of exponential thrombocyte reconstitution of TPO and 
placebo treated monkeys shows an early divergence after TBI, indicating an early effect 
ofTPO. In TPO treated normal nonhuman primates thrombocyte counts start to tise after 
a lag phase of 6 to 7 days. (17,18) Therefore, also from the effect on platelet nadir at day 8 
after TBI it can be concluded that the effect of TPO starts early after the first 
administration. 
Comparison of the regeneration patterns for TPO treated monkeys and monkeys treated 
with TPO and G-CSF displays an interesting phenomenon. The exponential phase of 
platelet reconstitution of the TPO/G-CSF monkeys is clearly biphasic, from day 10 to 14 
the slope is similar to that of monkeys treated with TPO alone (calculated doubling time 
3.4 days) and from day 14 to 19 the slope is similar to the placebo treated controls 
(calculated platelet doubling time 8 days). Apparently concurrent G-CSF administration 
alters the response of the megakaryocytic lineage to TPO. We hypothesize that the initial 
pattern results from a maturational effect of TPO inunediately after administration on late 
megakaryocyte progenitors, resulting in larger megakaryocytes able to produce more 
thrombocytes. However, whereas in monkeys treated with TPO alone this effect is 
maintained through an increased production of megakaryoctye progenitors from 
multilineage ancestral cells, in the presence of G-CSF the balance in lineage commitment 
is shifted. More cells differentiate into the granulocyte-macrophage lincage, as can also 
be concluded from the accelerated reconstitution of neutrophils in monkeys treatcd with 
TPO/G-CSF, compared to monkeys treated with either of the growth factors alone. Tllis 
apparently results in a slow-down in the release of tluombocytes because smaller number 
of megakaryocytes, that probably are still larger than in placebo treated animals, are 
produced. 
The exponential curve fit for thrombocytes for TPO treated monkeys was calculated for day 11 to 18, 
and rendered a platelet doubling time of 2.9 days. For TPO/G-CSF treated monkeys in the first phase 
of regeneration (days 10 to 14) the platelet doubling time was 3.4 days, and in the second phase of 
regeneration- (days 14 to 20) 10.0 days. For placebo treated monkeys the curve was fitted from day 
14 to 32, with a doubling time of 8.1 days. For reticulocyte regeneration the exponential curve fit for 
'fPO treated monkeys in the first phase of regeneration was calculated for day 9 to 12 with a doubling 
time of 0.95 days, and in the second phase for day 15 to 19 2.66 days. For placebo treated monkeys 
it was not possible to fit a curve in the first phase of regeneration and in the second phase (days 15 to 
24) the doubling time was 2.01 days. Correlation coefficients r2 ranged from 0.961 to 0.996 for the 7 
displayed exponential curve fits. 
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Another explanation for the reduction in thrombocyte production would be inhibition 
by G-CSF. The reported effects of G-CSF on thrombocyte production have been 
variable, most often no effect was demonstrated (64-67), sometimes a stimulatory effect 
was shown (68) and occasionally inhibition. (69-71) Using flow cytometry and 
radioreceptor assays it has been shown that platelets express the G-CSF receptor (72), 
and G-CSF receptor transcripts were demonstrated in mcgakaryocytes. (73) Apart from a 
priming effect of G-CSF on ill vitro platelet aggregation, a functional role has not yet 
been determined for the G-CSF receptor on platelets and megakaryocytes. A reduction 
in the mean ploidy of megakaryocytes was observed in mice genetically engineered to 
overexpress human G-CSF, and after G-CSF administration to 1l0lmai mice. (53) 
Furthermore, G-CSF down-modulated the effect of TPO on the ploidy of 
megakaryocytes. Peripheral blood platelet count and the number of megakaryocytes 
were unaltered. (53) Taken together, it can be concluded that G-CSF might exert a 
suppressive effect on the maturation of megakaryocytes. However, it is difficult to 
explain the biphasic pattern for thrombocyte reconstitution observed in the TPO/G-CSF 
treated monkeys solely from inhibition by G-CSF, although it might contribute to the 
effect. It is not clear why G-CSF induced inhibition of megakaryocyte maturation would 
not occur in the first week after TBI. It could be that G-CSF is unable to inhibit 
megakaryocyte maturation from a certain point in development (from precursors that are 
present at TBI), but able to do so in 'new' precursors stimulated by TPO in which the G-
CSF receptor is upregulated. Possibly, inhibition occurs through as yet unidentified 
factors released from neutrophils or their precursors that are stimulated by TPO and G-
CSF. 
Another explanation for the dampening effect of G-CSF on TPO stimulated thrombocyte 
regeneration could be altered pharmacokinetics of TPO due to G-CSF. Since plasma TPO 
levels were similar in both treatment groups at all data points measured (Chapter 2), this is 
unlikely. Also Harker et al (52) did not find alteration in plasma levels of either eytokine 
with concurrent administration of TPO and G-CSF. 
The TPO stimulated regeneration of red blood cells was subjected to a similar analysis 
(Fig 1). Reticulocyte regeneration reflects the production of new red blood cells. A 
biphasic pattern for reticulocyte reconstitution is common after myelosuppression, with a 
small, apparently abortive rise in the second week after TRI, and an exponential increase 
in the third. From the lag phase between TBI and the occurrence of the first wavc of 
reconstitution it can be concluded that the reticulocytes in the abortive rise develop from 
a precursor cell that is at a BFU-E stage at the time of TBI. The production time from 
BFU-E to mature red cells is approximately a week. Maturation of these precursor cells is 
dependent on EPO levels that start to rise with a decrease in hematocrit, explaining the 
occurrence in the second week after TBI. The second wave of reconstitution should 
then result from the multilineage ancestral cells responsible for sustained reconstitution. 
Continuation of blood cell production after radiation insult to the bone marrow 
progenitors is dependent on supplementation of progenitor cells from more immature 
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stadia of differentiation. Population sizes of various progenitor cells in steady state bone 
manow might vary, depending on the transit time from the previous stage of 
differentiation to the next. Therefore the effect of radiation on the number of cells at 
various stages of differentiation is dependent on the original number of cells in that 
stage, the radiation sensitivity of the cell type, the transit tbne required to produce new 
cells, and the mitotic potential. 
The interruption in the regeneration curve that occurs around day 15 in both TPO and 
placebo treated monkeys suggests that a certain stage during erythroid cell 
differentiation is more affected by irradiation than later and earlier cells, causing a gap in 
the production of reticulocytes. This can either be due to a decisive difference in 
radiation sensitivity or to the size of the original population. It has been demonstrated 
that CFU-E cells are for 70% in S-phase and are susceptible to cell cycle specific 
cytotoxins. (74) It is very well conceivable that this population is also more prone to 
radiation induced cell death. However, since maturation of CFU-E to reticulocytes 
requires approximately 3 to 4 days, this mainly explains the initial drop in reticulocytes 
occurring after TBI. If the abortive rise result from cells at the BFU-E stage at the time of 
TBI, the more susceptible precursor cell should be a pre-BFU-E. 
Because the first wave of reticulocyte regeneration is brief and not very pronounced in 
placebo treated monkeys, it is not possible to calculate a doubling time. In 1PO treated 
monkeys the abortive rise also occurs in the second week but is greatly stimulated and 
contributes to the reticulocyte regeneration that occurs 10 days earlier than in placebo 
treated monkeys. The doubling time for this specific cell population was approximately I 
day for TPO treated monkeys in the first phase, and 2.5 days in the second phase of 
regeneration, whereas it is two days for placebo treated controls. The difference between 
placebo and TPO treated monkeys in the first phase most likely results from synergism of 
TPO and EPO on erythroid progenitors. Since the appearance in time is not altered 
compared to placebo treated monkeys, the stimulation by 1PO is most probably 
dependent on erythropoietin, a result that is consistent with in vitro observations. 
(32,54,55) An anti-apoptotic effect of TPO (23-26) resulting in increased survival of 
progenitor cells might also contribute to the increased cell production. 
Monkeys treated with TPOfG-CSF display a regeneration for reticulocytes that is 
identical to that of monkeys treated with TPO alone. (Chapter 2) Apparently concurrent 
G-CSF administration does not influence TPO-stimulated red blood cell regeneration. 
This is consistent with the absence of detectable G-CSF receptors on erythrocytes or on 
erythroid precursors. 
In myelosuppressed mice it was demonstrated that administration of TPO early after TBI 
and a threshold plasma level to be reached in the first hours were critical for an optimal 
multilincage effect. (Chapter 6) Delayed administration causes an increasing decline in 
efficacy of TPO. (57,58) The presence of TPO in the first hours after radiation induced 
myelosuppression in mice influences hematopoietic reconstitution along several lineages, 
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whereas a delay in administration results in effects that arc predominantly 
megakaryocytic/thrombopoietic. Tills indicates an carly effect of TPO on a multilineage 
precursor cell that can subsequcntly respond to other cytokines required for proliferation 
and end cell production. Using short-term transplantation assays, ie colony-forming unit-
spleen (CFU-S) day 13 (CFU-S-13) and the more immature cell with IlllliTOW repopulating 
ability (MRA), it could be shown that TPO promoted CFU-S-13 and transiently depleted 
MRA (Fig 2). The Illultilineagc effect of TPO therefore most likely results from the 
stimulation of short teml multilineage repopulating cells represented by the CFU-S-13 at 
the expense of more llmnature ancestral cells. The short time interval available after TBI 
to exert these effects shows that TPO is able to intervene in mechanisms that result in 
functional depletion of its target cells shortly after TBI. 
CFU-Meg 
/ g~m~m~ 
CFU-S ~ m ---- red cells t 
m ---- platelets t 
LTRA MRA 
day ll-I3 0-+J, 
CFU-S day 7 
Figure 2. Schematic representation of the effects of TPO on immature murine bone marrow cells. 
MRA cells, following transplantation associated with sustained regeneration of the host, are transiently 
depleted, wheras CFU-S-13, following transplantation associated with rapid, transient regeneration, are 
stimulated. 
The mechanisms which require almost immediate TPO availability for optimal efficacy are 
not fully elucidated. It is clear that c-mpl is expressed on developmentally early, 
multilineage cells, and, therefore, a direct effect of TPO is most likely. TPO enhances 
survival of immature cells and suppresses apoptosis (23-26), and this might explain the 
importance of time of administration of TPO. In the absence of TPO, multilineage cells 
damaged by TBI may be subject to apoptosis. whereas in its presence those cells survive, 
become susceptible to proliferative stimuli such as TPO and other cytokines and lllay 
contribute thereby to hematopoietic reconstitution. 
Radiation-induced changes in the microenvironment might also innuence the 
hematopoietic regeneration potential. Hematopoietic reconstitution in the bone manow 
is dependent on complex interactions of hematopoietic cells with stromal cells, 
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extracellular macromolecules and cell adhesion molecules, together termed the 
hematopoietic microenvironment. It is possible that TPO modifies radiation induced 
(infiammatOlY) reactions, thereby making multilincage cells more accessible to either TPO 
itself or to other growth factors. However, stromal reactions to radiation and subsequent 
alterations thereof by cytokines, are difficult to assess ill vivo. 
It is also conceivable that TPO first induces other cytokines that subsequently act on 
muHiIineage cells to become responsive to TPO. However, induction of cytokine 
production takes at least several hours, which makes it unlikely that the change from a 
multilineage to an unilineage thrombopoietic effect of TPO in 24 hours would be 
mediated through such a mechanism. 
7.4 EFFECTS OF TPO ADIVllNISTRATION AFTER BMT 
After 8 Gy TBI and transplantation with limited numbers of selected bone mUlTOW cells, 
21 day administration of TPO unfortunately did not accelerate thrombocyte regeneration 
compared to placebo treated controls. (Chapter 5) Transplantation of larger un fractionated 
cell numbers was also perfollned, to exclude the possibility that the content of the graft 
was responsible for the lack of effect, but gave identical results. 111is lack of efficacy of 
TPO post-transplantation has also been observed by others, (75,76) More promising 
results after bone marrow or peripheral blood stem cell transplantation have been 
reported, but the degree of cytotoxicity in those models was more myelosuppressive 
than myeloablative (77,78), explaining the post-transplant effectiveness of TPO, 
Interestingly, transplantation of bone marrow from donor mice or rhesus monkeys that 
had been treated with TPO resulted in accelerated platelet and red cell reconstitution, 
although post transplantation TPO treatment did not further intluence the thrombocyte 
recovery, (75,76) The mechanism might well be similar to that proposed for the results 
described in chapter 6, in which also TPO pretreated bone marrow (be it from 
myelosuppressed mice) was injected into lethally irradiated recipients. and the effect 
could be attributed to an increased number of multilineage spleen repopulating cells. 
However, the usefulness of these observations in the clinical setting is probably limited 
to only a small number of patients eligible for ill vivo pretreatment and autologous bone 
marrow transplantation, 
The absence of a beneficial effect of TPO after higher doses of cytotoxic insult to the 
bone marrow is a disappointing feature, that has not been fully elucidated. After 
myelotoxic damage hematopoietic reconstitution relies on remaining or injected stem and 
progcnitor cells. Without growth factor treatment, endogenously produced cytokines 
regulate pcripheral blood reconstitution, resulting in the regeneration patterns of placebo 
treated animals. Placebo treated monkeys transplanted with autologous bone marrow 
cells and control monkeys in the myelosuppression model recover normal thrombocyte 
counts at approximately the same time (Fig 3). This similarity is not a coincidence: the cell 
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number transplanted was chosen so as to provide a similar reconstitution pattern as the 5 
Gy myelosuppression model. This suggests the availability of adequate numbers of bone 
marrow cells for platelet reconstitution in both models and makes it unlikely that the lack 
of effect of TPO after transplantation can be attributed to limited numbers of 
reconstituting cells after bone marrow transplantation. However, although placebo 
treated monkeys display similar thrombocyte regeneration patterns, TPO treatment was 
highly effective in the myelosuppression model but not at all after bone malTOW 
transplantation. 
10 
o 7 14 21 28 35 42 
time (days) 
Figure 3. Comparison of the effect of TPO on thrombocyte regeneration after transplantation of 
purified stem cells and after myelosuppression. Mean thrombocyte counts of 8 Gy irradiated, stem 
cell transplanted monkeys are represented with symbols and lines; the filled squares represent 4 TPO 
treated monkeys, the filled circles 3 placebo treated controls. The shaded areas represent means ± SDs 
of thrombocyte levels of 5 Gy irradiated monkeys after TBI; the upper shaded area represents 4 TPO 
treated monkeys, the lower shaded area 8 placebo treated controls. The dose and route of TPO were 
identical for all monkeys (10 ~(glkg/day, sc, days 1-21). 
Exogenously added growth factors might enhance regeneration if they accelerate 
effective plasma or tissue levels over endogenous production of the cytokine. We 
demonstrated that achieving threshold plasma levels of TPO in the first hours after TBl is 
crucial for optimal efficacy ofTPO in myelosuppressed mice. (Chapter 6) Apparently after 
bone manow transplantation. endogenous levels of TPO (above detection level 
approximately one week after TBI in placebo treated monkeys, chapter 5) are adequate 
for the thrombocyte reconstitution that occurs in both placebo and TPO treated 
monkeys after approximately three weeks. The reason why TPO administration in the 
first week is ineffective in accelerating thrombocyte reconstitution is not clear. 
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Possibly, the administration schedule ofTPOusedin this BMT model, although sufficient 
for a prominent thrombopoietic response in myelosuppressed rhesus monkeys, was not 
optimal (Chapter 6) and therefore did not excrt an effect on the transplanted cells. 
However, this is not very likely. From ongoing experiments in rhesus monkeys we know 
that starting TPD treatment concurrent with injection of the bone malTOW graft does not 
improve the results. (Hartong and Wagemaker, unpublished observations) 
Analysis of the regeneration pattern of 5 Oy irradiated TPO treated monkeys reveals, at 
least for reticulocyte reconstitution, a biphasic pattern. Two phases of thrombocyte 
regeneration were also clearly present in 5 Gy inadiated, TPO/G-CSF treated monkeys 
and could be obscured in animals treated with TID alone by the maximal thrombocyte 
production. Presumably regeneration enhancement in the first phase results from 
maturational effects of TID on conunilted progenitors, whereas the second phase of 
hematopoietic reconstitution results from more ancestral cells. It occurs later in time and 
is adequately regulated by endogenously produced cytokines as can be deduced from 
the reconstitution of placebo treated animals. Therefore the absence of a TPD effect in 
the second week after high dose TBI and BMT might be explained by differences in 
number or quality of committed progenitors. In the 5 Gy myelosuppression model, the 
residual cells are less than 2 orders of magnitude depleted in stem cells and progenitor 
cells, and remain in their normal stromal envirOIlllent. In contrast, in the 8 Oy model, there 
is a morc than 3 log stem cell depletion and the hematopoietic reconstitution pattern 
observed was dependent on infused, highly purified and progenitor-cell depleted stem 
cells, which needed to home into the hematopoietic sites. It is conceivable that although 
the graft is sufficient for sustained reconstitution, and regeneration in placebo animals is 
similar to that seen in myelosuppressed monkeys, it is deficient in committed progenitors 
and therefore the first phase cannot be stimulated by TPO. However, this still does not 
explain the lack of stimulation of cells responsible for sustained engraftment. These cells 
are present, as call be deduced from reconstitution in placebo treated monkeys, and can 
be stimulated by TPO, as can be deduced from results in TPO treated Illyelosuppressed 
monkeys. 
The differential effects ofTPO in normal and myclosuppressed animals indicate that (part 
of) the TPO response is dependent on endogenously produced co-factors. Stimulation of 
immature bone marrow progenitor cells by TPO in vitro also requires other cytokines, 
such as SCF and IL-3. (22,27-32) Differences in the extent of stromal damage resulting in 
different endogenous cytokine production profiles or other micro-environmental 
variations might therefore provide additional hypotheses to be explored. 
So, although it is possible to accelerate hematopoietic reconstitution after high dose TBI 
by giving a stem cell transplant, exogenous growth factors seem to add little to 
reconstitution. 
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7.5 EFFECTS OF TPO ADMINISTRATION IN PATIENTS 
The clinical data on TPO so far are scattered. In several phase I trials, administration of 
TPO to cancer patients prior to chemotherapy resulted in dose dcpendent 
thrombocytosis and increased numbers of bone marrow megakaryocytes, comparable to 
thc effects described in experimental animals. (79-8 I) Adverse effects attributable to drug 
administration or the high platclct counts were not seen. The platelets produccd were 
morphologically normal and showcd unchanged aggregation and ATP release responses 
in ill vitro assays. (82) These data arc promising with respect to the tolerability of 
pharmacological doscs of TPO in humans and the reproducibility of thc results obtained 
in animals, but not in itself predictive for the effects of TPO in myelosuppressed patients. 
Trials to assess the usefulness of TPO in accelerating platelet reconstitution should 
document an actual reduction in the number of thrombocyte transfusions needed, 
through an elevation of thrombocyte nadir andlor a decrease in the duration of 
thrombocytopenia. TItis means that clevation of the thrombocyte nadir with 11'0 
treatment after a chemotherapy regimen in which placebo treated patients do not 
becomc transfusion dependent (platelet nadir III xlO'/L) is clinically not rclevant. (83) 
Others did not observe obvious differences in the thrombocyte nadir or duration of 
thrombocytopenia (79), while only preliminmy data on TPO trcatment in de-novo AML 
patients exist, in which a slightly decreased the period of thrombocytopenia is 
accompanied by a reduction in thrombocyte transfusions requirements. (84) The report 
documenting these findings has not yet been published. Howcver, preliminmy 
unpublished evidence reveals more promising results if TPO is administered prior to 
chemotherapy at a dose of 2.4 Ilg/kg followed by a short course at thc same dose 
thereafter, results that could in our opinion be improved if the dose and/or schedule was 
adjusted to achieve a plasma level of 20-60 ng/mL throughout the chemotherapy course. 
(Chapter 6) 
The combination of MGDF and G-CSF has also been used, in patients with advanced 
solid tumors. (85) Differences were not found in platelet nadir or transfusion requirements 
(20 vs 29%) between placebo treated paticnts or any of the dosing groups, but recovery 
to baseline values was accelerated by MGDF. All patients were given G-CSF and co-
administration of TPO did not alter the neutrophil reconstitution. The frequency of 
chemotherapy dose reductions, one of the endpoints in the trial, was the same in all 
groups. (85) Numbers of peripheral blood progenitor cells werc also assessed as an 
indicator of the efficacy of 11'0 to mobilize hematopoietic stem cells into the peripheral 
blood. Patients treated with the combination of 11'0 and G-CSF had more circulating 
BFU-E, GM-CFC and Mcg-CFC, compared to patients treated with G-CSF alone (85). 
This most likely represents a spill-over into the peripheral blood from increased numbers 
of bone marrow progenitor celis, rather than growth factor induced selective 
mobilization. (86) In two other trials TPO was administered to high dose chcmotherapy 
patients and in both trials the transfusion requirement was not altered compared to 
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controls. (87,88) 
It is too early to conclude whether TPO can reduce the need for platelet support in 
clinical situations in which prolonged and severe thrombocytopenia occurs. In view of 
the results obtained with early administration of TPO and the preliminary results in a 
chemotherapy trial, it might be possible to improve the efficacy of TPO by adjusting the 
dose schedule, giving TPO concurrent with the chemotherapy in doses sufficient to 
overcome the initial c-mpl mediated clearance. 
7,6 FUTURE PROSPECTS 
Preclinical evaluation identified TPO as a potential major therapeutic agent to counteract 
radiation induced pancytopenia, and demonstrated pronounced stimulatory effects on 
reconstitution of inmmture hematopoietic cells with multilineage potential. The latter 
observation explained the potentiation of the hematopoeitic responses to G-CSF and 
GM-CSF when administered concomitantly. The heterogeneity of the TPO response 
encountered in the various models used for evaluation points to multiple mechanisms 
operating on the TPO response and to heterogeneity of its target cells. The finding that a 
single dose ofTPO might be sufficient for a clinically significant response emphasizes its 
potency and is of practical relevance. Adverse etTects of TPO administration to 
myelosuppressed or stem cell transplanted experimental animals were not observed. 
Paradoxically, the initial clinical trials, set up before the experimental animal data were 
fully completed and processed, failed to show a m'\ior benefit of TPO treatment. The 
mechanistic mouse studies demonstrated that the response of multilineage cells to a 
single administration of TPO shortly after TBI is quantitatively more important for optimal 
efficacy than the lineage-restricted response obtained at later intervals after TBI, and 
emphasized the importance of a relatively high dose of TPO to overcome initial c-mpl 
mediated clearance. An evaluation of the presently available data from clinical trials 
makes clear, that none of these have been designed in keeping with these two principles. 
It can therefore be predicted, that TPO treatment in, for instance, chemotherapy 
protocols, can be made effective by maintaining sufficiently high levels of TPO shortly 
before, during and shortly after chemotherapy treatment. Further elucidation of 
mechanisms determining efficacy might very well result in a further improvement. 
The initially unexpected action of TPO on immature reconstituting stem cells might be 
useful for both ex vivo expansion protocols, especially those that aim for improved 
platelet reconstitution of stem cell grafts, and in gene transfer protocols. Although TPO 
by itself did not appear to be a potent mobilizer of stem cells, its capacity to promote 
CD34+ cell reconstitution in the bone malTOW may point to a useful role of TPO in stem 
cell mobilization protocols in conjunction with other growth factors, and may have the 
added advantage of accelerated platelet reconstitution. Also patients with 
thrombocytopenias resulting from HlV infection and those due to large field (>20% of 
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total bone marrow irradiated) radiotherapy (especially with concurrent chemotherapy) 
might benefit from well designed TPO treatment protocols. TPO treatment might be tried 
in thrombocytopenias resulting from primary marrow failure such as MDS and aplastic 
anemia. 
From the basic point of view, there is still much to learn on the mechanisms involved in 
the action of TPO on very immature cells and its role in stem cell physiology. Especially 
its role in maintaining stem ce1l numbers in the bone marrow is as yet insufficiently 
explored, while the rapid disappearance of lllultilineage TPO responsive cells following 
cytoreductive TBl is unexplained and might contain a clue to mechanisms operating all 
stem cell reconstitution. Further elucidation might be highly relevant for understanding 
deficiencies in hematopoietic reconstitution and ineffective growth factor treatment, 
such as has been encountered after transplantation of limited numbers of stem cells. 
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Thrombocytopenia, a serious condition that may cause hemorrhage and may in some 
cases result in mortality, is either the result of increased destmction of platelets or of 
decreased production. Decreased platelet production due to myelotoxicity of anti-cancer 
treatment is a well known problem in clinical oncology, and accounts for an increase in 
morbidity, dose reductions and treatment delays. The possibility to stimulate platelet 
regeneration would be beneficial for patient care. Counteracting the thrombocytopenia 
that occurs after bone malTOW transplantation would be another application for a 
potential platelet stimulating factor. With thc cloning of the gene for thrombopoietin 
(TPO) in 1994, enabling production of the recombinant protein, this factor has become 
available for investigation in (pre)clinical studics. 
The aim of this study was to assess the efficacy of TPO in stimulating peripheral blood 
platelet regeneration after myelosuppression and after bone marrow transplantation in 
rhesus monkeys. Furthermore, the combination of TPO with the myeloid growth factors 
G·CSF and GM·CSF was tested to evaluate possible stimulatory and/or adverse 
interactions. To establish optimal dose and dose schedule and to elucidate the cellular 
basis of the multilineage effects, a separate set of experiments was carried out in mice. 
To gain a rapid insight into the thrombocyte regeneration enhancement potential of TPO, 
the initial experiments were carried out in a well established model for myelosuppression 
in rhesus monkeys. Rhesus monkeys were irradiated with 5 Gy TBI, a dose that results in 
approximately two log stem cell kill and a period of three weeks of pancytopenia. The 
dose and dose schedule of TPO were based on pilot experiments in normal mice and 
monkeys and on experience with other hematopoietic cytokines such as OM-CSF and 
G·CSF. TPO was highly effective in preventing thrombocytopenia, thereby abolishing 
the need for thrombocyte transfusions, and in addition stimulated erythrocyte 
regeneration. Combination of TPO and G·CSF resulted in improved neutrophil nadirs 
and enhanced neutrophil reconstitution. Furthermore, the recovery of inul1ature CD34 
positive bone marrow cells was stimulated by TPO administration. (Chapter 2) The 
prominent erythropoietic stimulation resulted in the depletion of already borderline body 
iron stores, explaining the development of a microcytic anemia in TPO treated monkeys. 
(Chapter 3) 
The initial dose schedule used for TPO was morc intensive than necessary to obtain the 
main goal of treatment, prevention of the need for thrombocyte transfusions. In an 
extension of the study, administration of TPO was reduced to a single dose. (Chapter 4) In 
these experiments combination treatment with O-CSF was compared with the 
combination TPOIGM·CSF. TPOIGM·CSF was more effective than either the single dose 
of TPO or TPOIG·CSF in stimulating thrombocyte and reticulocyte regeneration. TPOIG· 
CSF and TPOIGM·CSF were similarly effective in stimulating neutrophil regeneration. 
TPOIGM·CSF treatment also significantly increased reconstitution of CD34 positive 
bone marrow cells and progenitor cells such as GM·CFU and BFU·E. 
To evaluate the efficacy of TPO after bone marrow transplantation, TPO was 
administered to rhesus monkeys that were irradiated with 8 Gy TBI and transplanted 
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with limited numbers of CD34+JHLA-DR"" bone marrow cells. Placebo treated monkeys 
develop a profound pancytopenia and need four to five trombocyte transfusions. In this 
setting TPO did not stimulate platelet recovery and neither promoted neutrophil 
regeneration if coadministered with G-CSF. (Chapter 5) The reason for this lack of 
efficacy after high dose TEl is as yet not fully elucidated. 
Finally, to optimize dose and dose schedule and to investigate the origin of the 
Illultilincage response to TPO, more basic experiments were carried out in mice. It was 
demonstrated that a single dose of TPO shortly after 6 Gy TBI prevented the severe 
thrombocytopenia observed in control mice and in addition stimulated red and white 
blood cell regeneration. A threshold level of TPO required to overcome initial c-mpi 
mediated clearance was defined. Using short-term transplantation assays, Le. colony-
forming unit-spleen day 13 and the more immature cells with matTOW repopulating 
abilitity it was shown that TPO stimulated CFU-S-13 and transiently depleted MRA. 
(Chapter 6) 
In conclusion, 1PO is a hematopoietic cytokine that regulates and stimulates 
thrombocytopoiesis and, in addition, has important actions on immature, multilineage 
hematopoietic stem ceils, e.g., in suppression of apoptasis. In preclinical animal models it 
proved to be useful in counteracting radiation induced thrombocytopenia and 
enhancement of neutrophil regeneration and that of other myeloid lineages. The effects 
arc partly mediated through the actions of TPO on immature bone marrow cells. Further 
elucidation of the mechanisms involved might lead to improved treatment modalities 
using TPO in chemotherapy patients as well as in BMT recipients. 
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Samenvatting III 
Thrombocytopenie, cen tekort aan bloedplaatjes, is een ernstige aandoening omdat het 
kan leiden tot bloedingen en daardoor soms de dood tot gevolg kan hebben. Een tckort 
aan bloedplaatjes of thrombocyten kan ontstaan door een verhoogde atbraak of een 
venninderde productie. Een verminderde thrombocytenproductie als gevolg van de 
beenmerg toxiciteit van bepaalde chemotherapeutica is cen bekend probleem in de 
oncologic. Het leidt tot verhoogde morbiditeit, dosis aanpassingen en/of uitstel van 
chemo1.'uren. Als het mogelijk zou zijn het herstcl van het aantal bloedplaatjes te 
stimuleren zou dit de behandeling van de patient ten goede komen. Een andere 
tocpassing van een bloedplaatjes-stimulerende factor zou het behandelen van de 
thrombocytopenic die voorkomt na beenmcrgtransplantatie kunnen zijn. Doordat in 
1994 het gen voor thrombopoietine (TPO) is gecloncerd, wam'door het recombinante 
eiwit gcproducccrd kon worden, is deze factor beschikbaar gekomen voor (pre)k1inisch 
ondcrzoek. 
Het doel van de preklinische studic met rhesusapen was om de effcctivitcit van TPO te 
onderzoeken in het bevorderen van het herstel van het aantal bloedplaatjes na 
beenmergsuppressie en na beenmergtransplantatie. Verder is de combinatic van TPO met 
de myeloide groeifactoren G-CSF and GM-CSF onderzocht op eventuele stimulerende 
en/of negative interacties. am de dosis en het toedieningsschema te optimaliseren en om 
de cellulaire basis van het geobserveerde multilineage effect op te helderen werden 
experimenten met muizen gedaan. 
Om snel inzicht te krijgen in het stimulerende effect van TPO op het herstel van 
bloedplaatjes werden de eerste expedmenten uitgevoerd in een bekend model voor 
beenmergsupprcssie in rhesusapen. De apen werden bestraald met een dosis van 5 Gy 
TBI, een straIingsdosis die resulteert in een reductic van ongeveer twee log van het 
aantal hematopoietische stamcellen in het beenmerg en een ongeveer drie weken 
dllrende pancytopenie. Oasis en toedieningsschema van TPO waren gebaseerd op 
experimenten in llormale muizell en apen en op de ervaring met andere hematopoietische 
groeifactoren zoals G-CSF en GM-CSF. TPO was in dit model zeer effectief in het 
voorkomen van thrombocytopenie en daannee was de noodzaak tot het geven van 
thrombocyten transfusies verdwenen. Bovendien stimuleerde 'fPO de regeneratie van 
het aantal rode bloedcellen. De combinatie van TPO Cll G-CSF leidde tot een minder 
ernstige afname van het aantal witte bloedcellen en versnelde het hcrstel daarvan. 
Verder werd ook het herstel van het aantal CD34 positieve cellen in het beenmerg 
versneld door TPO. (Hoordstuk 2) Het opmerkelijke effect op de rode bloedcel reeks 
resuIteerde in een uitputting van al marginale ijzervoorraden in het lichaam, wat het 
ontstaan van cen microcytaire anemie in TPO behandclde apen verklaart. (Hoofdstuk 3) 
Het gebruikte toedieningsschema van TPO was intensiever dan nodig om het 
bclangrijkste behandelingsdoel, het voorkomen van thrombocyten transfllsies, te 
bereikcn. In een vervolgstudie werd de toediening van TPO teruggebracht tot een 
eenmalige dosis. (Hoofdstuk 4) In deze studie werd de combinatie TPO/G-CSF vergeleken 
met TPO/GM-CSF. TPO/GM-CSr was effectiever dan TPO allcen of TPO/G-CSF in het 
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stimuleren van het hers tel van bloedplaatjcs en rode blocdcellen. Beide combinaties 
waren even effecticf in het stimuleren van het herstel van witte bloedcellen. 
Behandeling met TPO/GM-CSF versnelde ook significant het herstcl van CD34 
positieve beenmergcellen en voorlopercellen zoals dc GM-CFU en de BFU-E. 
Om de effectiviteit van TPO na becnmergtransplantatie te evaluercll werd TPO 
toegediend aan apen die waren bestraald met een dosis van 8 Gy TEI gevolgd door een 
beenmergtransplantatie met CD34'IHLA-DR'"" cellen. Apen die werden behandeld Illet 
placebo ontwikkeldcn een diepc pancytopenic en hadden vicr tot vijf thrombocyten 
transfusies nodig. In deze situatie had 1PO gccn effect op het hers tel van de 
bloedplaatjes en, in combinatie Illet G-CSF, ook niet op het herstel van witte bloedcellen. 
(Hoofdstuk 5) Dc reden voor dit gebrek aan effect na hoge dosis TBI is tot op heden niet 
bekend. 
AIs laatste werden mcer basale cxperimcnten uitgevoerd in muizen, om dosis en 
toedieningsschema te optimaliseren en OIll de basis van het multilineage effect van TPO 
te onderzoeken. Een eCllllalige dasis TPO, kart na 6 Oy TBI, was voldoendc om de 
ernstige thrombocytopenic die gezien werd in contra Ie rnuizen te voorkomen en 
stimuleerde bovendien het hers tel van rode en witte bloedcellen. Een drempelwaarde 
voor TPO, nodig om de initiele clearance door binding aan c-mpl op bloedplaatjes te 
overkomen, werd gedefinieerd. Gebruik makend van korte termijn transplantatie assays, 
de colony-forming unit-spleen dag 13 (CFU-S-13) en de mcer onrijpe eel met beenmerg 
repopulerend vennogen (MRA), werd aangetoond dat TPO de CFU-S-13 stimuleerde 
terwijl het de MRA tijdelijk uitputte. (Hoofdstuk 6) 
Conclusie: TPO is een hematopoietisehe groeifactor die de thrombocytopoiese reguleert 
en stimuleert en bovendien belangrijke effecten heeft op inunature muitilineage 
hematopoietische stamcellen, onder meer blijkend uit de onderdrukking van apoptose. In 
prcklinische diennodellen bleek het cffectief in het tegengaan van stralingsgeinduceerde 
thrombocytopenie en het bevorderen van de regeneratie van witte bloedcellen. Deze 
effecten worden deels gemedieerd door de effecten van TPO op inul1ature beenmerg 
cellen. Verdere opheldering van de betrokken mechanismen zou kUllnen leiden tot een 
verbctcring van de behandelillg met TPO in patientcn die chemotherapie krijgcn en in 
patienten die cen bcenmergtransplantatie ondergaan. 
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